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 ABSTRACT 
Mesenchymal stromal cells (MSC) suppress the inflammatory infiltrate through 
crosstalk with neighbouring endothelium. However, this response is lost at chronic 
inflammatory sites where stromal cells instead support leukocyte recruitment and 
upregulate expression of podoplanin. The mechanism and function by which this 
inflammatory phenotype is established is unknown. We hypothesise that MSC 
modulation of endothelium is also altered by exposure to inflammatory cytokines, and 
that expression of podoplanin confers an invasive phenotype, enabling the interaction 
of these perivascular MSC with circulating platelets. 
MSC resisted functional transformation during acute or prolonged exposure to 
tumour necrosis factor alpha, instead maintaining their ability to suppress neutrophil 
recruitment in a flow-based assay. Expression of podoplanin promoted MSC 
migration through Ras-related C3 botulinum toxin substrate dependent signalling, 
enabling perivascular MSC to interact with cells confined to the circulation. Indeed, 
podoplanin induced the activation of platelets from flow through MSC protrusions in 
the endothelial lining. 
The retention of MSC suppressive function under inflammatory conditions supports 
their use in equivalent environments for therapy. However, the implications of platelet 
CLEC-2 activation by its ligand, podoplanin on inflamed stroma have yet to be 
elucidated and warrant further investigation, with specific focus drawn to the 
pathophysiology of thromboinflammation and associated disorders. 
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1.1. OVERVIEW 
This thesis explores the interactions that occur between mesenchymal stromal cells 
(MSC) and their microenvironment, and how these interactions are modified by 
inflammation. The following introductory chapter will encompass the biology of MSC, 
detailing their immunosuppressive crosstalk with endothelium and how the 
inflammatory microenvironment transforms the phenotype of stroma in general. It will 
further describe the role of the mucin-like protein podoplanin (PDPN) in this 
transformation, and the functional properties it confers. 
 
1.2. MSC BIOLOGY 
1.2.1. INTERNATIONAL SOCIETY FOR CELL THERAPY CRITERIA FOR DEFINING MSC 
MSC are endogenous multipotent precursor cells, localised to the perivascular niche 
of many tissues (Crisan et al. 2008). Due to their pleiotropic nature, guidelines were 
written in 2006 by the ‘International Society for Cell Therapy’ (ISCT) (Dominici et al. 
2006), stating the minimal criteria for MSC characterisation requires they; 
• Are plastic-adherent under standard culture conditions. 
• Differentiate into adipocytes, chondroblasts, and osteoblasts. 
• Express a panel of surface markers: ‘human leukocyte antigen’ (HLA)-
DR-, CD14-, CD19-, CD34-, CD45-, CD73+, CD90+, and CD105+. 
However, the criteria set out by the ISCT also defines other stromal cells such as 
fibroblasts, hence these markers describe a heterogenous population of cells that are 
likely to have equally varied functions (Halfon et al. 2011; Kundrotas 2012). 
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Furthermore, even standardised nomenclature cannot address the differences 
observed between tissue-specific sources of MSC, suggesting that cell function is 
influenced by their individual microenvironments (see Chapter 4) (Kern et al. 2006). 
In addition to their homeostatic function of replacing cell turnover via self-renewal and 
differentiation, MSC are also potent modulators of the immune system and are likely 
to play a key role in the regulation and resolution of inflammation [reviewed by (Ma et 
al. 2013)]. As such, these properties along with their low immunogenicity, make them 
a popular choice for cell-based therapies [reviewed by (Squillaro et al. 2016)]. 
 
1.2.2. MSC REPARATIVE FUNCTION 
MSC self-renewal and multipotent differentiation enables these cells to maintain, 
replenish, and repair the stromal environment in response to apoptosis, senescence, 
and tissue damage [reviewed by (Huang & S. Li 2008)]. Endogenous perivascular 
MSC have been shown to migrate toward sites of tissue damage in teeth, whereupon 
they aid in the repair process through differentiation into odontoblasts (Feng et al. 
2011). Indeed, ‘bone marrow derived MSC’ (BMMSC) repaired and replaced 
senescent myocardium in 18 month old mice (Khan et al. 2011). Interestingly, the 
age of donor BMMSC negatively correlated with their reparative capacity (Khan et al. 
2011), suggesting their reparative function may diminish with age. Whereas, 
intradermal injection of BMMSC in a murine model of wound repair saw BMMSC-
mediated recruitment of macrophages and endothelial progenitor cells at the site of 
damage, resulting in enhanced repair (Chen et al. 2008). Furthermore, only 
conditioned medium from BMMSC, but not dermal fibroblasts, was found to promote 
endothelial angiogenesis at the wound site and aid tissue repair (Chen et al. 2008; 
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Wu et al. 2007). However, this supportive role of MSC is not always beneficial. For 
instance, at locations where BMMSC have integrated into the intercellular junctions 
of ‘human umbilical vein endothelial cells’ (HUVEC) in vitro, HUVEC apoptosis and 
loss of neocapillary network structure has been observed, along with the release of 
reactive oxygen species (Otsu et al. 2009). Furthermore, BMMSC promoted tumour 
growth when co-injected with B16 melanoma cells in C57BL/6 mice (K. Suzuki et al. 
2011). ‘Umbilical cord derived MSC’ (UCMSC) were also found to contribute to the 
maintenance of vascular integrity in HUVEC by increasing the endothelial expression 
of cell-cell adhesion proteins; ‘vascular endothelial’ (VE)-cadherin and b-catenin 
(Pati, Khakoo, et al. 2011). These studies indicate that MSC can respond and 
migrate toward sites of damage where they utilise their multipotent differentiation 
capacity to replace cells, and paracrine signalling to support tissue proliferation and 
angiogenesis. 
 
1.2.3. MSC MIGRATION: LINKS WITH REPAIR 
Endogenous MSC are enriched within the perivascular niche (Crisan et al. 2008), 
where they are aptly positioned to communicate with the endothelium and influence 
angiogenesis, tissue repair/turnover, vascular permeability, and regulation of 
leukocyte recruitment during inflammation. MSC preferentially migrate toward sites of 
injury and inflammation to exert their reparative and immunomodulatory effector 
functions [reviewed by (Spaeth et al. 2008), also see Section 1.2.4 below]. Stromal 
cells can migrate either as single cells or as a collective group with coordinated 
movements, where both types of migration require a dynamic interaction with the 
substratum on which the cells are attached [reviewed by (Friedl & K. Wolf 2010)]. 
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Collective migration differs in that it requires the retention of cell-cell junctions and 
mostly relies on the coordinated cycles of cellular protrusions at the leading edge, as 
the trailing edge remains adherent to other cells or extracellular matrix components 
(Farooqui & Fenteany 2005). Mesenchymal migration is defined by a multistep cycle 
that involves a synchronised redistribution of the actin cytoskeleton from a 
continuously extending and anchoring cellular protrusion, to stabilisation of the actin 
cytoskeleton at leading edge and eventual detachment of the trailing edge, which 
results in the cell body being pulled forward (Grinnell 2008). Cellular protrusions are 
formed of podosomes, invadopodia, filopodia and lamellipodia [reviewed by (Alblazi 
& Siar 2015)]. Lamellipodia are responsible for driving cell migration through broad 
flat protrusions at the leading edge, whilst filopodia are utilised in cell direction by 
probing the space around the leading edge through thin tubular projections (Suraneni 
et al. 2012). Podosomes and invadopodia are F-actin rich protrusions on the basal 
surface of the cell which contribute to the invasive properties of the cell through 
degradation of the extracellular matrix [reviewed by (Sibony-Benyamini & Gil-Henn 
2012)]. Podosomes are numerous and small at approximately 0.4µm in length and 
1µm in diameter, whilst invadopodia are smaller in diameter and can extend over 
2µm [reviewed by (Alblazi & Siar 2015)]. These cellular protrusions adhere to the 
substratum through regulation of the Rho family of ‘small guanine triphosphate’ 
(GTP)ases, RhoA, Rac1, and Cdc42 (Nobes & Hall 1999). MSC utilise a combination 
of these processes during single cell mesenchymal migration, however the 
mechanisms of the migration-related signalling pathways in MSC specifically are 
poorly defined. 
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In general, ‘Rho-associated protein kinase’ (ROCK) signalling controls retraction of 
the trailing edge through actomyosin-mediated signalling and together with Rac1-
mediated protrusions they form the basis of the migration cycle [reviewed by (Ridley 
2003)]. Rac1 drives mesenchymal-type migration by stabilising lamellipodia 
formation, indeed overexpression of Rac1 in Rat2 fibroblasts resulted in membrane 
ruffling and localisation of Rac1 to the leading edge of the cell (Ridley et al. 1992). 
Rac1 also interacts with RhoA, and RhoA with ROCK in promoting the formation of 
the actin stress fibres required for inducing actomyosin contraction of the cell through 
myosin light chain (MLC) (Ridley et al. 1992; Amano et al. 1997). Blockade of Rac1 
in melanoma cells either with the Rac1 inhibitor (NSC23766) or siRNA targeting Rac1 
impaired mesenchymal migration was shown to confer a rounded ‘amoeboid-like’ 
morphology (Sanz-Moreno et al. 2008). Furthermore, Rac1 formed part of a larger 
signalling cascade with the melanoma metastasis gene ‘neural precursor cell 
expressed developmentally downregulated protein’ (NEDD)9 signalling through 
‘dedicator of cytokinesis’ (DOCK)3, Rac1, and lastly ‘Wiskott-Aldrich syndrome 
protein family member’ (WASF)2, which regulates the ‘actin-related protein’ (Arp)2/3 
complex to promote actin filament reorganisation (Sanz-Moreno et al. 2008). This 
Rac1-involved signalling pathway had the overall effect of promoting mesenchymal 
migration and hindering amoeboid-like migration (Sanz-Moreno et al. 2008). Indeed, 
amoeboid-like migration of cells such as leukocytes has been shown to be separately 
regulated by Rho/ROCK signalling in tumour cells, as shown by the use of inhibitors 
(Rho, TAT-C3; ROCK, Y27632) (Lämmermann & Sixt 2009; Sahai & Marshall 2003). 
These studies demonstrate the generic mechanisms involved in mesenchymal 
migration and how these might be perturbed. 
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1.2.4. MSC TRANSMIGRATION THROUGH ENDOTHELIUM 
MSC-specific migration has mostly been explored in their therapeutic context, with a 
focus on their extravasation into tissue from the circulation [reviewed by (Nitzsche et 
al. 2017)]. This is of importance as few cells reach the target tissue after systemic 
infusion, with most becoming trapped within the lungs (Fischer et al. 2009). Indeed, 
BMMSC have been shown to adhere to HUVEC stimulated with ‘interleukin’ (IL)-1 or 
‘tumour necrosis factor’ (TNF)-a in a dose-dependent manner (Luu et al. 2013). 
However, this only occurred at extremely low flow rates indicating that BMMSC are 
not recruited from flow in the same fashion as leukocytes (see Section 1.2.5 below) 
and are likely to become trapped in smaller vessels given their size. In vitro culture of 
BMMSC on endothelial monolayers have shown them to spread over the surface and 
integrate with the endothelium, the addition of platelets enhanced both BMMSC 
migration in a model of scratch-induced wounds (scratch-wound assay) and 
endothelial integration in a basic fibroblast growth factor (FGF)-dependent manner 
(Langer et al. 2009). Indeed, BMMSC have been shown to transmigrate through 
TNF-a stimulated lung and cardiac microvascular endothelium using CD106 
(VCAM1)-rich gaps in the endothelial monolayer, termed ‘transmigratory cups’, 
whereby BMMSC undergo non-apoptotic membrane blebbing and take on a rounded 
morphology (Teo et al. 2012). Regarding the mechanisms of BMMSC transmigration, 
inhibition of ROCK (Y27632) was shown to promote BMMSC migration through brain 
microvascular endothelium, whilst a phosphoinositide 3-kinase (PI3K) inhibitor 
(LY294002) prevented this process (Lin et al. 2013). Indeed, treatment of prostate 
cancer cells with LY294002 was shown to significantly inhibit cell migration and 
reduce Rac1 activity, suggesting PI3K interacts with Rac1 to promote cell migration 
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(Henderson et al. 2015). MSC were also shown to transmigrate in response to 
external stimuli. Indeed, BMMSC migrated through HUVEC monolayers seeded on 
collagen gels in a ‘C-X-C motif chemokine receptor’ (CXCR)4 dependent manner in 
response to a ‘C-X-C motif chemokine ligand’ (CXCL)12 gradient established in a 
custom microfluidic device (Park et al. 2017). Furthermore, the addition of inhibitors 
against ROCK (Y27632) or Rac1 (NSC23766) significantly impaired CXCL12-
induced migration of BMMSC (Park et al. 2017). All the above studies investigated 
MSC migration through the apical surface of endothelium in an extravasation model, 
whether alternative mechanisms are employed for endogenous MSC migration 
through the basal surface in an intravasation model have yet to be determined. It 
would appear that exogenous factors are capable of influencing the migration of MSC 
toward sites of tissue damage or inflammation whereby they can exert their 
reparative functions. 
 
1.2.5. MSC IMMUNOMODULATORY FUNCTION 
MSC have well-documented immunomodulatory abilities capable of regulating both 
the innate and adaptive immune response through both direct cell contact and a 
range of paracrine factors, such as ‘transforming growth factor’ (TGF)-b, IL-6, 
‘programmed death 1’ (PD-1) ligand, ‘indoleamine 2,3-dioxygenase’ (IDO), and 
‘prostaglandin E2’ (PGE2) (Trivanović et al. 2013). MSC modulation of leukocytes is 
well described within the literature, with most studies focussing on their ability to 
suppress T-cell proliferation [reviewed by (Haddad & Saldanha-Araujo 2014; 
Lotfinegad et al. 2014; Munir & McGettrick 2015)]. Briefly, MSC from different 
sources have been shown to inhibit activated T-cells through IDO-mediated 
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catabolism of tryptophan (Meesuk et al. 2016; François et al. 2012; Meisel et al. 
2004; Ling et al. 2014). Moreover, direct coculture of BMMSC with ‘natural killer’ (NK) 
cells inhibited their proliferation, ‘interferon’ (IFN)-g secretion, and cytotoxic activity 
(Spaggiari et al. 2008). In addition, soluble mediators released by the crosstalk of 
BMMSC with monocytes was sufficient to impair the differentiation into ‘dendritic 
cells’ (DC) and bias differentiation of monocytes towards an anti-inflammatory ‘M2’ 
macrophage phenotype (Jiang et al. 2005; François et al. 2012). Selmani et al., 
(2008) showed that IL-10 induction of HLA-G was capable of attenuating IFN-g 
secretion and cytotoxicity of NK cells, as well as promoting the expansion of 
regulatory T-cells (Selmani et al. 2008). Whilst MSC are clearly capable of directly 
suppressing leukocyte function in inflamed tissue, we will focus on their ability to 
regulate endothelium and hence hinder entry of the inflammatory infiltrate into 
underlying tissue. 
 
Adhesion assays represent a robust means of investigating the mechanism by which 
MSC modulate endothelium and the resulting effect on leukocyte recruitment. Static 
adhesion assays enable high-throughput analysis of leukocyte adhesion to 
endothelial monolayers. Leukocytes can be labelled to roughly determine adhesion to 
endothelium by measuring the fluorescent signal for each well with a microplate 
reader. Conditioned medium can also be collected from MSC and used to pre-treat 
the endothelium in these assays to determine the impact of soluble 
immunomodulatory factors. Indeed, conditioned medium generated from BMMSC 
coculture with pulmonary endothelium (PEC), but not monoculture controls, was 
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shown to decrease the surface expression of CD54 (ICAM1) and VCAM1 on TNF-a 
stimulated PEC (Pati, Gerber, et al. 2011). This was associated with a reduction in 
the adhesion of a calcein-labelled monocytic leukaemia cell line (U937) to PEC, as 
measured by a microplate reader (Pati, Gerber, et al. 2011). Phase-contrast 
microscopy of adherent leukocytes will permit further analysis in their ability to 
transmigrate through the endothelial monolayer where they take on a phase-dark 
morphology. In-depth analysis of migration is better suited to a 3D multicellular 
collagen gel construct where leukocytes can be tracked as they migrate through the 
endothelium and penetrate through the gel in the presence of stromal cells (Jeffery et 
al. 2013). However, these static assays are primarily limited in that the cells aren’t 
exposed to flow-derived shear stress, overlooking rolling capture mechanics and 
instead biasing adhesion through the sedimentation of leukocytes. Alternatively, flow-
based adhesion assays have enabled us to better our understanding of the different 
stages of leukocyte recruitment by mimicking in vivo conditions. This methodology 
has also demonstrated stromal cells to be potent regulators of the inflammatory 
infiltrate through their ability to regulate endothelium, though the response differs with 
the source of stroma [reviewed by (McGettrick et al. 2012)]. Indeed, both neutrophil 
and lymphocyte adhesion to inflamed HUVEC are reduced in MSC coculture 
compared to controls (Munir et al. 2016; Luu et al. 2013). However, UCMSC and 
‘trabecular bone-derived MSC’ (TBMSC) required proximity to the endothelium (i.e. 
neighbouring on opposite sides of a filter) to exert these effects, whereas, BMMSC 
could exert suppressive actions distally (Munir et al. 2016). This indicated tissue 
specific differences in the degree of cell contact or utility of soluble mediators was 
required for the communication of MSC with endothelium. Further interrogation 
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revealed the mechanism of suppression to occur through the release of soluble 
mediators, namely IL-6, in coculture, which signalled via the ‘suppressor of cytokine 
signalling’ (SOCS)3 to regulate endothelial responses to TNF-a stimulation (Figure 1-
1) (Luu et al. 2013). Collectively, these studies demonstrate that MSC suppress the 
endothelial response to inflammation, through crosstalk with soluble mediators. Fully 
understanding the mechanisms by which this occurs in different tissues will allow the 
development of therapeutic targets capable of reducing leukocyte-mediated tissue 
damage in chronic inflammatory diseases. However, further work is required to 
understand whether these cross-talk pathways are modified at sites of acute and 
chronic inflammation.   
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1.2.6. NEUTROPHIL RECRUITMENT CASCADE 
This thesis will partly focus on MSC immunomodulation of endothelium, using 
neutrophil recruitment as a readout and thus necessitating a brief overview of this 
process [reviewed by (Kolaczkowska & Kubes 2013)]. The recruitment of neutrophils 
into tissue typically occurs in the post-capillary venules in response to endothelial 
activation by pro-inflammatory mediators and upregulation of adhesion molecules 
(Sadik et al. 2011). The post-capillary venules are subject to low haemodynamic 
shear, under which conditions erythrocytes stack together into larger aggregates 
known as rouleaux in the centre of blood vessels (Goldsmith & Spain 1984). The 
increased density of erythrocytes in the centre of the vessel forces leukocytes and 
platelets to the circumference of the vessel, proximal to the endothelial lining in a 
process known as margination (Goldsmith & Spain 1984).  
 
Initial capture is mediated through tethering and rolling of neutrophils along the apical 
surface of the endothelium via transient interactions with selectin molecules (CD62) 
(McEver 2002). During rolling, neutrophils are exposed to CXCL-2, -5, and -8 
presented on the endothelium by heparin sulfate, which induce an activating 
conformational change in the ligand-binding domains of β2-integrins (CD11a/CD18 
and CD11b/CD18) heterodimers [reviewed by (Mould & Humphries 2004)]. This 
change enables prolonged interactions with rolling neutrophils, causing them to come 
to a complete arrest through CD11a/CD18 complex binding to ICAM1 (Smith et al. 
1989). Arrest is followed by cytoskeletal reorganisation and intraluminal crawling of 
neutrophils toward endothelial junctions (Phillipson et al. 2006).  
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Transendothelial migration of neutrophils into the tissue can occur either by 
paracellular or transcellular means, through interactions with cell adhesion 
molecules, CD31 (PECAM1), CD99, and ‘junctional adhesion molecules’ (JAMs) 
[reviewed by (Hyun & Hong 2017)]. After migrating through the endothelial lining, 
neutrophils must then navigate the basement membrane and pericytes in a process 
known as abluminal crawling, with pericytes shown to enhance neutrophil 
transmigration in vivo by intravital microscopy in mice (Proebstl et al. 2012). In some 
instances, neutrophils are capable of ‘reverse migration’, whereby they intravasate 
from the abluminal space in a stimulus specific manner (Colom et al. 2015). 
Otherwise, neutrophils continue to infiltrate into the inflamed tissue in response to 
CXCR2 ligand gradients, whereupon they exert their effector functions [reviewed by 
(Sadik et al. 2011)].  
 
As indicated above, endothelial cells act as reporters of their local environment with 
their responses either facilitating or hindering the recruitment cascade. Indeed, 
endothelial monocultures may not accurately reflect the physiological situation, thus 
highlighting the importance of establishing stromal coculture for the inflammatory site 
of interest. Conversely, chronically inflamed endothelium may also modify MSC 
function and thus leukocyte recruitment. 
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1.3. MSC RESPOND TO ENVIRONMENTAL CUES 
1.3.1. REGULATION OF MSC DIFFERENTIATION  
MSC differentiation can be regulated through a variety of means as illustrated below: 
Stimulation of BMMSC with TGF-b over 6 days was sufficient to induce differentiation 
into a smooth muscle cell (SMC) phenotype based on expression of SMC markers 
such as alpha smooth muscle actin when compared to untreated controls (Ross et al. 
2006). Alternatively, BMMSC differentiation into osteoblasts (as determined by MSC 
mineralisation and expression of osteogenic genes such as BMP2 and RUNX2) was 
induced through vibrations of a nanoscale amplitude in the absence of soluble 
osteogenic differentiation factors (Tsimbouri et al. 2017). The same effect was 
observed through changes in the tension of BMMSC extracellular matrix, with rigid 
gels (34 kPa) also biasing toward an osteogenic transcriptional profile, whereas 
intermediate (11 kPa) or soft gels (1 kPa) were associated with myogenic and 
neurogenic markers respectively (Engler et al. 2006). These responses were often 
dependent on the tissue specific microenvironment, with soluble factors, mechanical 
strain, and the extracellular matrix all applying various outcomes on MSC reparative 
function and the lineage MSC differentiate down. These aspects of MSC biology are 
of importance to the regenerative medicine field. 
 
1.3.2. ENVIRONMENTAL REGULATION OF MSC MIGRATION  
With regard to the role of the microenvironment on MSC migration, overexpression of 
hypoxia-inducible factor (HIF)-1a resulted in significantly increased ‘dental pulp-
derived MSC’ (DMSC) migration in the closure of scratch-wound assay and in a 
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model of single cell migration across a porous filter (transwell assay) (Ciria et al. 
2017). The addition of a gamma-secretase ‘RO4929097’ inhibitor that impairs Notch 
receptor processing abrogated this response, thus implicating the Notch signalling 
pathway in HIF-1a induced DMSC migration (Ciria et al. 2017). Indeed, HIF-1a has 
been shown to regulate BMMSC migration in a transwell assay through increased 
expression of the signalling proteins ROCK1 and Rac1/2/3 which are involved in 
regulating cell motility through the actin cytoskeleton (Choi et al. 2016). These 
studies indicate that MSC migration is enhanced by hypoxic environments. 
 
The presence of certain cytokines and chemokines within the stromal 
microenvironment are also capable of promoting MSC migration. The MSC tissue 
source (bone marrow, adipose, or gingival) was shown to have no effect on collective 
migration in scratch-wound assays, however stimulation with IL-3 significantly 
increased wound closure compared to untreated controls (Barhanpurkar-Naik et al. 
2017). IL-3 treatment was also found to upregulate (bone marrow, adipose, or 
gingival) MSC expression of CXCR4, to a similar extent as pro-inflammatory 
cytokines TNF-a and IL-17A, and enhanced MSC chemotaxis toward CXCL12 in 
transwell assays (Barhanpurkar-Naik et al. 2017). Indeed, BMMSC 
migration/chemotaxis through transwells has been shown to be enhanced by a 
number of factors including IL-6, CXCL12, ‘vascular endothelial growth factor’ 
(VEGF), or FGF (Schmidt et al. 2006). TGF-b1 has also been shown to act as an 
TBMSC chemoattractant in vivo when it is released from the trabecular surface 
during osteoclast bone remodelling (Yi Tang et al. 2009). Indeed, BMMSC migration 
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was significantly impaired in Tgfb1-/-Rag2-/- mice (Yi Tang et al. 2009). In contrast, 
TGF-b-mediated MSC migration has been reported to detrimental contributing to the 
progression of arterial calcification in mice (W. Wang et al. 2014). TGF-b release 
from injured endothelium was found to increase numbers of circulating MSC and their 
subsequent recruitment to arteriolar lesions, whereupon vascular calcification was 
driven through osteogenic differentiation (W. Wang et al. 2014). Thus, MSC migration 
is dependent on the context of their microenvironment. However, the exact 
mechanisms and circumstances by which MSC enter the circulation in response to 
environmental factors is unknown. 
 
The expression of certain surface markers are also associated with enhanced 
migratory function. Indeed, the ‘pseudo tyrosine kinase receptor’ (PTK)-7 is found to 
be overexpressed in colorectal cancers where it confers increased motility when 
tracked in vitro and increased metastatic potential in a mouse xenograft model 
(Lhoumeau et al. 2015). The ‘collagen triple helix repeat containing’ (CTHRC)-1 is a 
similar marker found to promote the migration of ‘synovial fibroblasts isolated from 
‘rheumatoid arthritis’ (RA) patients’ (RASF) (Shekhani et al. 2016). Furthermore, 
CTHRC-1 was induced by the inflammatory environment with expression significantly 
increased compared to normal synovium (Shekhani et al. 2016). Another pro-
migratory marker that is upregulated by the inflammatory environment is the 
glycoprotein PDPN (Del Rey et al. 2014; Payne et al. 2017; Inoue et al. 2015), which 
colocalises with CD44 at plasma membrane protrusions to promote directional cell 
migration (Martin-Villar et al. 2010). Thus, expression of cell surface markers confer 
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prolonged changes to stromal cell function in response to their environment, here we 
will focus on the role of PDPN in this response as discussed below. 
 
1.3.3. ROLE OF PODOPLANIN IN REGULATING STROMAL CELL MIGRATION 
PDPN is a 43-kD, heavily glycosylated, mucin-type, transmembrane protein 
(Breiteneder-Geleff et al. 1997). It is enriched at cellular protrusions where its short 
cytoplasmic tail directly interacts through the ezrin, radixin, moesin (ERM) family of 
proteins to connect with the actin cytoskeleton (Martín-Villar et al. 2006). PDPN is 
typically expressed by kidney podocytes, lymphatic endothelial cells, lymphoid 
stromal cells, thymic epithelial cells, and inflammatory macrophages (Breiteneder-
Geleff et al. 1997; Farr et al. 1992; Schacht et al. 2003; Kerrigan et al. 2012).  
 
PDPN function is linked with cell migration, as well as cancer invasiveness and 
metastasis (Yuan et al. 2006; Kunita et al. 2007; Y.-Y. Li et al. 2015; Takemoto et al. 
2017; Takagi et al. 2014; Yurugi et al. 2017; Wicki et al. 2006; Martin-Villar et al. 
2010; Martín-Villar et al. 2006). Incidentally, PDPN is induced in cancer-associated 
fibroblasts (CAF) in response to hypoxia, with its expression promoting migration and 
invasion (Wicki et al. 2006; Tejchman et al. 2017; Neri et al. 2015). PDPN is also 
upregulated on stroma in hypoxic tissues, such as cancer and RA (Schacht et al. 
2005; Croft et al. 2016; Del Rey et al. 2014), though its role on stromal cell migration 
is still under debate. However, hypoxia was previously shown to promote MSC 
migration (Ciria et al. 2017; Choi et al. 2016). Importantly, we have recently 
demonstrated that UCMSC differentially express PDPN (Dr L Sheriff, University of 
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Birmingham, 2017, personal communication), indicating that it may have a role in 
MSC function, in particular their migration.  
 
The mechanisms by which MSC intravasate into the circulation, particularly with 
regard to the endogenous MSC ‘homing’ literature have not been described. A 
popular source of these circulating MSC-like cells are derived from the process of 
epithelial-mesenchymal transition (EMT), whereby epithelial cells lose apical-basal 
polarity and reorganise their cytoskeleton to take on a motile and invasive phenotype 
[reviewed by (Lamouille et al. 2014)]. Indeed, Martín-Villar et al., (2006) showed that 
PDPN induces EMT in ‘Madin-Darby canine kidney‘ (MDCK) cells through 
interactions with ‘ezrin, radixin, and moesin’ (ERM) proteins at the cytoplasmic tail of 
PDPN and subsequent activation of RhoA GTPase (Martín-Villar et al. 2006). 
However, the exact role of EMT in tumour pathogenesis is under debate. 
Transfection of PDPN into CHO cells was shown to promote pulmonary metastasis 
formation compared to PDPN-negative controls through formation of platelet 
aggregates when injected intravenously into mice (Kunita et al. 2007). Indeed, 
Takemoto et al., (2017) recently demonstrated that PDPN-mediated activation of 
platelets aids invasion through the endothelial lining via the release of platelet TGF-b 
inducing EMT of tumour cells (Takemoto et al. 2017). Furthermore, FGF derived from 
activated platelets was also shown to promote BMMSC migration and their 
integration with the endothelial monolayer (Langer et al. 2009). The role of PDPN 
and the intravasation capacity of MSC requires much work, even though the process 
of MSC luminal to abluminal transmigration has been studied in detail. 
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With regard to protein interactions, PDPN is the only known ligand for CLEC-2, with 
expression of CLEC-2 in platelets, neutrophils, B-cells, and dendritic cells (Lowe et 
al. 2015). PDPN mediates the migration of lymphatic endothelium (LEC), with 
crosslinking of PDPN inhibiting vascular endothelial growth factor (VEGF)-induced 
migration of lymphatic endothelium in a transwell assay (Langan et al. 2017). 
Furthermore, the presence of the PDPN receptor, CLEC-2 on platelets also impaired 
VEGF-induced LEC migration (Langan et al. 2017). This suggests that activation of 
PDPN inhibits its associated functions. Indeed, recombinant CLEC-2 was found to 
inhibit PDPN-mediated contraction of fibroblastic reticular cells (Astarita et al. 2015). 
We have recently described the first instance of PDPN expression in UCMSC, 
however its role and mechanism of action in the migration of UCMSC has yet to be 
determined (Dr L Sheriff, University of Birmingham, 2017, personal communication).  
 
Discrepancies have been observed in downstream signalling of PDPN. 
Overexpression of PDPN in several adenocarcinoma cell lines (MSU1.1, Hs578, 
MDCK, and MCF7) resulted in increased RhoA, but no effect on Cdc42 or Rac1 
(Martín-Villar et al. 2006; Suchanski et al. 2017), whilst another study saw decreases 
in all three GTPases (Wicki et al. 2006). Furthermore, knockdown of PDPN in 
lymphatic endothelium resulted in reduced RhoA expression, but increased Cdc42 
expression (Navarro et al. 2011). It appears that downstream signalling for PDPN 
varies between different cell types, though all studies demonstrated that expression 
of PDPN conferred a pro-migratory phenotype on these cells. The significance of this 
and the GTPase linked to PDPN in MSC remains unclear. However, it could be 
General introduction 
 21 
dependent on the preferred form of migration by these cell types, whether that be 
amoeboid- or mesenchymal-like migration. 
 
PDPN is thought to interact with other surface proteins on the parent cell to modify its 
signal transduction and functional consequences [reviewed by (Astarita et al. 2012)]. 
Colocalisation of the tetraspanin CD9 with PDPN, inhibited PDPN-mediated 
pulmonary metastasis and platelet aggregation when PDPN-positive ‘Chinese 
hamster ovary cells’ (CHO) were intravenously administered (Nakazawa et al. 2008). 
CD44 also colocalises with PDPN at cellular protrusions in HN5 oral carcinoma and 
transfected MDCK cells, both PDPN and CD44 were required for directional cell 
migration, as shown by siRNA knockdown of CD44 (Martin-Villar et al. 2010). It is 
possible that changes in the co-receptors linked with PDPN may influence the 
downstream signalling elicited and ultimately the functional output from PDPN 
engagement.  
 
1.3.4. EFFECT OF ACUTE INFLAMMATION ON MSC FUNCTION 
MSC appear to be primed by inflammatory cytokines with augmented functions 
conferred (Table 1-1, Table 1-2). Some of which are beneficial: as observed with 
inflammation-induced secretion of TGF-b3 by BMMSC reducing tissue fibrosis 
through the impaired proliferation and extracellular matrix deposition of 
myofibroblasts (Wu et al. 2015). Indeed, resolution of fibrosis through secretion of 
TGF-b3 could hold true for similar studies, where the administration of MSC in rat 
models of chemically or surgically induced tissue damage was associated with a 
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reduction of fibrosis at the site of injury (Abdel Aziz et al. 2007; Semedo et al. 2009; 
L. Li et al. 2008). Attempts to model acute inflammation in vitro using cytokine 
priming models have enabled a cause and effect study of MSC responses to specific 
stimuli, but with conflicting results (Table 1-1). Treatment of UCMSC with TNF-a or 
lipopolysaccharide (LPS) over 48 hours increased the expression and secretion of 
both TGF-b1 and TGF-b3 when compared to unstimulated controls (Wu et al. 2015). 
However, 6-hour priming of murine BMMSC with IFN-g or TNF-a increased PGE2 
secretion and HGF expression, but decreased TGF-b1 secretion (English et al. 
2007). Furthermore, 72-hour IFN-g pre-treatment increased PGE2 secretion and IDO 
activity in both BMMSC and UCMSC, but 72-hour TNF-a treatment decreased 
hepatocyte growth factor (HGF) secretion in UCMSC (Prasanna et al. 2010). 
Differences in TGF-b1 secretion and HGF expression might be accounted for by 
species-specific responses, or that prolonged priming may induce refractory HGF 
expression.  
 
Stimulation of MSC toll-like receptors (TLR) appears to induce differential 
inflammatory responses. TLR-3 activation of MSC promotes neutrophil survival in 
vitro through MSC secretion of IL-6, IFN-b, and granulocyte macrophage colony-
stimulating factor (Cassatella et al. 2011; Raicevic et al. 2011; Liotta et al. 2008). The 
same survival response is observed with TLR-4 stimulation, but with the additional 
secretion of the neutrophil chemoattractants, CXCL8 and CXCL10 by MSC (Brandau 
et al. 2010; Raicevic et al. 2011; Liotta et al. 2008). However, Waterman et al., 
(2010) reported that BMMSC are ‘polarised’ to an anti-inflammatory or pro-
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inflammatory phenotype with TLR-3 or TLR-4 stimulation respectively (Waterman et 
al. 2010). Specifically, PGE2 secretion increased, TGF-b1/3 expression decreased, 
and IDO expression increased in response to TLR-3 stimulation with poly(I:C), 
whereas TLR-4 priming with LPS caused BMMSC to deposit more collagen 
(associated with fibrosis) and no longer suppress T-cell proliferation (Waterman et al. 
2010). These studies would suggest that ISCT criteria used to define MSC do not 
describe a homogenous population of cells, indeed numerous factors such as; donor 
age and species, isolation methodology, culture conditions, tissue-source, and 
experimental parameters can all modify the experimental outcome. 
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In other instances, cytokine priming directly modifies the immunomodulatory function 
of MSC on other cells (Table 1-2) [reviewed by (Najar et al. 2017; Lee et al. 2015)]. 
Briefly, IL-10 stimulation potentiates BMMSC function through the release of another 
soluble factor, HLA-G5 (Selmani et al. 2008). HLA-G5 attenuated natural killer cell 
IFN-g secretion and cytotoxicity, as well as promoting BMMSC suppression of T-cell 
proliferation and the expansion of regulatory T-cells, though the mechanisms of 
action were unknown (Selmani et al. 2008). Thus, MSC are likely to respond to 
changes in their microenvironment that may have beneficial or adverse effects on 
their function – aiding resolution or contributing to pathology. Whether prolonged 
priming with cytokines or environmental changes influences the ability of MSC to 
regulate leukocyte recruitment is unclear. Further work to delineate the mechanisms 
involved and any tissue specific, disease specific responses is required. 
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1.4. TRANSFORMATION OF STROMA IN DISEASE 
MSC immunomodulation can be either pro-inflammatory or anti-inflammatory 
depending on the context of their microenvironment [reviewed by (Bernardo & Fibbe 
2013)]. Other stromal cells from sites of chronic inflammation acquire a transformed 
phenotype. As is the case with RA, whereby RASF lose their ability to suppress 
recruitment of lymphocytes to cytokine-stimulated HUVEC compared with fibroblasts 
from non-inflamed sites (Filer et al. 2017). Even to the extent that RASF were 
capable of promoting lymphocyte recruitment in the absence of cytokine treatment 
(Filer et al. 2017). However, the effect of the chronic inflammatory environment on 
MSC function is unclear. 
 
Ex vivo studies have shown that BMMSC isolated from RA patients displayed an 
altered transcriptional profile, with reduced proliferative capacity, senescent 
morphology, and impaired support of haematopoiesis compared to healthy controls 
(Kastrinaki et al. 2008; Papadaki et al. 2002). Furthermore, Kastrinaki et al., (2008) 
also noted a reduction in gene expression of cyclin-D and upregulation of its 
inhibitors in RA BMMSC compared to healthy controls, which was suggested to be 
attributable to exhaustive replicative senescence in response to chronic inflammation 
(Kastrinaki et al. 2008) (Table 1-3). 
 
These functional abnormalities were also observed in BMMSC isolated from patients 
with ‘immune thrombocytopenic purpura’ (ITP), whereby their proliferative capacity 
and ability to suppress activated T-cell proliferation was impaired compared to 
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healthy controls (Pérez-Simón et al. 2009) (Table 1-3). Indeed, several studies have 
also reported that BMMSC from systemic lupus erythematosus (SLE) exhibit a low 
proliferative rate (L. Sun et al. 2007; Nie et al. 2010). SLE-derived BMMSC also 
showed a significant reduction in IL-6 and IL-7 gene expression (L. Sun et al. 2007), 
impaired osteogenesis (Yu Tang et al. 2013), and a senescent morphology (Nie et al. 
2010) (Table 1-3). A caveat of these studies is that they were all performed using 
BMMSC, where only systemic inflammatory factors would reach this compartment. 
As of yet, no work has investigated differences in MSC functional capacity when 
isolated from the chronically inflammatory microenvironment compared to healthy 
tissue.
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Interestingly, MSC that have undergone a high number of passages in culture lose 
their capacity to suppress neutrophil adhesion to endothelium (Munir et al. 2016). 
However, tissue-specific differences appear to occur with UCMSC retaining their 
immunosuppressive capacity at higher passages than their BMMSC counterparts 
(Munir et al. 2016). This may hint that inflammation-induced replicative senescence 
of MSC impairs their immunomodulatory function. Conversely, oncogenic 
transformation of BMMSC in several sarcoma models showed significantly increased 
proliferative capacity of BMMSC compared to healthy or non-immortalised controls, 
but an inability to suppress activated T-cell proliferation (Rodriguez et al. 2014). 
Moreover, healthy BMMSC have been shown to upregulate gene expression of the 
immunomodulatory components, IL-6 and IDO in response to culture in 20% synovial 
fluid from osteoarthritis patients (van Osch 2012). Whilst MSC differentiation usually 
repairs damaged tissue, it can also be detrimental and sometimes an undesirable by-
product of disease. Indeed, ectopic fat deposits have been reported in inflammatory 
arthritis (Arend et al. 2013), type II diabetes (Goodpaster & D. Wolf 2004), and 
Duchenne muscular dystrophy (Uezumi et al. 2010). In addition, BMMSC-derived 
adipocytes have been shown to lose their ability to suppress neutrophil recruitment to 
TNF-a stimulated endothelium (Munir et al. 2017). However, mature adipocytes or 
MSC-derived from adipose tissue retain this suppressive function (Munir et al. 2017). 
These few examples demonstrate the ways in which MSC may experience change of 
phenotype and function as a result of their microenvironment. However, there isn’t 
sufficient evidence within the literature to state whether MSC are modified at sites of 
chronic inflammation. 
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1.5. ROLE OF PDPN IN VASCULAR BIOLOGY AND THROMBOINFLAMMATION 
The physiological function of PDPN is mostly unknown, but appears to have roles in 
cell migration (see Section 1.3.3), platelet aggregation, and epithelial-mesenchymal 
transition (Kato et al. 2003; Wicki & Christofori 2007; Wicki et al. 2006). 
Overexpression of ‘prospero homeobox protein’ (Prox)1 in blood vascular endothelial 
cells induces PDPN expression and differentiation into lymphatic endothelium, as 
evidenced through adoption of a lymphatic transcription profile (Petrova 2002). 
However, deletion of Prox1 in mice prevents formation of the lymphatics (Wigle & 
Oliver 1999), suggesting that PDPN is required lymphatic development. Indeed, 
PDPN knockout mice die at birth from lymphedema and respiratory failure (Schacht 
et al. 2003). Whilst, an inducible deletion of T-synthase, which regulates O-
glycosylation in the extracellular domain of PDPN causes leakage of blood into the 
lymphatics, suggesting that o-glycosylation is required for PDPN function (Fu et al. 
2008). Deletion of the PDPN receptor in Clec2-/- bone marrow chimaera mice 
resulted in similar bleeding at mucosal lymph nodes to that observed in PDPN 
knockouts. Finally, post-natal deletion of PDPN in lymphatic endothelium resulted in 
impaired dendritic cell migration toward the lymph nodes and blood-filled lymphatics 
(Bianchi et al. 2017). These data highlight an important role for PDPN/CLEC-2 
interactions in the embryonic development of the blood and lymphatic vasculature, as 
well as in the maintenance of vascular integrity in adult tissue. 
 
Platelets are now recognised as active participants in the inflammatory response, 
with overarching roles in leukocyte recruitment [reviewed by (Ed Rainger et al. 
2015)], maintenance of inflamed vascular integrity [reviewed by (Ho-Tin-Noé et al. 
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2011)], liver regeneration and fibrosis [reviewed by (Chauhan et al. 2016)], as well as 
metastasis and thromboinflammation [reviewed by (Franco et al. 2015)]. Under 
normal conditions platelet CLEC-2 cannot interact with PDPN due to separation of 
the stromal and circulatory compartments by the endothelial lining. However, PDPN 
is upregulated in the perivascular space in response to hypoxia-induced sterile 
inflammation (Payne et al. 2017). Surprisingly, Payne et al., (2017) demonstrated 
that blocking PDPN-CLEC2 interactions regulates the size of thrombi (Payne et al. 
2017). However, the mechanisms by which these PDPN/CLEC-2 interactions occur 
are unknown.  
 
During inflammation platelet CLEC-2 has been shown to be an essential component 
in maintaining vascular integrity, with thrombocytopenic CLEC-2 knockout mice 
having inflammation-induced haemorrhage (Boulaftali et al. 2013). Boulaftali et al., 
(2013) suggested that CLEC-2 activation by PDPN inhibits the leakage of platelets 
from hyperpermeable vessels during inflammation, though the mechanisms 
regulating this were not deciphered (Boulaftali et al. 2013). Herzog et al., (2013) 
reported that the integrity of ‘high endothelial venules’ (HEV) is maintained by 
sphingosine-1-phosphate (S1P) release from platelets in response to CLEC-2 
activation by PDPN-expressing fibroblastic reticular cells (Herzog et al. 2013). S1P 
upregulates HEV cadherin expression and thus was suggested to prevent the blood-
filled lymph nodes observed in CLEC-2 knockout mice (Herzog et al. 2013). These 
data indicate the importance of PDPN/CLEC-2 interactions (i.e. stromal-platelet 
interactions) in the maintenance of vascular integrity and prevention of haemorrhage 
during inflammatory responses. This raises the question as to whether perivascular 
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PDPN expressing MSC may interact with CLEC-2 on circulating platelets during 
inflammation to elicit a protective vascular response. 
 
PDPN expression is elevated in pathological conditions (Kawase et al. 2008; Shields 
et al. 2010; Inoue et al. 2015; Payne et al. 2017). Indeed, fibroblasts from a pro-
inflammatory environment, such as those in the synovial lining of RA, constitutively 
express PDPN and can further upregulate expression in response to IL-1b or TNF-a 
stimulation (Del Rey et al. 2014; Ekwall et al. 2011; Croft et al. 2016). In contrast, 
TGF-b has been shown to upregulate PDPN in fibrosarcoma (H. Suzuki et al. 2008), 
but not RASF (Croft et al. 2016). Whilst upregulated PDPN expression is associated 
with pathology, it may not be directly contributing to pathogenesis. For example, 
interactions between PDPN and CLEC-2 have been shown to suppress inflammation 
and tissue damage in an inducible Clec1b deleting mouse model of inflammatory 
arthritis (Desanti et al. 2017). However, the mechanism of this protective outcome is 
unknown. 
 
Many systemic inflammatory disorders predispose to thrombosis in a process known 
as thromboinflammation, though its pathogenesis varies widely and includes 
disorders such as Behçet disease, RA, SLE, and inflammatory bowel disease 
[reviewed by (Aksu et al. 2012)]. Hyperglycemia is strongly associated with acute 
ischaemic stroke (Muir et al. 2011). Rat models of hyperglycemia also observe 
thrombosis of the post-capillary venules at sites of neutrophil and platelet adhesion 
(Desilles et al. 2017). Indeed, scanning electron micrographs of TNF-a stimulated 
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inferior vena cava in mice saw localisation of thrombi to sites of increased leukocyte 
transmigration (Eriksson et al. 2005). Platelet counts were also shown to be 
significantly reduced in patients with PDPN-positive brain tumours, and were 
associated with a high incidence of venous thromboembolism (Riedl et al. 2017). 
Finally, thrombosis can observed at disrupted atherosclerotic lesions, with these 
plaques typically harbouring PDPN-positive stroma and macrophages, particularly 
where necrotic cores are present (Hatakeyama et al. 2012; Inoue et al. 2015). 
Overall, these studies show a possible link between areas of increased leukocyte 
transmigration and the subsequent formation of thrombi, with PDPN being a possible 
culprit for inducing platelet activation in thromboinflammation. 
 
In an S. Typhimurium mouse model of systemic non-sterile inflammation, PDPN-
mediated platelet coagulation induces localised thrombosis which serves to contain 
bacteria and contribute toward its clearance (Hitchcock et al. 2015). Infection resulted 
in extensive liver thrombosis at sites of perivascular inflammation, typically within 
branches of the portal vein (Hitchcock et al. 2015). Confocal microscopy of liver 
vasculature identified an upregulated expression of PDPN in the perivascular space 
with thrombus formation at openings within the endothelial lining. Clodronate-loaded 
liposome treatment saw depletion of both phagocytic macrophages and thrombi 
within the liver, but little effect on liver PDPN staining at inflammatory lesions 
(Hitchcock et al. 2015). This suggests that in non-sterile inflammation, thrombosis is 
driven by platelet CLEC-2 interactions with PDPN-expressing inflammatory 
macrophages. However, PDPN-expressing inflammatory macrophages were 
localised deeper within the stroma, with another population of CD105+ PDPN+ cells 
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proximal to the endothelium (Hitchcock et al. 2015). In RA, CD105+ PDPN+ cells 
describe RASF whose interactions with resident macrophages are essential for the 
resulting inflammatory response [reviewed by (Kinne et al. 2007)]. These data 
suggest an underlying role for perivascular PDPN expression by stromal cells in 
inflammation-induced thrombosis, however it is unclear what the outcome of these 
stromal-myeloid interactions are as well as the mechanism by which PDPN is 
presented to platelet CLEC-2. We hypothesise that perivascular MSC express PDPN, 
utilising its invasive properties to present PDPN to circulating platelets and induce 
their activation. 
 
1.6. HYPOTHESIS AND AIMS 
Depending on the context of their microenvironment perivascular stromal cells such 
as MSC are capable of suppressing leukocyte recruitment to inflamed endothelium 
(Luu et al. 2013; Munir et al. 2016; Filer et al. 2017; Munir et al. 2017). However, 
chronic inflammatory disorders are associated with excessive immune infiltrates. 
Therefore, the inflammatory microenvironment may transform MSC in such a way 
that they are rendered ineffective or take on a stimulatory role in promoting 
pathogenesis. Expression of the protein PDPN is also associated with the 
inflammatory microenvironment, with contact of its receptor, CLEC-2 inducing platelet 
activation (Ekwall et al. 2011; Inoue et al. 2015; Payne et al. 2017; Hitchcock et al. 
2015). However, the mechanism by which these proteins interact at inflammatory 
sites and the function of such an interaction is unclear. Therefore, we hypothesise 
that (i) MSC modulation of endothelium is transformed in chronic inflammation; (ii) 
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that perivascular MSC expression of PDPN has implications in thromboinflammation 
or maintenance of vascular integrity. With this in mind, the aims of this project were: 
1. To assess in vitro models of neutrophil recruitment. 
2. To determine the effect of exogenous TNF-a priming on the transcription 
profile of MSC and their modulation of endothelium. 
3. To characterise PDPN expression and function in MSC. 
4. To assess signalling pathways downstream of PDPN. 
5. To determine the mechanism by which perivascular PDPN interacts with 
CLEC-2 on circulating platelets. 
  
 
 
 
Chapter 2. METHODS 
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2.1. ETHICS 
The study was conducted in compliance with the Declaration of Helsinki. All 
samples were obtained with written, informed consent and approval. ‘Umbilical 
cord-derived MSC’ (UCMSC) and HUVEC were sourced with approval of the 
Human Biomaterial Resource Centre (Birmingham, UK; 12-073) and the North 
East – Tyne & Wear South Ethics Committee (Birmingham, UK; 15-NE-0285) 
from umbilical cords obtained from women undergoing elective caesarean 
section. Fibroblasts were sourced with approval of the West Midlands and Black 
Country Research Ethics Committee (07H1204191) from synovial tissue 
obtained from patients undergoing joint replacement therapy. Whole blood was 
sourced from healthy adult volunteers with approval of the University of 
Birmingham Local Ethical Review Committee (ERN-12-0079). 
 
2.2. CELL ISOLATION AND CULTURE 
2.2.1. HUMAN MESENCHYMAL STROMAL CELLS FROM UMBILICAL CORD 
UCMSC were isolated by enzymatic digestion from umbilical cords as 
previously described (Munir et al. 2015). Briefly, a bilateral incision was made 
through the amnion. Vessels were resected and the remaining Wharton’s jelly 
and amnion washed of residual blood with ‘phosphate-buffered saline’ (without 
calcium and magnesium; PBS; Sigma-Aldrich, Dorset, UK) before roughly 
cutting into 2mm3 pieces with a 10A scalpel (Swann-Morton, Sheffield, UK). The 
diced tissue was incubated with 1mg/mL clostridium histolyticum collagenase 
type II and 50U/mL bovine hyaluronidase (both Sigma-Aldrich) in ‘phosphate-
buffered saline’ (with calcium and magnesium; PBS+) at 37°C for 5 hours on a 
Methods 
 39 
tube roller (Cole-Parmer, Staffordshire, UK). Remaining tissue fragments were 
removed by diluting in five volumes of PBS prior to filtration through a 100µm 
cell strainer (Greiner Bio-One, Stonehouse, UK). The filtered cell suspension 
was centrifuged at 400g for 10 minutes, before washing the pellet in PBS and 
centrifuging at 400g for 5 minutes at room temperature. The pellet was re-
suspended and subsequently cultured in ‘MSC low glucose medium’ (MSCLG), 
which consists of ‘Dulbecco’s modified Eagle medium’ (DMEM) - low glucose 
formulation (Biosera, Boussens, France) supplemented with 10% foetal bovine 
serum (FBS), 100U/ml penicillin, and 100µg/ml streptomycin (all from Sigma-
Aldrich) and seeded into a ‘75cm2 tissue culture treated flask’ (T75; BD Falcon, 
Scientific Laboratory Supplies, Nottingham, UK) before incubating at 37°C and 
5% CO2. MSCLG was initially replaced after 24 hours, and then every 3 days. 
The cells were subcultured at a ratio of 1:3 (Section 2.3). The cells were used in 
experiments or cryopreserved (Section 2.4) at passage three unless stated 
otherwise. All donors were phenotyped according to ISCT guidelines (Section 
1.2.1) (Dominici et al. 2006). 
 
2.2.2. HUMAN MESENCHYMAL STROMAL CELLS FROM BONE MARROW 
Cryopreserved bone marrow-derived MSC (BMMSC; Lonza, Basel, 
Switzerland) were purchased at passage two. Cells were thawed by warming in 
a 37°C water bath for 1 minute before sterilising the cryovial exterior with 70% 
ethanol (ThermoFisher Scientific, Paisley, UK). The cells were re-suspended in 
pre-warmed ‘MSC growth medium’ (MSCGM), as recommended by the 
manufacturer which consists of human MSC basal medium supplemented with 
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hMSC SingleQuot Kit containing; 10% heat-inactivated FBS, 2% L-glutamine, 
30mg/mL gentamicin, and 15µg/mL amphotericin (all from Lonza). The cell 
suspension was centrifuged at 400g for 5 minutes at room temperature. The 
pellet was re-suspended and subsequently cultured in T75 flasks with MSCGM 
replaced every 3 days. The cells were subcultured at a 1:3 ratio (Section 2.3). 
The cells were used in experiments or cryopreserved (Section 2.4) at passage 
five unless stated otherwise. All donors were phenotyped according to ISCT 
guidelines (Section 1.2.1) (Dominici et al. 2006).  
 
2.2.3. HUMAN WHOLE BLOOD AND ISOLATED NEUTROPHILS 
Whole venous blood was collected in tubes containing citrate-phosphate-
dextrose with adenine solution at a 10:1 ratio (Sigma-Aldrich) and used in whole 
blood platelet adhesion and aggregation assays as described (Sections 2.8.3 
and 2.15). In some experiments platelets were labelled by incubating whole 
blood with mouse anti-human CD41a-PE antibody (Dako, Cheshire, UK) for 10 
minutes. 
 
Alternatively, neutrophils were isolated as previously described (Munir et al. 
2015). Briefly, venous blood was collected in K3EDTA-coated (1.6mg/mL) tubes 
(Sarstedt, Leicester, UK). A histopaque density gradient was setup by adding 
2.5mL histopaque 1119 to a round-bottom tube followed by 2.5mL histopaque 
1077 (both Sigma-Aldrich), 5mL of whole blood per tube was layered on the 
histopaque gradient and centrifuged at 1200g for 30 minutes at room 
temperature. The neutrophils sediment 2cm above the haematocrit, this band 
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was collected and washed twice in ‘basal medium 199’ (M199) with 0.15% 
bovine serum albumin (BSA) (MBSA; both Gibco, ThermoFisher) by 
centrifugation at 400g for 5 minutes at room temperature. The neutrophil pellet 
was re-suspended in MBSA and the cell concentration determined using a Z2-
series Coulter Counter (Beckman Coulter, High Wycombe, UK), before further 
diluting to 1´106 cells/mL in MBSA. 
 
2.2.4. HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS 
Endothelial cells were isolated using a collagenase digest of the veins as 
previously described (Munir et al. 2015). Briefly, the vein was cannulated and 
washed with PBS+ to remove blood. The PBS+ was aspirated, the vein filled 
with 1mg/mL collagenase type Ia (all Sigma-Aldrich) diluted in PBS+ and 
incubated for 15 minutes at 37°C and 5% CO2. The cord was massaged and 
the endothelial cell suspension collected by flushing the vein with PBS followed 
by air. The suspension was centrifuged at 400g for 5 minutes and the pellet 
resuspended in HUVEC medium, which consists of M199 supplemented with 
20% FBS, 35µg/mL gentamicin, 1µg/mL hydrocortisone, 10ng/mL epidermal 
growth factor (all from Sigma-Aldrich), and 2.5µg/mL amphotericin B 
(ThermoFisher). The isolated endothelium were cultured to confluence 
(approximately 5 days) in a 25cm2 tissue culture treated flask (T25; BD Falcon), 
with HUVEC medium replaced every other day. The cells were used for 
experiments at the first passage. 
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In some experiments, Ibidi microslides were prepared as previously described 
(Munir et al. 2015). Briefly, HUVEC (1.25´105 cells/channel) were seeded onto 
a 6-channel Ibidi microslide (µ-Slide VI0.4; Ibidi, Thistle Scientific, Glasgow, UK) 
(Figure 2-6A) in MSCGM and incubated at 37°C and 5% CO2 for 1 hour. The 
channels were washed three times with MSCGM to remove non-adherent cells 
and incubated at 37°C and 5% CO2 for 24 hours. HUVEC was treated with 
‘recombinant human tumour necrosis factor alpha’ (TNF-a; R&D Systems, 
Oxford, UK) at 0, 10, or 100U/mL diluted in MSCGM, then incubated for a 
further 4 hours at 37°C and 5% CO2 prior to setup in the Ibidi microchannel 
flow-based adhesion assay (Section 2.8.10). 
 
2.2.5. HUMAN DERMAL BLOOD ENDOTHELIAL CELLS 
Cryopreserved human dermal blood endothelial cells (BEC; PromoCell, 
Heidelberg, Germany) were purchased at passage two and thawed. The cells 
were subsequently cultured in T75 flasks using BEC growth medium (BECGM), 
as recommended by the manufacturer which consists of endothelial cell basal 
medium MV supplemented with endothelial cell growth medium MV Supplement 
Mix containing; 5% FBS, 0.4% bovine hypothalamic extract, 10ng/mL human 
epidermal growth factor (EGF), 90µg/mL heparin, and 1µg/mL hydrocortisone 
(all from PromoCell). BECGM was replaced every 3 days. The cells were 
subcultured at a 1:3 ratio (Section 2.3). The cells were used in experiments or 
cryopreserved (Section 2.4) at passage four unless stated otherwise. 
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2.2.6. HUMAN FIBROBLASTS 
Synovial fibroblasts were obtained from patients with established, treated RA 
undergoing knee replacement surgery at the Royal Orthopaedic Hospital 
(Birmingham, UK). They were isolated as previously described (Salmon et al. 
1997), and provided by Dr. A. Filer (Rheumatology Research Group, University 
of Birmingham, UK) in a cryopreserved state at passage four. All patients 
conformed to the 1987 American College of Rheumatology definition of RA 
(Arnett et al. 1988). All donors were female and positive for rheumatoid factor, 
age was 51±15 years, ‘disease activity score’ (DAS)28 baseline was 6.1±1.2, 
disease duration was 910±150 weeks (data expressed as median ± standard 
deviation). Fibroblasts were thawed and subsequently cultured in T75 flasks 
using fibroblast growth medium (FGM), which consists of ‘Roswell park 
memorial institute’ (RPMI) 1640 medium supplemented with 1x MEM non-
essential amino acids, 2mM L-glutamine, 1mM sodium pyruvate, 100U/mL 
penicillin and 100µg/mL streptomycin (all from Sigma-Aldrich), and 10% FBS 
(Labtech, East Sussex, UK). Two-thirds of the medium was replaced every 7 
days. The cells were subcultured at a 1:3 ratio (Section 2.3). The cells were 
used in experiments or cryopreserved (Section 2.4) at passage six to nine 
unless stated otherwise. 
 
2.2.7. HUMAN EMBRYONIC KIDNEY 293T CELLS 
An immortalised ‘human embryonic kidney’ (HEK293T) cell line was gifted by 
Dr. M. Tomlinson (Biosciences, University of Birmingham, UK) in a proliferating 
state (Reyat et al. 2017). The cells were cultured in T75 flasks with MSCLG 
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replaced every 3 days. The cells were subcultured at a 1:5 ratio (Section 2.3). 
The cells were used in experiments or cryopreserved (Section 2.4). 
 
2.3. SUBCULTURE 
Briefly, plastic-adherent cells were subcultured at 80% confluence by washing 
with 2mM EDTA for 1 minute, before incubating with 2.5mg/mL trypsin (from 
porcine pancreas; both Sigma-Aldrich) at room temperature. A phase-contrast 
microscope was used to determine when the adherent cells had detached, at 
which point one volume of respective cell culture medium was added to quench 
the reaction. The cell suspension was centrifuged at 400g for 5 minutes at room 
temperature and the resulting pellet re-suspended in respective cell culture 
medium and either; seeded into tissue culture treated flasks for further 
expansion at 37°C and 5% CO2, used in experiments, or cryopreserved 
(Section 2.4). 
 
2.4. CRYOPRESERVATION 
For cryopreservation, cells at 80% confluence were subcultured (Section 2.3) 
and the pellet re-suspended in cryo-SFM (PromoCell) and stored in 1.5mL 
cryovials (Greiner Bio-One, Stonehouse, UK). Cryovials were slowly cooled to -
80°C before storing in liquid nitrogen. 
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2.5. ESTABLISHING COCULTURES ON TRANSWELL FILTERS 
Seeding cells onto filters and establishing cocultures were performed as 
previously described (Munir et al. 2015). The cells were subcultured (Section 
2.3) and re-suspended in their respective culture medium.  
 
For cocultures, BMMSC or UCMSC were seeded at 1.0´104 cells/mm2 or 
2.4´103 cells/mm2 respectively onto the basal surface of an inverted 6-well 
transwell filter (BD Falcon) for 1 hour at 37°C and 5% CO2. Following which, the 
filter was inverted again and suspended in a matched culture plate containing 
MSCGM for 24 hours at 37°C and 5% CO2. RASF, HUVEC, or BEC, were 
subcultured, re-suspended in MSCGM, and seeded at 1.0´104 cells/mm2 on the 
apical surface of the filter for 24 hours at 37°C and 5% CO2 (Figure 2-7A, B). 
For comparison, BMMSC, UCMSC, RASF, HUVEC, or BEC monocultures were 
established as controls. In some experiments, BMMSC were stimulated with 
100U/mL TNF-a in MSCGM for 24 or 72 hours at 37°C and 5% CO2 prior to 
coculture with BEC. Conditioned medium from 24 hours of cell culture was 
collected from untreated or TNF-a pretreated monocultures and cocultures; 
cellular debris was pelleted by centrifugation at 1200g for 10 minutes and the 
supernatant collected and stored at -80°C until used for measuring the 
concentration of IL-6 by ‘enzyme-linked immunosorbent assay’ (ELISA) (Section 
2.10). BMMSC-HUVEC/BEC cocultures and the respective endothelial 
monoculture control were stimulated with 100U/mL TNF-a for 4 hours at 37°C 
and 5% CO2 prior to the flow assay (Section 2.8.2). In other experiments, 
BMMSC-RASF cocultures and the respective monoculture controls were 
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analysed for gene expression (Section 2.7.5). In other experiments, UCMSC 
monocultures or UCMSC-BEC cocultures and the respective monoculture 
controls were setup and used in platelet adhesion and aggregation assays 
(Sections 2.8.2 and 2.15). 
 
2.6. MIGRATION OF MSC THROUGH TRANSWELL FILTERS 
For migration assays, UCMSC were seeded at 2.4´103 cells/mm2 on an 8.0µm 
pore 12-well transwell filter (BD Falcon) and cultured for 48 hours at 37°C and 
5% CO2. Migration was assessed by detaching cells from the upper and lower 
surfaces of the filter using 2.5mg/mL trypsin with 0.5mM EDTA. Cell 
suspensions were quantified using a Z2-series Coulter Counter (Beckman 
Coulter). Data are expressed as the number of cells that had migrated to the 
lower chamber as a percentage of the total number of cells counted in both 
chambers. 
 
In some experiments, PDPN was crosslinked to induce receptor clustering and 
downstream signalling. At 1 hour post-seeding, PDPN-positive UCMSC were 
incubated with 2μg/mL anti-human podoplanin (NZ-1.3) for 30 minutes 
(ThermoFisher) at 37°C and 5% CO2. An additional 30μg/mL of goat anti-rat 
IgG2a (ThermoFisher) was added to induce crosslinking for 47 hours at 37°C 
and 5% CO2. 
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In other experiments, cells were treated with inhibitors against; Ras homolog 
gene family GTPases (Rho) at 1, 2, or 4µg/mL (CT04; Cytoskeleton Inc, 
Colorado, USA), Rho-associated protein kinase (ROCK) at 10 or 100µM 
(Y27632; Sigma Aldrich), or Ras-related C3 botulinum toxin substrate one 
(Rac1) at 1 or 10µM (NSC23766; Calbiochem, Merck Millipore, Nottingham, 
UK) for the experiment duration. 
 
2.7. MSC CHARACTERISATION 
2.7.1. FLOW CYTOMETRY 
Expression of MSC ISCT surface markers was determined by flow cytometry; 
CD105, CD90, CD73, CD45, CD34, CD19, CD14, and HLA-DR (Dominici et al. 
2006). In some experiments PDPN (gp38; NZ-1.3) expression was also 
determined. The cells were detached from culture plastic and the pellet re-
suspended in ice-cold MACS buffer (PBS with 2mM EDTA and 1% BSA) at 
3´104 cells/100µl/tube prior to staining with conjugated antibodies or respective 
isotype controls (Table 2-1). Samples were incubated for 20 minutes at 4°C in 
the dark. The cells were washed twice with MACS buffer at 400g for 5 minutes 
at 4°C. The cells were analysed on the CyAn ADP flow cytometer (Beckman 
Coulter) within an hour of staining. Data were analysed using FlowJo (FlowJo 
LLC, Ashland, Oregon) and expressed as ‘median fluorescence intensity’ (MFI) 
with the IgG isotype control subtracted, unless indicated otherwise. BMMSC 
and UCMSC were positive for CD73, CD90 and CD105 expression, and 
negative for CD45, CD34, CD19, CD14, and HLA-DR; thus, conforming to the 
criteria set out by the ISCT for defining MSC (Figure 2-1) (Dominici et al. 2006).
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2.7.2. ADIPOGENESIS 
MSC adipogenic differentiation was induced using human MSC Adipogenic 
Differentiation BulletKit (adipogenic medium; Lonza), which consists of human MSC 
adipogenic induction basal medium supplemented with human MSC SingleQuot Kit 
containing human recombinant insulin, L-glutamine, MCGS, dexamethasone, 
indomethacin, 3-isobutyl-1-methyl-xanthine, 30mg/mL gentamicin, and 15µg/mL 
amphotericin (all from Lonza). MSC were seeded onto 6-well culture plastic at 2´104 
cells/cm2 in MSCGM till 80% confluent. Differentiation was induced using adipogenic 
medium, which was replaced every 5 days for a total of 21 days. Differentiated MSC 
were washed in PBS and subsequently fixed in 10% neutral-buffered formalin (4% 
formaldehyde, 40mg/mL sodium phosphate monobasic, 65mg/mL sodium phosphate 
dibasic anhydrous [all from Sigma-Aldrich] diluted in distilled water) overnight before 
washing again in distilled water. Adipogenic MSC were stained with 60% isopropanol 
for 5 minutes followed by filtered 0.1% Oil Red O (Sigma-Aldrich) in 60% isopropanol 
for 15 minutes at room temperature. Stained cells were imaged with an EOS 450D 
digital SLR camera (Canon, Surrey, UK). Adipogenesis was confirmed by the 
presence of Oil Red O stained lipid droplets within the cell cytoplasm (Figure 2-2C, 
D). 
 
2.7.3. OSTEOGENESIS 
MSC osteogenic differentiation was induced using MesenCult Osteogenic 
Stimulatory Kit (osteogenic medium; STEMCELL Technologies, Cambridge, UK), 
Human MesenCult MSC Basal Medium supplemented with: 15% osteogenic 
Methods 
 51 
stimulatory supplement, 10nM dexamethasone, 50µg/ml ascorbic acid (all 
STEMCELL Technologies). MSC were seeded onto 6-well culture plastic at 6´103 
cells/cm2 in MSCGM till 80% confluent. Differentiation was induced using osteogenic 
medium which was replaced every three days until multi-layering of cells is observed, 
upon which 3.5mM b-glycerophosphate (STEMCELL Technologies) was added to 
osteogenic medium for a further 14 days. Osteogenic MSC were washed and fixed 
as above, before being stained with 20mg/mL Alizarin Red S solution (Sigma-Aldrich) 
diluted in distilled water, (adjust pH to 4.1-4.3 with 0.1% NH4OH) for 45 minutes at 
room temperature in the dark. Stained cells were imaged with an EOS 450D digital 
SLR camera (Canon). Osteogenesis was confirmed by the presence of Alizarin Red 
S stained calcium deposits on mineralised cells (Figure 2-2E, F).  
 
2.7.4. CHONDROGENESIS 
MSC chondrogenic differentiation was induced using MesenCult-ACF Chondrogenic 
Differentiation Medium (chondrogenic medium, STEMCELL Technologies) which 
consists of MesenCult-ACF Chondrogenic Differentiation Basal Medium 
supplemented with: 5% MesenCult Chondrogenic Differentiation Supplement (all 
from STEMCELL Technologies). MSC were centrifuged at 400g for 10 minutes at 
5´105 cells per polypropylene tube in chondrogenic medium. The pellets were 
cultured in said tubes at 37°C and 5% CO2, with the caps loosened a quarter-turn to 
allow gas exchange. Chondrogenic medium was replaced every 3 days for a total of 
21 days. Chondrogenic MSC spheroids were delivered to musculoskeletal pathology 
(NHS, Birmingham, UK) where they were embedded in paraffin, sectioned into 7µm 
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slices, and melted onto glass slides. Upon receipt, the slides were deparaffinised in 
xylene, stepwise rehydrated and stained with 0.1mg/mL Alcian Blue 8GX (Alfa Aesar, 
Heysham, UK) dissolved in 40% acetic acid (ThermoFisher) and 60% ethanol for 30 
minutes at room temperature in the dark. Spheroids were washed twice with 
destaining solution (40% acetic acid and 60% ethanol) for 20 minutes each, before 
counterstaining with nuclear fast red (Vector Laboratories, Peterborough, UK) for 10 
minutes. Slides were washed under running tap water for 10 minutes prior to 
stepwise dehydration with ethanol and final xylene clearing. The slides were mounted 
with VectaMount (Vector Laboratories) and stored at room temperature in the dark. 
Stained cells were imaged with an EOS 450D digital SLR camera (Canon). 
Chondrogenesis was confirmed by the presence of sulfated proteoglycans stained 
with Alcian Blue (Figure 2-2G, H). 
!"#$%&'(
( FB(
(
!"#$%&'()(' +,-'4%")0"9&=#&'@"AA&%&94"=4"19'8"B4101#3'
LH:.4(!,-(7"6"(9H=#H6"&(24(;C?'!,-U!(%6(;D?'!,-MUC(%6(;-E'F?'.&2/%0"429(
:"&2H:C(%6(;GE'!?'%'#"%0"429(:"&2H:C(%6(;HE'I?'9$%4&6%0"429(:"&2H:C(#$"4('#.24"&(
H'240(%2=(6"&(JC(.=2S.624(6"&(,C(%6(.=92.4(8=H"(6"'/"9#23"=GI(P:.0"'(.6"(6"/6"'"4#.#23"(%1(
4Q)KX(&211"6"4#(&%4%6'(1%6(".9$(9"==(#G/"I(,9.="(8.6(6"/6"'"4#'(EDh:I(-269="'(.4&(ijk(
&"4%#"(.6".'(%1(%2=(6"&(J('#.24240(1%6(=2/2&'I(ilk(&"4%#"'(.6".'(%1(.=2S.624(6"&(,('#.24240(
1%6(9.=92H:(&"/%'2#'I(N66%7'(&"4%#"(.6".'(%1(.=92.4(8=H"('#.24240(1%6('H=1.#"&(
/6%#"%0=G9.4'I( (
Methods 
 54 
2.7.5. MESSENGER RIBONUCLEIC ACID ISOLATION AND QUANTITATIVE POLYMERASE 
CHAIN REACTION 
Messenger ribonucleic acid (mRNA) was isolated from BMMSC, UCMSC, 
adipocytes, osteoblasts, and chondroblasts using an RNeasy Mini kit (Qiagen, 
Manchester, UK) as per the manufacturer’s instructions. The cells were subcultured 
and the resulting pellets vigorously re-suspended in 350µL of RLT lysis buffer 
(supplemented with 1:100 b-mercaptoethanol; Sigma-Aldrich) and stored at -80°C. 
Within 14 days of initial storage, the samples were vigorously mixed with 350µl of 
70% ethanol and further vortexed for a minimum of 30 seconds. The mixture was 
transferred to RNeasy columns and centrifuged at 10000g for 1 minute. The column 
was washed once with RW1 buffer and twice with RPE by centrifugation at 10000g 
for 1 minute for each treatment. Any flow-through was discarded. The column was 
dry spun at 10000g for 2 minutes, prior to elution of RNA with RNase-free water 
(Qiagen) by centrifugation at 10000g for 1 minute. The elution step was repeated 
with the flow-through to maximise mRNA recovery, and the purity and concentration 
determined using a NanoDrop 1000 spectrophotometer (ThermoFisher). RNA purity 
was deemed acceptable when the 260/280nm and 260/230nm absorbance ratio 
were both within a range of 1.8-2.1. 
 
Isolated mRNA was reverse transcribed into cDNA as described (Chimen et al. 
2015). Briefly, 0.5µg mRNA was annealed with 1µg random primers (Promega, 
Southampton, UK) in 15µL of RNase-free water for 5 minutes at 70°C, followed by 
the addition of 11.63µL of master mix per sample comprising 5´ M-MLV buffer, 
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10mM dNTP mix (dATP, dCTP, dGTP, dTTP), 200U M-MLV reverse transcriptase, 
and 40U RNasin Plus (all from Promega) diluted in RNase-free water. RT-PCR was 
performed at 37°C for 1 hour using Touchgene Gradient PCR thermal cycler 
(Techne, Staffordshire, UK). Quantitative PCR (qPCR) was performed using TaqMan 
Gene Expression Assays according to the manufacturer’s instructions in a 384-well 
optical reaction plate (Applied Biosystems, ThermoFisher). Each sample was run in 
triplicate and reactions were composed of 0.5µL cDNA, 4µL TaqMan universal PCR 
master mix, 5µL RNase-free water, and 0.5µL FAM-labelled TaqMan gene 
expression assay primers and probes (all from Applied Biosystems) for each gene 
analysed (Table 2-2). Samples were run on a 7900HT Real Time PCR machine for 
40 cycles and subsequently analysed using SDS 2.2 software (both from Applied 
Biosystems). Triplicates were averaged to obtain the threshold cycle (CT) for each 
sample, and subtracted from the average CT value for the housekeeping control; 18S 
or GAPDH (DCT). Technical repeats outside of 1 CT were discarded. ‘Relative 
expression units’ (REU) for each gene were calculated with the following formula. 
!"# = 2&D'( 
MSC adipogenesis was determined by upregulation of PPARg, C/EBPa, and FABP4 
adipogenic genes compared to untreated MSC (Rosen et al. 2002; Garin-Shkolnik et 
al. 2014). BMMSC significantly upregulated PPARg in response to adipogenic 
medium (Figure 2-3A), however no effect was observed for UCMSC, or C/EBPa and 
FABP4 in BMMSC (Figure 2-3). MSC osteogenesis was determined by upregulation 
of RUNX2 and BMP2 osteogenic genes compared to untreated MSC (Jang et al. 
2012). No effect of osteogenic medium was observed on MSC expression of 
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osteogenic genes (Figure 2-4). UCMSC chondrogenesis was determined by 
upregulation of SOX5 and SOX9 chondrogenic genes compared to untreated 
UCMSC (Liu & Lefebvre 2015). UCMSC significantly upregulated expression of 
SOX5 but not SOX9 in response to chondrogenic medium (Figure 2-5). In other 
experiments, BMMSC or RASF were stimulated with 100U/mL TNF-a in MSCGM for 
24 or 72 hours at 37°C and 5% CO2, or BMMSC-RASF cocultures and respective 
monocultures were also determined by qPCR. 
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Figure 2-3 MSC adipogenic differentiation qPCR 
(A, C, E) BMMSC or (B, D, F) UCMSC were cultured in the presence or absence of 
adipogenic medium for 21 days. Gene expression for adipocyte markers (A, B) PPARg, 
(C, D) C/EBPa, and (E, F) FABP4 were measured by qPCR. Data are mean ± SEM 
from n=4-6 independent experiments using four or six different donors for each cell 
type. * = p<0.05 by paired t-test.  
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Figure 2-4 MSC osteogenic differentiation qPCR 
(A, C) BMMSC or (B, D) UCMSC were cultured in the presence or absence of 
osteogenic medium for 14 days. Gene expression for osteoblast markers (A, B) RUNX2 
and (C, D) BMP2 were measured by qPCR. Data are mean ± SEM from n=4 
independent experiments using four different donors for each cell type.  
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Figure 2-5 UCMSC chondrogenic differentiation qPCR 
UCMSC were cultured in the presence or absence of chondrogenic medium for 21 
days. Gene expression for chondroblast markers (A) SOX5 and (B) SOX9 were 
measured by qPCR. Data are mean ± SEM from n=4 independent experiments using 
four different donors. * = p<0.05 by paired t-test.  
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2.8. ADHESION ASSAYS 
2.8.1. IBIDI MICROSLIDE FLOW-BASED ADHESION ASSAY SETUP 
The flow system was setup as shown and described (Figure 2-6C). The Ibidi 
microslide channel inlet was connected by a female to male Luer elbow fitting 
(Labhut, Pennsylvania, USA) with a 10mm length piece of flexible silicon rubber 
2/4mm tubing overlapping the end of 1/3mm tubing (both from ThermoFisher) which 
was in turn connected to the outlet port of an electronic switching valve (Lee 
Products, Gerards Cross, UK). The electronic switching valve selected flow from two 
fluid reservoirs. The ‘sample reservoir’ was directly connected to the valve inlet via 
5mm length 1/3mm tubing with overlapping 5mm length 2/4mm tubing connected to 
an inverted 2mL syringe (without plunger, BD Falcon), filled with a neutrophil 
suspension (1´106 cells/mL in MBSA). The ‘wash reservoir’ was indirectly connected 
to the second valve inlet via 5mm length 1/3mm tubing with overlapping 2/4mm 
tubing connected to the three-way tap and an inverted 20mL syringe (without 
plunger, BD Falcon), filled with cell-free MBSA. A third 5mL syringe (with plunger) 
filled with cell-free MBSA was attached to the three-way tap to manually remove air 
bubbles. The Ibidi microslide channel outlet was connected by a female to male Luer 
elbow fitting with a 10mm length of 2/4mm tubing overlapping a 5mm length of 
1/3mm tubing overlapping Portex blue line manometer tubing (Smiths-Medical, 
Luton, UK) connected to a 50mL Popper Micro-Mate glass syringe mounted on a 
withdrawal syringe pump (both from Harvard Apparatus, Cambridge, UK). The tubing 
was primed with cell-free MBSA and any bubbles were removed prior to performing 
the flow-based adhesion assay (Section 2.8.3). 
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2.8.2. TRANSWELL COCULTURE FLOW-BASED ADHESION ASSAY SETUP 
The transwell coculture adhesion assays were setup as previously described (Munir 
et al. 2015). Pre-stimulated BMMSC-HUVEC/BEC or UCMSC-BEC cocultures, or 
respective monocultures were subsequently incorporated into a bespoke parallel 
plate chamber as described (Munir et al. 2015). Briefly, the filters were cut out with a 
10A scalpel onto a glass coverslip (76´26mm – ThermoFisher) with the apical filter 
surface or endothelial monolayer facing up. The coverslip and filter were covered 
with a paraffin film gasket (Parafilm, Neenah, Wisconsin, USA) with a central 
20´4mm slot cut into it to form the flow channel overlaying the filter (Figure 2-6B). 
The combination of the coverslip, filter, and gasket were placed into a custom flow 
chamber as shown and described (Figure 2-6C). The tubing for the parallel plate 
chamber was setup as described for the Ibidi microslide with the following 
exceptions. The channel inlet was connected by a 10mm length piece of Portex blue 
line manometer tubing underlapping 1/3mm tubing which was in turn connected to 
the outlet port of an electronic switching valve. The parallel plate chamber channel 
outlet was connected by Portex blue line manometer tubing to a 50mL Popper Micro-
Mate glass syringe.  
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2.8.3. FLOW-BASED ADHESION ASSAY 
The Ibidi microslide or parallel plate chamber was placed inside a Perspex chamber 
that was maintained at 37°C, then attached to a perfusion system mounted on an 
IX71 inverted phase-contrast video microscope (Olympus, Southend-on-Sea, UK) 
with a Hitachi KP-M1AP digital camera (Hitachi, Maidenhead, UK) attached (Figure 
2-6C). Perfusion was controlled from the outlet tubing with a withdrawal syringe 
pump (Harvard Apparatus) to maintain a constant shear rate of 150s-1 for CD41a-
labelled whole blood (Navarro-Nunez et al. 2015), or a wall shear stress (τw) of 
0.05Pa for Ibidi microslide or 0.1Pa for filter flow chambers. The necessary flow rate 
(Q) to achieve a wall shear stress of 0.05Pa or 0.1Pa for the Ibidi microslide or 
parallel plate flow chamber respectively, was calculated using the below formula 
where: η	= viscosity of perfused medium (@ 0.7´10-3Pa for aqueous buffer at 37°C); w 
= width (3.8mm for Ibidi; 4mm for the chamber); h = height (0.4mm for Ibidi; 0.133mm 
for the chamber). 
τ/ = 	6123ℎ5  
The Ibidi microchannel or parallel plate chamber were initially perfused with MBSA or 
PBS with 0.15% BSA and 5U/mL heparin (PBSAH; Sagent Pharmaceuticals, 
Schaumburg, Illinois, USA) for 2 minutes to either wash out residual TNF-a and or 
acclimatise the endothelium. A 4-minute bolus of purified neutrophils or 5- or 10-
minute bolus of CD41a-labelled whole blood, was subsequently perfused over the 
apical surface of the filter or endothelium before returning to cell-free MBSA for 2 
minutes or PBSAH for 5 minutes. For purified neutrophils, phase-contrast images of 
five random fields along the centre line were recorded every second for 30 seconds, 
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at 2 and 9 minutes’ post-perfusion (Figure 2-7A). For CD41a-labelled whole blood, 
fluorescent images of 5 random fields were taken along the centre line of the channel 
after washout with PBSAH. The total number of neutrophils per field and their 
behaviour was analysed offline using Image-Pro Plus 7.0 software (Media 
Cybernetics, Rockville, USA). Total adhesion was assessed at 2 minutes’ post-
perfusion and expressed as the number of adherent neutrophils per mm2 of 
endothelium per 1x106 neutrophils perfused (cells/mm2/106). It was calculated using 
the below formula: where: µ	= mean adherent neutrophils per field, A = field area 
(mm2), C = leukocyte concentration (106/mL), Q = flow rate (mL/minute), t = bolus 
duration (minutes). 
789:;	:<ℎ=>?8@ = 	 ABC29 
Furthermore, rolling, stationary, and migratory behaviour was assessed at both 2 and 
9 minutes’ post-perfusion and expressed as a percentage of the total adherent 
neutrophils. These classes were defined as: (i) rolling adherent neutrophils that were 
phase-bright, spherical and rolled across the apical endothelial surface; (ii) firmly 
adherent neutrophils that were phase-bright and migrated across the surface of the 
endothelium; or (iii) transmigrated neutrophils that were phase-dark, flattened and 
migrated underneath the endothelial monolayer; as previously characterised (Luu et 
al. 1999). 
 
Platelet adhesion and aggregation was expressed as average size using ImageJ 
software (NIH) particle analysis of fluorescence. In some experiments, UCMSC were 
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treated with 30µg/mL of human recombinant CLEC-2 protein (R&D systems) for 10 
minutes prior to perfusion (Suzuki-Inoue et al. 2007). In others, CD41a-labelled 
whole blood was perfused in the presence of 9µM integrilin (Sigma-Aldrich), an 
inhibitor of αIIbβ3-integrin that mediates activated platelet-platelet binding (Thomas et 
al. 2011). 
 
2.8.4. SEEDING CELLS INTO COLLAGEN GELS  
Collagen gel adhesion assays were setup and performed as previously described 
(Jeffery et al. 2013). Rat tail type I collagen (2.15mg/ml; First Link Ltd, West 
Midlands, UK) was mixed with 10´ M199 and neutralised with 1N NaOH. MSC 
(2.5´104 cells in FBS) were added to the gel solution (500µl/well of a 12-well plate), 
before setting at 37°C and 5% CO2 for 30 minutes. Once set, the gel was equilibrated 
in MSCGM for 24 hours at 37°C and 5% CO2. To form the coculture, HUVEC (4´105 
cells in MSCGM) were seeded onto the gel and incubated at 37°C and 5% CO2 for 24 
hours (Figure 2-7C, D). These collagen gels were subsequently used in collagen gel 
migration assays (Section 2.8.5). For spheroid migration assays, the gel was set in 
the absence of any cells (Section 2.9). 
 
2.8.5. COLLAGEN GEL MIGRATION ASSAY 
HUVEC monocultures and MSC:HUVEC cocultures were treated with 100U/mL TNF-
a for 4 hours. After stimulation, neutrophils (1´106 cells/mL, at 1mL/well) were 
incubated with the endothelium for 20 minutes at 37°C and 5% CO2. Non-adherent 
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neutrophils were washed off the endothelium with MBSA, the plate was placed on the 
stage of an IX71 inverted phase-contrast microscope within a Perspex chamber 
maintained at 37°C. The stage was connected via a computer-operated motorised 
focus. Four random z-stacks were imaged with a digital camera at 2µm intervals 
through the gel. After 2-hours at 37°C and 5% CO2, the endothelium was washed 
and another four z-stacks imaged (Figure 2-7C, D). The data were analysed offline 
using Image-Pro Plus 7.0 software, whereby the number of cells within each stack of 
the gel were analysed and assigned to a designated depth based on their distance 
from the apical surface of the gel. Adhesion was expressed as the average number 
of phase-bright adherent neutrophils as a percentage of those initially added. Gel 
penetration is expressed as the number of migrated neutrophils that had entered the 
gel as a percentage of adherent between 50µm intervals. Gel depth is expressed as 
the distance between the apical and basal surface of the gel.  
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2.9. COLLAGEN GEL SPHEROID MIGRATION ASSAY 
UCMSC were re-suspended at 2.5´104 cells in 35µL MSCLG droplets onto the inner 
surface of a Petri dish lid (BD Falcon). Distilled water was added to the Petri dish 
base to humidify the dish. The lid was inverted to suspend the cells as a hanging 
droplet over 48 hours, and allow the cells to form spheroids under gravity. Spheroids 
were subsequently placed on the surface of the collagen gel and MSC migration onto 
the gel imaged after 24 and 48 hours. Marginal cells were determined as the number 
of ‘tubules’ using AngioSys2.0 software (Cellworks, Buckingham, UK) semi-
automated analysis (Figure 2-8). Data were expressed as the number of marginal 
cells migrating into the collagen matrix as a percentage of the total number initially 
seeded within the spheroid. 
 
2.10. IL-6 ENZYME-LINKED IMMUNOSORBENT ASSAY 
Human IL-6 concentration was measured in conditioned media collected from 
untreated or TNF-a stimulated BMMSC-BEC coculture and respective monoculture 
controls, using Quantikine ELISA (D6050; R&D Systems). Data were expressed as 
pg/mL as determined by subtracting the absorbance readings at 450nm from 550nm 
then cross-referencing against a standard curve, according to the manufacturer’s 
instructions (Figure 2-9).  
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Figure 2-9 IL-6 ELISA standard curve 
A serial dilution of human recombinant IL-6 was analysed using Quantikine ELISA kit 
and spectrometry. Mean optical density for technical replicates were plotted against IL-6 
concentration and linear regression analysis performed. The equation of the line was 
calculated as y = 0.002x + 0.045, and R2 = 0.99.  
0 200 400 600
0.0
0.5
1.0
1.5
2.0
Human IL-6 Concentration (pg/mL)
O
pt
ic
al
 D
en
si
ty
Methods 
 72 
2.11. UMBILICAL CORD IMMUNOHISTOCHEMISTRY 
Umbilical cord was cut into 2cm2 pieces before flash freezing in liquid nitrogen vapour 
and storage at -80°C. Frozen umbilical cord pieces were embedded in optimum 
cutting temperature compound (Sakura Finetek, Thatcham, UK) and loaded onto the 
cryostat (CM1950, Leica, Milton Keynes) for sectioning into 10µm slices at -30°C. 
Sections were mounted onto Superfrost Ultra Plus Adhesion Slides (ThermoFisher) 
and left to dry at room temperature. Tissue was rehydrated in PBS+ for 5 minutes 
prior to blocking with Bloxall (Vector Laboratories) for 10 minutes. The slides were 
stained with an IgG2 rat anti-human isotype control (eBR2a) (ThermoFisher) or rat 
anti-human PDPN (NZ-1.3) at 5µg/mL for 1 hour at room temperature. The slides 
were washed in PBS+ for 5 minutes before incubating with 5µg/mL secondary rabbit 
anti-rat horseradish peroxidase (P0450, Dako) for 45 minutes. The slides were 
washed in PBS+ for 5 minutes before staining with haematoxylin and 3,3’-
diaminebenzidine (both from Vector Laboratories). Slides were washed again in 
running tap water for 5 minutes prior to mounting with VectaMount (Vector 
Laboratories). Slides were imaged using the AxioScan.Z1 and Zen lite 2012 software 
(both from Carl Zeiss, Cambridge, UK). Data were quantified using ImageJ software, 
and expressed as the percentage area of PDPN staining for the entire umbilical cord 
cross-section. 
 
2.12. SIRNA KNOCKDOWN OF PODOPLANIN AND EFFECT ON UCMSC PROLIFERATION 
PDPN-positive UCMSC were seeded in 12-well tissue culture plates (BD Falcon) at 
4.2´103 cells/mm2 in MSCLG. The cells were incubated at 37°C and 5% CO2 till 80% 
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confluence, upon which the siRNA duplexes against PDPN or a single scrambled 
siRNA duplex control (all Sigma-Aldrich) (Table 2-3) were mixed with Lipofectamine 
RNAiMAX (ThermoFisher) and added to the cells at 50nM. The cells were incubated 
for a further 6 hours at 37°C and 5% CO2 before replacing the medium with fresh 
MSCLG and analysing gene or protein expression 24, 48, and 72 hours post-
transfection by qPCR (Section 2.7.5) or flow cytometry (Section 2.7.1).  
 
In some experiments, cell proliferation was recorded over 72 hours in response to 
PDPN siRNA knockdown using a Cell-IQ Imagen and associated software (both 
Chipman Technologies, Tampere, Finland). Data were normalised as the average 
number of cells per field over time compared to 0 hours, with time representing the 
number of hours post-transfection. 
 
2.13. CRISPR/CAS9 KNOCKOUT OF PODOPLANIN 
2.13.1. CUSTOM CRISPR/CAS9 MOLECULAR CLONING 
Three ‘guide RNA’ (gRNA) sequences were assigned using the CRISPR Finder 
online browser tool (WTSI Genome Editing) for PDPN with off-target counts in less 
than the tenth percentile (Table 2-4). Reverse sequences were generated and sticky 
ends complimentary to the ‘pSpCas9n(BB)-2A-Puro (PX459) V2.0’ plasmid BbsI 
restriction site were added (plasmid was gifted by Feng Zhang (Addgene plasmid # 
62988). The custom ‘single-gRNA’ (sgRNA) sequences were ordered from Sigma-
Aldrich, and the forward and reverse strands annealed to form three distinct   
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oligonucleotide duplexes, the following methodology was adapted from Ran et al., 
(2013) and repeated for each duplex (Ran et al. 2013). Briefly, 1µL 100µM forward 
sgRNA, 1µL 100µM reverse sgRNA, 1µL T4 DNA ligase buffer (10´), 1µL T4 
polynucleotide kinase (both from ThermoFisher), and 6µL distilled water were 
incubated at 37°C for 30 minutes, then 95°C for 5 minutes, and slowly reduced to 
25°C (by 5°C per minute). The resulting oligonucleotide duplex was diluted 1:200 
with distilled water.  
 
The plasmid vector was cut at the BbsI site by restriction enzyme digest. Briefly, 5µg 
plasmid DNA was incubated at 37°C for 3 hours with 2µL NEBuffer 2.1 (10´) and 1µL 
Bbs1 (both from New England Biolabs, Hitchin, UK) then made up to 20µL with 
distilled water. The restriction digest products were stained with 4µL DNA gel loading 
dye (6´) (ThermoFisher) and ran on a 1% agarose gel (Sigma-Aldrich) containing 
1:10000 SYBR safe DNA gel stain (ThermoFisher) at 100V for 30 minutes.  
 
The plasmid vector was extracted from the gel using QIAquick gel extraction kit 
(Qiagen) as per the manufacturer’s instructions. Briefly, the heavy band from the gel 
was excised using a sterile scalpel blade under ultraviolet light. QG buffer (Qiagen) 
was added at 3µL per mg of gel and incubated for 10 minutes at 50°C until dissolved. 
An equivalent volume of isopropanol (3µL per mg of initial gel; ThermoFisher) was 
added to the mixture and centrifuged at 10000g for 1 minute in the provided QIAquick 
spin columns (Qiagen). The flow-through was discarded and 750µL Buffer PE 
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(Qiagen) was left to stand within the column for 5 minutes at room temperature 
before centrifuging at 10000g for 1 minute. The flow-through was discarded and the 
column spun dry by centrifugation at 10000g for 1 minute. The column was placed in 
a sterile 1.5mL Eppendorf tube (Scientific Laboratory Supplies) and the plasmid 
vector eluted with 40µL of Buffer EB (Qiagen) then the flow-through passed through 
the column a second time, both were centrifuged at 10000g for 1 minute. 
 
The plasmid vector (100ng) was ligated with 2µL of the diluted oligonucleotide duplex 
prepared earlier, with 2µL T4 DNA ligase buffer (10´), made up to 19µL with distilled 
water, and 1µL of T4 DNA ligase (both ThermoFisher) added last. The ligase mixture 
was incubated at room temperature for 30 minutes, then 5µL was transferred to a 
sterile Eppendorf tube with 50µL of competent bacteria (E. coli – DH5a; 
ThermoFisher) for 30 minutes on ice. The Eppendorf tube was subsequently placed 
in a water bath at 42°C for 30 seconds to induce heat shock, before returning to ice 
for 2 minutes. A plasmid vector only control was also prepared. Super optimal broth 
with catabolite repression (200µL; S.O.C.; ThermoFisher) was added to the 
Eppendorf tube and incubated at 37°C for 1 hour in an orbital shaker at 200rpm. 
Each mixture was inoculated by spreading on a pre-poured ‘Luria-Bertani’ (LB) agar 
plate with 100µg/mL ampicillin (Sigma-Aldrich) and incubating at 37°C overnight 
(None or few colonies should be visible on the plasmid vector control inoculated 
plate). Four colonies (and colony absent control; PCR mix without bacterial colony) 
were picked from the LB agar plate and mixed with 25µL REDTaq ReadyMix PCR 
reaction mix (Sigma-Aldrich), 23µL distilled water, 1µL plasmid forward primer 
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(MT5470; U6 promoter region; GAGGGCCTATTTCCCATGATTCC) (Sigma-Aldrich), 
and 1µL plasmid reverse primer (respective reverse sgRNA). The PCR mixture was 
cycled as follows: 
1. 95°C for 5 minutes. 
2. 95°C for 30 seconds. 
3. 55°C for 15 seconds. 
4. 72°C for 60 seconds. 
5. Repeat steps 2-4 for 35 cycles. 
6. 72°C for 5 minutes. 
The PCR products and control were stained with 4µL DNA gel loading dye (6´) (New 
England Biolabs) and ran on a 1% agarose gel containing 1:10000 SYBR safe DNA 
gel stain at 100V for 30 minutes. A 100bp DNA ladder (New England Biolabs) was 
placed in the first lane to verify the size of the PCR products. A 268bp product 
indicated that the oligonucleotide duplex had been correctly inserted; all colonies 
except ‘gRNA1, colony a’ were successful (Figure 2-10). A successful colony for 
each gRNA was picked and used to inoculate 100mL of LB medium with 100µg/mL 
ampicillin (both Sigma-Aldrich) each, then incubated at 37°C overnight in an orbital 
shaker (Cole-Parmer) at 300rpm.
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Figure 2-10 Custom PDPN CRISPR plasmid PCR validation 
The products of the pSpCas9n(BB)-2A-Puro (PX459) V2.0 plasmid vector and 
oligonucleotide duplex ligation were amplified by competent cell transformation and 
the resulting colonies were validated using PCR for the correct orientation of the 
inserted oligonucleotide duplex, using a U6 promoter forward primer and the reserve 
sgRNA as a complimentary reverse primer. Colony absent PCR mixtures were used 
as a negative control. A 268bp product (white arrow) indicated correct orientation and 
integration of the oligonucleotide duplex with the plasmid vector.  
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The plasmids from the resulting culture were isolated using a plasmid maxi kit 
(Qiagen) as per the manufacturer’s instructions. Briefly, the bacterial cells from 50mL 
of culture were harvested after 4°C centrifugation at 6000g for 15 minutes. The 
supernatant was discarded and the pellet vortexed in 10mL of Buffer P1 with RNase 
A and LyseBlue supplements (Qiagen) until no cell clumps remain. Buffer P2 
(Qiagen) was added to the mixture and inverted until a homogenous blue suspension 
was achieved, then incubated at room temperature for 5 minutes. Chilled Buffer P3 
(Qiagen) was added to the mixture and inverted until a homogenous clear 
suspension was achieved. The plasmid-containing supernatant was harvested after 
4°C centrifugation at 20000g for 30 minutes, this step was repeated once. Meanwhile 
a QIAGEN-tip 500 was equilibrated with 10mL of Buffer QBT (both Qiagen) and 
allowed to empty by gravity flow. The plasmid-containing supernatant was loaded 
into the QIAGEN-tip and allowed to enter the resin by gravity flow, before washing 
twice with 30mL Buffer QC (Qiagen), any flow-through was discarded. The plasmid 
was eluted with 15mL of Buffer QF (Qiagen), then the plasmid precipitated by adding 
10.5mL of isopropanol, and the plasmid pellet harvested after 4°C centrifugation at 
15000g for 30 minutes. The plasmid pellet was washed with 70% ethanol and 
centrifuged at 15000g for 10 minutes. The supernatant was decanted, and allowed to 
air-dry for 10 minutes before dissolving in 1mL of distilled water. The purity and 
concentration of the yield was determined using a NanoDrop 1000 
spectrophotometer. DNA purity was deemed acceptable when the 260nm 
absorbance was within a range of 0.1-1.0. The plasmids for each gRNA were 
sequenced by the University of Birmingham sequencing facility (Figure 2-11). 
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2.13.2. PUROMYCIN KILL CURVE 
The ‘pSpCas9n(BB)-2A-Puro (PX459) V2.0’ plasmid contained a puromycin 
resistance cassette to select cells that had successfully been transfected. The 
minimum concentration of puromycin required to kill 100% of cells had previously 
been determined for HEK293T cells (2.5µg/mL) but not UCMSC [An email (PJ Noy 
2016, personal communication, 7th July) confirming the protocol for puromycin 
selection in HEK293T cells]. Briefly, UCMSC were seeded in a 24-well tissue culture 
plate (BD Falcon) until 80% confluence. UCMSC were incubated with increasing 
doses of puromycin (ThermoFisher) over 0-2µg/mL for 48 hours, before washing off 
non-adherent cells with PBS+. Data were expressed as the percentage survival, as 
determined by the percentage of adherent cells remaining after 48 hours of 
puromycin treatment. 
 
2.13.3. CRISPR/CAS9 TRANSFECTIONS 
HEK293T cells or UCMSC positive for PDPN expression were transfected using 
Lipofectamine 2000 (ThermoFisher) or P1 Primary Cell 4D-Nucleofector X Kit L 
(Lonza). Lipofectamine 2000 transfections were performed as per the manufacturer’s 
instructions. Briefly, cells were seeded in 6-well tissue culture plates (BD Falcon) at 
4.2´103 cells/mm2 in MSCLG. The cells were incubated at 37°C and 5% CO2 till 80% 
confluence, upon which the custom plasmid (pSpCas9n(BB)-2A-Puro (PX459) V2.0 + 
gRNA1/2/3) was diluted to 0.1µg/µL in 150µL OptiMEM (ThermoFisher) and mixed 
with 150µL Lipofectamine 2000, then incubated at room temperature for 5 minutes. 
The DNA-lipid complex was added to the cells and incubated for 24 hours at 37°C 
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and 5% CO2 before replacing the medium with MSCLG containing 2.5 or 1.0µg/mL 
puromycin for HEK293T cells or UCMSC respectively and cultured for 48 hours at 
37°C and 5% CO2. MSCLG was replaced and cells cultured to 80% confluence 
before analysing PDPN protein expression by flow cytometry (Section 2.7.1).  
 
Alternatively, cells were transfected by electroporation with a 4D-Nucleofector X Unit 
and P1 Primary Cell 4D-Nucleofector X Kit (both Lonza) as per the manufacturer’s 
instructions. Briefly, the cells were subcultured and 500,000 were re-suspended in 
100µL P1 Nucleofector solution (Lonza) with 5µg custom, commercial (U6-
gRNA/CMV-Cas9-GFP; Hs0000333287; Sigma-Aldrich), or pmaxGFP control 
plasmid (Lonza). The re-suspended cells were transferred to a Nucleofector cuvette 
(Lonza) and electroporated using the FW-105 program on the 4D-Nucleofector X 
Unit. The electroporated cells were incubated for 10 minutes at room temperature to 
allow for plasmid uptake, prior to diluting in MSCLG and incubating at 37°C and 5% 
CO2. At 72 hours post-transfection, PDPN protein expression was measured by flow 
cytometry (Section 2.7.1). 
 
In some experiments the PDPN knockout population of HEK293T cells were isolated 
by fluorescence activated cell sorting (MoFlow Astrios; Beckman Coulter) using the 
flow cytometry staining protocol and the gating strategy described in Figure 2-12. The 
cells were subsequently cultured at 37°C and 5% CO2 as described.  
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2.14. CONFOCAL MICROSCOPY 
MSC (1.6´102 cells/mm2) were seeded in Ibidi microslides (µ-Slide VI0.4) for 24 hours 
in the presence or absence of 10µM NSC23766. Cells were fixed with 10% neutral-
buffered formalin for 30 minutes, permeabilised with 0.5% Triton-X-100 (both Sigma-
Aldrich) in PBS+ for 10 minutes, followed by blocking with 1% BSA and 10% goat 
serum (Vector Laboratories) for 1 hour. Effects of PDPN on cytoskeletal structures 
were assessed by staining cells with 5µg/mL anti-human PDPN antibody and then 
10µg/mL polyclonal goat anti-rat Alexa647 antibody (ThermoFisher) for 1 hour for 
each step. Cells were washed three times with PBS+ between each step. Samples 
were counterstained with 16.5nM Alexa488-conjugated phalloidin (f-actin probe; 
ThermoFisher) for 30 minutes, and mounted in ProLong Gold Antifade Mountant with 
DAPI (ThermoFisher). Cells were imaged using Zen software on an LSM780 confocal 
microscope (both from Carl-Zeiss). Representative fluorescent images were taken of 
MSC to identify PDPN localisation with respect to cytoskeletal and nuclear staining. 
Images were false coloured using ImageJ software. Average cell area was 
expressed as the total area of f-actin staining divided by the number of nuclei. 
Average PDPN intensity was expressed as the integrated density function for the 
PDPN channel divided by the number of nuclei (both using ImageJ software). The 
percentage of cells expressing peripheral PDPN was determined by counting those 
with PDPN expression at the cell edge alone compared to the total number of cells. 
 
2.15. ADDITIONAL WHOLE BLOOD PLATELET AGGREGATION ASSAYS 
For cell suspension aggregation assays, HEK293T cells or UCMSC were subcultured 
and resuspended in whole blood at 500,000 cells/mL in round-bottomed Eppendorf 
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tubes on the slow setting of a tube roller for 30 minutes at 37°C. The platelet count 
was measured using the ABX Pentra 60 (Horiba, Middlesex, UK). Data was 
expressed as the percentage reduction in platelet count in sample compared to 
platelet count in the whole blood-only control. 
 
For static adhesion assays, CD41a-labelled whole blood was incubated for 1 hour 
37°C and 5% CO2 in the upper chamber of a 0.4, 3.0, or 8.0µm pore 6-well cell 
culture insert (all BD Falcon), with UCMSC monocultures on the basal surface of the 
filter. The filter was washed and the remaining adherent platelets were imaged by 
fluorescence microscopy and platelet adhesion and aggregation was expressed as 
average size using ImageJ software particle analysis. 
 
2.16. STATISTICAL ANALYSIS 
Data are mean ± SEM of n independent experiments using individual biological 
replicates. In some instances, a biological replicate was taken as the mean of 
multiple technical replicates. In some data sets outliers where excluded using 
Grubbs’ experimental outliers test. For modelling the relationship between two 
variables, linear regression was used. For non-parametric data sets, variation 
between multiple comparisons was evaluated by Friedman test. For parametric data 
sets, single treatments were compared using paired or unpaired t-test where 
appropriate. Variation between multiple comparisons was evaluated using a one-way 
or two-way analysis of variance (ANOVA), followed by Dunnett or Bonferroni post-
test where appropriate. A p-value of <0.05 was considered statistically significant. 
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3.1. INTRODUCTION 
The underlying mechanisms of leukocyte recruitment have been widely studied, 
using techniques that range from simple adhesion assays to complex whole-tissue 
experiments and in vivo imaging systems (Munir et al. 2015; Jeffery et al. 2013; 
Chimen et al. 2015). 
 
Static in vitro cell adhesion assays to endothelial monolayers present an ideal 
platform for analysing multiple variables through the prior addition of small molecule 
inhibitors or function-blocking antibodies to endothelial monolayers (Chimen et al. 
2015). The disadvantage of such a simple assay is that it is far removed from 
physiological leukocyte recruitment in terms of cellular sedimentation by gravity and 
the absence of dynamic flow. A solution to this is to use flow-based assays. Whilst 
they still do not truly represent a physiological recruitment response, they allow the 
study of real-time leukocyte capture dynamics over recombinant protein or 
endothelium at different shear stress or turbulent flow (Navarro-Nunez et al. 2015; 
Munir et al. 2015). Indeed, flow-based systems enable researchers to scrutinise each 
individual step of the recruitment cascade from capture to transmigration. However, 
they lack the high-throughput nature of the static adhesion assay, and both assays 
fall short of being able to model leukocyte penetration into the underlying stroma. 
 
Extracellular matrix components such as collagen have been used to create 3-D 
matrix models of the stromal microenvironment and study the inflammatory infiltrate. 
These can be combined with the static adhesion assay by culturing endothelium 
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above the 3-D matrix and using Z-stacks to monitor leukocyte penetration over time, 
or their interactions with cocultured stromal cells (Jeffery et al. 2013). Indeed, 
coculture assays take us a step closer to understanding the crosstalk that occurs in a 
multicellular system during an inflammatory response. It is necessary to incorporate 
these coculture systems in both flow-based adhesion assays and 3-D matrices to 
develop an appropriate physiological model in vitro. 
 
Here we describe a static 3-D matrix and two flow-based assays in which MSC can 
be cocultured with endothelium; of the latter, the Ibidi microchannel utilises multiple 
single surface channels whilst in the parallel-plate model cells can be cultured on 
either side of a porous filter. Thus, these models enable us to investigate how 
stromal cells modulate endothelial recruitment of leukocytes, and provide a platform 
for studying the effects of inflammatory stimuli on this system (Luu et al. 2013; Jeffery 
et al. 2013). Specifically, we aim to address which of these models is most suited for 
studying the result of stromal-endothelial crosstalk, and hypothesise that 
microvascular endothelium serves as a suitable and physiologically relevant 
alternative to HUVEC. 
 
3.2. RESULTS 
3.2.1. COMPARISON OF FLOW-BASED MODELS OF VASCULAR INFLAMMATION 
Using TNF-a as a model for inflammation, we stimulated HUVEC in both the Ibidi 
microchannel and parallel plate models to determine whether there was any model 
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variation using the same conditions. We tested its effect on the ability to recruit 
neutrophils from flow and analysed their subsequent behaviour in terms of rolling and 
transendothelial migration. In the microchannel model of flow, neutrophil adhesion 
was negligible in unstimulated HUVEC, but there was a dose-dependent increase in 
adhesion with TNF-a concentration (Figure 3-1). There was no effect of TNF-a 
concentration on neutrophil rolling over HUVEC at 2 minutes (Figure 3-2A), however 
a significant increase in neutrophil transmigration was observed with both TNF-a 
concentration and time post-perfusion (Figure 3-2B). Similarly, a significant dose-
dependent increase in neutrophil adhesion to TNF-a treated HUVEC was observed 
in the parallel-plate model (Figure 3-3). In contrast to the microchannel model, there 
was no effect of TNF-a concentration or time on neutrophil behaviour (Figure 3-4). In 
future experiments, 100U/mL TNF-a allowed maximal neutrophil adhesion and 
therefore was selected to stimulate the endothelium. Furthermore, the parallel-plate 
model was chosen to establish cell coculture, as this model allows stromal cells to be 
seeded in a perivascular location and not to integrate into the endothelial monolayer. 
 
Leukocyte recruitment typically occurs at the endothelium of the post-capillary 
venules (Goldsmith & Spain 1984). Historically numerous groups have analysed 
leukocyte recruitment using HUVEC, a macrovascular endothelial cell (Burns & 
DePaola 2005; Sheikh et al. 2005; Patel 1999). Here we compared HUVEC with 
human dermal blood microvascular endothelial cells (BEC) which more closely 
represent the endothelium of the post-capillary venules (i.e. where recruitment occurs 
physiologically). No difference was observed between neutrophil adhesion to TNF-a   
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Figure 3-1 Effect of TNF-a stimulation on neutrophil adhesion from flow 
using Ibidi microchannels. 
HUVEC were seeded into Ibidi microchannels for 24 hours prior to stimulation with 0, 
10, or 100U/mL of TNF-a for 4 hours. A 4-minute neutrophil (1x106 cells/mL) bolus 
was perfused at 0.05Pa, and adhesion assessed at 2 minutes’ post-perfusion. 
ANOVA showed a significant effect of treatment on adhesion; p<0.01. Data are mean 
± SEM from n=3-5 independent experiments using at least three different donors for 
each cell type. * = p<0.05, ** = p<0.01 compared to untreated HUVEC (0U/ml) by 
Dunnett post-test.  
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Figure 3-2 Effect of TNF-a stimulation on the behaviour of recruited 
neutrophils using Ibidi microchannels. 
HUVEC were seeded into Ibidi microchannels for 24 hours prior to stimulation with 10 
or 100U/mL of TNF-a for 4 hours. A 4-minute neutrophil (1x106 cells/mL) bolus was 
perfused at 0.05Pa, and neutrophil (A) rolling and (B) transmigration assessed at 2 
and 9 minutes’ post-perfusion. In B, ANOVA showed a significant effect of treatment, 
but not time, on transmigration; p<0.01. Data are mean ± SEM from n=3-5 
independent experiments using at least three different donors for each cell type. * = 
p<0.05 by Bonferroni post-test.  
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Figure 3-3 Effect of TNF-a stimulated HUVEC on neutrophil recruitment 
from flow using a filter-based assay. 
HUVEC were seeded onto a 0.4μm transwell filter for 24 hours prior to stimulation 
with 0, 10, or 100U/mL of TNF-a for 4 hours. A 4-minute neutrophil (1x106 cells/mL) 
bolus was perfused at 0.1Pa, and adhesion assessed at 2 minutes’ post-perfusion. 
ANOVA showed a significant effect of cytokine treatment on adhesion; p<0.01. Data 
are mean ± SEM from n=5-9 independent experiments using at least five different 
donors for each cell type. ** = p<0.01 compared to untreated HUVEC (0U/ml) by 
Dunnett post-test.  
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Figure 3-4 Effect of TNF-a stimulated HUVEC on the behaviour of recruited 
neutrophils using a filter-based assay. 
HUVEC were seeded onto a 0.4μm transwell filter for 24 hours prior to stimulation 
with 10 or 100U/mL of TNF-a for 4 hours. A 4-minute neutrophil (1x106 cells/mL) 
bolus was perfused at 0.1Pa, and neutrophil (A) rolling and (B) transmigration 
assessed at 2 and 9 minutes’ post-perfusion. Data are mean ± SEM from n=5-8 
independent experiments using at least five different donors for each cell type.  
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treated HUVEC or BEC (Figure 3-5). However, both rolling and transmigration 
occurred at significantly lower levels on BEC compared to HUVEC at 2 and 9 
minutes’ post-perfusion respectively (Figure 3-6). 
 
3.2.2. IMMUNOMODULATORY POTENTIAL OF BMMSC 
Next, we established BMMSC coculture with HUVEC or BEC and compared 
neutrophil adhesion and behaviour against an endothelial monoculture control. MSC 
have previously been shown to suppress the responses of HUVEC (Luu et al. 2013; 
Munir et al. 2016), however, the immunosuppressive capacity of BMMSC on BEC 
was undefined. BMMSC coculture had no effect on neutrophil adhesion to HUVEC 
(Figure 3-7), nor their subsequent behaviour (Figure 3-8). However, BMMSC 
coculture significantly suppressed neutrophil recruitment to BEC in the presence of 
TNF-a (Figure 3-9). No effect was observed for neutrophil rolling with BMMSC 
coculture (Figure 3-10A), but neutrophil transmigration was significantly increased at 
both 2 and 9 minutes’ post-perfusion (Figure 3-10B). As BEC coculture resulted in 
suppression of neutrophil adhesion, we used BEC as the endothelial source in future 
flow-based adhesion assays. 
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Figure 3-5 Effect of endothelial source on neutrophil recruitment from flow 
using a filter-based assay. 
HUVEC or BEC were seeded onto a 0.4μm transwell filter for 24 hours prior to 
stimulation with 100U/mL of TNF-a for 4 hours. A 4-minute neutrophil (1x106 
cells/mL) bolus was perfused at 0.1Pa, and adhesion assessed at 2 minutes’ post-
perfusion. Data are mean ± SEM from n=12-17 independent experiments using at 
least three different donors for each cell type.  
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Figure 3-6 Effect of endothelial source on the behaviour of recruited 
neutrophils using a filter-based assay. 
HUVEC or BEC were seeded onto a 0.4μm transwell filter for 24 hours prior to 
stimulation with 100U/mL of TNF-a for 4 hours. A 4-minute neutrophil (1x106 
cells/mL) bolus was perfused at 0.1Pa, and neutrophil (A) rolling and (B) 
transmigration assessed at 2 and 9 minutes’ post-perfusion. ANOVA showed a 
significant effect of endothelial source on (A) rolling and (B) transmigration; p<0.01 
for both. Data are mean ± SEM from n=14-18 independent experiments using at least 
three different donors for each cell type. * = p<0.05, ** = p<0.01 by Bonferroni post-
test.  
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Figure 3-7 Effect of HUVEC:MSC coculture on neutrophil recruitment from 
flow using a filter-based assay. 
HUVEC-BMSMC coculture (coculture) was established by seeding HUVEC on the 
opposite side of a 0.4μm transwell filter to BMMSC for 24 hours prior to stimulation 
with 100U/mL of TNF-a for 4 hours. HUVEC monocultures were seeded as controls 
(HUVEC). A 4-minute neutrophil (1x106 cells/mL) bolus was perfused at 0.1Pa, and 
adhesion assessed at 2 minutes’ post-perfusion. Data are mean ± SEM from n=6-12 
independent experiments using at least three different donors for each cell type.  
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Figure 3-8 Effect of HUVEC:MSC coculture on the behaviour of recruited 
neutrophils using a filter-based assay. 
HUVEC-BMMSC coculture (coculture) was established by seeding HUVEC on the 
opposite side of a 0.4μm transwell filter to BMMSC for 24 hours prior to stimulation 
with 100U/mL of TNF-a for 4 hours. HUVEC monocultures were seeded as controls 
(HUVEC). A 4-minute neutrophil (1x106 cells/mL) bolus was perfused at 0.1Pa, and 
neutrophil (A) rolling and (B) transmigration assessed at 2 and 9 minutes’ post-
perfusion. Data are mean ± SEM from n=6-12 independent experiments using at 
least three different donors for each cell type.  
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Figure 3-9 Effect of BEC:MSC coculture on neutrophil recruitment from 
flow using a filter-based assay. 
BEC-BMMSC coculture (coculture) was established by seeding BEC on the opposite 
side of a 0.4μm transwell filter to BMMSC for 24 hours prior to stimulation with 
100U/mL of TNF-a for 4 hours. BEC monocultures were seeded as controls (BEC). A 
4-minute neutrophil (1x106 cells/mL) bolus was perfused at 0.1Pa, and adhesion 
assessed at 2 minutes’ post-perfusion. Data are mean ± SEM from n=18-19 
independent experiments using at least three different donors for each cell type. ** = 
p<0.01 by paired t-test compared to BEC mono-cultures.  
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Figure 3-10 Effect of BEC:MSC coculture on the behaviour of neutrophils 
recruited from flow using a filter-based assay. 
BEC-BMMSC coculture (coculture) was established by seeding BEC on the opposite 
side of a 0.4μm transwell filter to BMMSC for 24 hours prior to stimulation with 
100U/mL of TNF-a for 4 hours. BEC monocultures were seeded as controls (BEC). A 
4-minute neutrophil (1x106 cells/mL) bolus was perfused at 0.1Pa, and neutrophil (A) 
rolling and (B) transmigration assessed at 2 and 9 minutes’ post-perfusion. In B, 
ANOVA showed a significant effect of culture conditions, but not time, on 
transmigration; p<0.01. Data are mean ± SEM from n=18-19 independent 
experiments using at least three different donors for each cell type. * = p<0.05 by 
Bonferroni post-test.  
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3.2.3. NEUTROPHIL RECRUITMENT TO 3-D COLLAGEN GELS INCORPORATING HUVEC 
AND BMMSC COCULTURE 
3-D collagen matrices have previously been shown to be effective models of the 
inflammatory infiltrate (Jeffery et al. 2013). To confirm this HUVEC were stimulated 
with or without 100U/mL TNF-a and subsequent leukocyte adhesion, migration, and 
penetration recorded. Neutrophil adhesion was significantly increased with TNF-a-
treatment of HUVEC (Figure 3-11A), but cytokine treatment had no effect on 
neutrophil migration or gel penetration (Figure 3-11B and Figure 3-11C). BMMSC 
coculture had no effect on neutrophil adhesion to TNF-a-treated HUVEC (Figure 3-
12A). Coculture caused a significant decrease in neutrophil penetration of the gel at 
20 minutes’ post-incubation (Figure 3-12B), but this effect was lost by 2 hours (Figure 
3-12C). BMMSC coculture also significantly reduced the depth of the collagen gel 
(Figure 3-12D). These data suggest that in static models MSC have little impact on 
neutrophil adhesion, but delayed their migration into the inflammatory sites at early 
time-points.   
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Figure 3-11  Effect of TNF-a stimulated HUVEC on neutrophil recruitment 
and infiltration into collagen gels. 
HUVEC were seeded onto the surface of a collagen gel for 24 hours prior to 
stimulation with 100U/mL TNF-a for 4 hours. Neutrophils (1´106) were incubated with 
the endothelium for 20 minutes. (A) Adhesion was assessed immediately after 
neutrophil incubation. Gel penetration was assessed after both (B) 20 minutes and 
(C) 2 hours. In B and C, ANOVA showed a significant effect of treatment on gel 
penetration; p<0.05. Data are mean ± SEM from n=4 independent experiments using 
four different donors for each cell type. * = p<0.05 by (A) paired t-test or (B) 
Bonferroni post-test compared to untreated control (0U/ml).  
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Figure 3-12  Effect of HUVEC:MSC coculture on neutrophil recruitment and 
infiltration into collagen gels. 
BMMSC were incorporated into a collagen gel and HUVEC seeded on the surface for 
24 hours prior to stimulation with 100U/mL TNF-a for 4 hours. Neutrophils (1´106) 
were incubated with the endothelium for 20 minutes. (A) Adhesion was assessed 
immediately after neutrophil incubation. Gel penetration was assessed after both (B) 
20 minutes and (C) 2 hours. (D) Gel depth was assessed immediately after neutrophil 
incubation. In B and C, ANOVA showed a significant effect of coculture on gel 
penetration; p<0.01. Data are mean ± SEM from n=4 independent experiments using 
four different donors for each cell type. * = p<0.05, ** = p<0.01 by (B, C) Bonferroni 
post-test or (D) paired t-test compared to monoculture controls.  
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3.3. DISCUSSION 
In this chapter, we evaluated and optimised several adhesion assays to determine 
which was best suited for studying the interactions between MSC and inflamed 
endothelium. We observed a TNF-a dose dependent increase in neutrophil 
recruitment to HUVEC in the Ibidi microchannel, parallel-plate, and collagen gel 
models. An increase in neutrophil transmigration was also observed when we used 
the Ibidi microchannel and collagen gel model, but not the parallel-plate model. 
Whilst inflamed HUVEC and BEC supported comparable levels of binding, we 
observed less cells rolling and migrating on BEC compared to the HUVEC. 
Surprisingly, BMMSC had no effect on HUVEC responses, in the context of 
neutrophil recruitment when using the parallel-plate model. BMMSC did, however, 
impede neutrophil penetration into the collagen gel. In contrast, BMMSC suppressed 
BEC responses to TNF-a, such that fewer neutrophils were recruited. Collectively, 
we have explored the suitability of several different in vitro models, and shown that 
BMMSC suppress neutrophil recruitment to microvascular, but not macrovascular 
endothelium. We propose that the parallel-plate model allows the most flexibility in 
future experiments, and that MSC preferentially modulate the microvascular 
compartment during an inflammatory response.  
 
The effect of TNF-a dose responses are well described for neutrophil recruitment in 
HUVEC; with the concentration of TNF-a describing a positive correlation for CD62, 
VCAM1, and b1-integrin surface expression by HUVEC (W. Y. Sun et al. 2010), as 
well as neutrophil adhesion and transmigration (Butler et al. 2005). We also observed 
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the same response in HUVEC using the Ibidi microchannel model, however 
transmigration was unaffected by TNF-a stimulation in the parallel-plate model.  
 
Regarding differences between the Ibidi microchannel and parallel-plate flow assays, 
we found that neutrophil adhesion was dramatically reduced in the Ibidi microchannel 
compared to the parallel-plate model. Though neutrophil rolling and transmigration 
were similar between models, the Ibidi microchannel was more sensitive to changes 
in TNF-a concentration regarding neutrophil transmigration. However, a lower wall 
shear stress was used to compensate for the resident time in which neutrophils are 
recruited to endothelium in the microchannel model. An equivalent wall shear stress 
would restrict neutrophil capture to the channel outlet. Adhesion of promyelocytic 
leukaemia cells (HL-60) to CD62 coated surfaces has been shown to exhibit a 
biphasic profile to increasing wall shear stress, with peak adhesion at 0.05Pa or 
0.025Pa for CD62P or CD62E coatings respectively (Lawrence et al. 1997). Whilst 
contrary to our results, this study demonstrates that there isn’t a simple negative 
correlation between increasing wall shear stress and neutrophil adhesion. Indeed, it 
may instead be the case that this biphasic adhesion profile is shifted toward higher 
wall shear rates in HUVEC than on recombinant selectin coatings, though more 
studies are required. 
 
HUVEC are widely used in adhesion assays due to the accessibility of umbilical 
cords. However, leukocyte recruitment primarily takes place within the post-capillary 
venules; studies directly comparing endothelial-specific recruitment are scarce and 
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show mixed results. CD62E is known to support neutrophil rolling during recruitment, 
however gene expression of CD62E was shown to be 40% lower in BEC compared 
to HUVEC when pre-stimulated with 10ng/mL TNF-a for 2 hours (Vora et al. 1996). 
This also agreed with our finding of significantly reduced neutrophil rolling in BEC 
compared to HUVEC. Indeed, wild-type mice stimulated with local injections of 0.5µg 
TNF-a for 2-3 hours also exhibited reduced leukocyte rolling in microvascular post-
capillary venules when compared to the macrovasculature of the inferior vena cava 
(Eriksson et al. 2005). Conversely, another study showed that 5-20ng/mL TNF-a 
stimulation over 12 hours causes BEC to upregulate CD62E to a greater extent than 
HUVEC, but saw reductions in CD31 and VCAM1 (Murakami et al. 2001). Gene 
expression of ICAM1 and VCAM1 have also been shown to be greatly reduced in 
BEC compared with HUVEC when pre-stimulated with 25 ng/mL TNF-a over 4 hours, 
however no difference in lymphocyte rolling was observed (Oostingh et al. 2007). 
Though another study showed equivalent binding of HL-60 cells to TNF-a treated 
HUVEC and BEC (J. H. Li et al. 2003), agreeing with our observations for neutrophil 
adhesion. There appears to be no consensus within the literature on leukocyte rolling 
or adhesion at different vascular sites, though all used different methods of TNF-a 
stimulation. 
 
Regarding leukocyte transmigration in macro versus microvasculature, Chimen et al., 
(2015) observed no difference in lymphocyte transmigration for HUVEC or BEC 
under static conditions (Chimen et al. 2015). This disagreed with our observations 
where we saw a significant reduction in the number of transmigrating neutrophils in 
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BEC compared to HUVEC. VE-cadherin expression is involved in maintaining 
vascular integrity through endothelial cell-cell adhesions, under 25 ng/mL TNF-a 
stimulation over 4 hours it was found to be reduced in BEC compared to HUVEC 
(Oostingh et al. 2007). Interestingly, antibody-mediated blockade of VE-cadherin 
interactions in vivo have proven to enhance neutrophil transmigration into inflamed 
mouse peritoneum (Gotsch et al. 1997). This would suggest that neutrophil 
transmigration was increased in BEC due to lower expression of VE-cadherin than 
HUVEC, however, we observed decreased transmigration. Intravital microscopy of 
TNF-a induced neutrophil transmigration in several mouse models, has shown to be 
also dependent on the actions of ICAM2, JAM-A, and PECAM1 (Woodfin et al. 
2009). However, direct comparisons of the expression of these adhesion molecules 
in TNF-a stimulated HUVEC and BEC have yet to be made. These studies suggest 
that differential expression of endothelial adhesion molecules may have explicit 
outcomes on leukocyte recruitment at post-capillary venules compared to large veins. 
 
Stromal coculture has been shown to regulate expression of these adhesion 
molecules by endothelium, as discussed below. Indeed, treating pulmonary 
endothelial cells with conditioned medium from BMMSC coculture inhibited leukocyte 
adhesion in a static adhesion assay through downregulation of ICAM1 and VCAM1, 
but had no effect on CD62E and CD62P surface expression (Pati, Gerber, et al. 
2011). Indeed, BMMSC coculture with BEC suppressed adhesion, but had no effect 
on rolling of neutrophils in our flow-based assays. BMMSC coculture has previously 
been shown to suppress the adhesion of both neutrophils and lymphocytes to 
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cytokine stimulated HUVEC, with reduced or equal neutrophil transmigration to 
stimulated HUVEC monoculture (Luu et al. 2013; Munir et al. 2016). Here we have 
shown that BMMSC coculture has no effect on neutrophil adhesion, rolling, or 
transmigration on HUVEC. Indeed, we also observed increased neutrophil 
transmigration in microvascular BEC in the presence of BMMSC coculture. However, 
the reasons behind these contrasting results are unclear without further interrogation 
of this system or the contribution of similar studies. 
 
Other stromal cell populations have also been shown to regulate the inflammatory 
infiltrate. Human hepatocytes promote lymphocyte adhesion to liver sinusoidal 
endothelium through upregulation of VCAM1 and CD62E, with TNF-b stimulation 
further enhancing coculture-mediated induction of PECAM1 and ICAM1 expression 
(Edwards et al. 2005). Furthermore, pathogenic secretory smooth muscle cells 
(SMC) also display a pro-recruitment phenotype, with increased monocyte 
transmigration through aortic endothelium in the presence of SMC coculture, on the 
opposite side of a porous filter (Takaku et al. 1999) or underlying a collagen matrix 
(Navab et al. 1988). Whilst fibroblasts were observed to switch between a 
suppressive or pro-recruitment phenotype depending on the inflammatory state of the 
tissue (Filer et al. 2017). In contrast, coculture of podocytes with glomerular 
endothelium on opposite sides of a porous filter saw reduced neutrophil recruitment 
in response to stimulation with TNF-a (Kuravi et al. 2014). However, podocyte 
coculture with HUVEC saw no suppression of neutrophil recruitment indicating site-
specific crosstalk (Kuravi et al. 2014). These studies have shown that the 
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perivascular stromal compartment has a profound effect on the regulation of 
leukocyte recruitment, whether to promote or suppress the inflammatory infiltrate in a 
tissue and context specific manner. 
 
The parallel-plate model closely resembles the perivascular inflammatory response, 
in such that MSC are proximal to the endothelial lining in vivo and are an appropriate 
model of the anti-inflammatory mesenchymal cell types residing within the tissue 
stroma (Méndez-Ferrer et al. 2010; McGettrick et al. 2012). It enables scrutiny of the 
process of leukocyte recruitment in a flow-based setting. However, static 3D gel 
models have the benefit of dissecting the interactions that occur between leukocytes 
and stromal cells within tissue. Indeed, the answer to which model is better largely 
depends on the experimental question being asked. Jeffery et el., (2013) utilised 
collagen gels to study the infiltration of lymphocytes through inflamed tissue, and the 
effect of stromal cells on this process compared to transwell filter models (Jeffery et 
al. 2013). Coculture of dermal fibroblasts on the opposite side of a porous filter to 
HUVEC was found to have no effect on lymphocyte adhesion, but instead enhanced 
transmigration through HUVEC treated with TNF-a and IFN-g (Jeffery et al. 2013). 
Whereas suspension of dermal fibroblasts within the collagen gel was found to have 
no effect on lymphocyte adhesion or transmigration across HUVEC treated with TNF-
a and IFN-g, nor the penetrance of adherent lymphocytes into the collagen gel 
(Jeffery et al. 2013). In a comparable study, neutrophil adhesion to HUVEC treated 
with TNF-a was shown to be suppressed in the presence of BMMSC coculture, to a 
similar extent in both the transwell filter and collagen gel models (Munir et al. 2017). 
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However, like the transwell filter model, the suppressive effect of BMMSC coculture 
on HUVEC in a collagen gel was also lost in our hands. Here we have shown that 
treatment of HUVEC with TNF-a increases adhesion and penetration into the 
collagen gel. In contrast, BMMSC coculture has no effect on adhesion, but impedes 
the penetration of recruited neutrophils into the gel. However, this could be a 
mechanical effect rather than a result of soluble factors as the depth of the collagen 
gel was contracted in the presence of BMMSC. These data also disagreed with 
another study reporting that substrate stiffness induces endothelial contraction, 
resulting in decreased endothelial cell-cell adhesion and increased neutrophil 
transmigration (Stroka & Aranda-Espinoza 2011). Collectively, these studies suggest 
a role for 3D gel models in understanding the process of leukocyte infiltration into the 
inflamed tissue. 
 
In conclusion, the microchannel model was best suited for studying the capture 
dynamics of leukocytes to endothelial monocultures, whilst the parallel-plate model 
had advantages of being able to study the effect of coculture without disrupting the 
endothelial monolayer. The collagen gel model also allowed for coculture of cells in a 
physiologically relevant structure, with the benefit of investigating leukocyte infiltration 
into tissue, however the restriction to static leukocyte adhesion made it less suitable 
than the flow-based assays for investigating recruitment as a readout of endothelial 
function. The literature comparing leukocyte recruitment to micro and macrovascular 
endothelium was scarce and varied in their results as well as the methodology and 
readouts used. However, they do indicate differential leukocyte recruitment between 
these vessels. Indeed, we have shown similar levels of neutrophil adhesion, but 
Enabling technologies 
 111 
reduced rolling and transmigration in BEC compared to HUVEC. Coculture of 
BMMSC with these sources of endothelium revealed preferential modulation of the 
microvascular compartment with suppression of neutrophil adhesion and increased 
transmigration compared to endothelial monoculture controls. However, we were 
unable to investigate the reasons behind a lack of response in HUVEC-BMMSC 
coculture compared to previous results in the literature nor the mechanisms 
governing the increased neutrophil transmigration in BEC-BMMSC coculture. We 
would suggest a comparison in the endothelial gene expression of adhesion 
molecules such as ICAM1 and VCAM1, in both coculture systems. Overall, we have 
shown that these models provide an effective means of observing site-specific 
functional changes within the inflammatory microenvironment brought forth by 
multicellular crosstalk.
  
 
 
 
Chapter 4. EFFECT OF THE INFLAMMATORY 
MICROENVIRONMENT ON MSC IMMUNOMODULATION 
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4.1. INTRODUCTION 
The MSC field indicates that priming of MSC is required for enhanced function 
[reviewed by (Najar et al. 2017; Lee et al. 2015)]. However, this is not always the 
case. At sites of chronic inflammation, stromal cells acquire a pathogenic phenotype 
that allows them to perpetuate the disease state (Filer et al. 2017; Croft et al. 2016). 
Indeed, the context of the MSC microenvironment has been shown to directly modify 
the extent of their function (Munir et al. 2017; Munir et al. 2016; Kastrinaki et al. 
2008). This leads us to hypothesise that mimicking the conditions of chronic 
inflammation alters MSC cross-talk with endothelium, such that it is no longer 
immunosuppressive. 
 
4.2. RESULTS 
Here we utilised the flow-based coculture adhesion model as a method of 
investigating the functional immunomodulatory actions of BMMSC on BEC, and how 
these responses might be perturbed in the context of either acute or prolonged TNF-
a stimulation. 
 
BMMSC coculture suppressed neutrophil recruitment to inflamed endothelium as 
described in the previous chapter. Priming BMMSC with 24 hours of TNF-a had no 
effect on neutrophil adhesion to inflamed BEC in coculture (Figure 4-1). Again, 
BMMSC coculture significantly increased neutrophil transmigration at 9 minutes’ 
post-perfusion as described in the previous chapter, but 24-hour TNF-a-priming 
inhibited the increase in neutrophil migration observed with coculture (Figure 4-2B).  
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Figure 4-1 Effect of acute priming of MSC with TNF-a on their cross-talk 
with endothelium and recruitment of neutrophils from flow.  
BMMSC were seeded onto the basal surface of a 0.4μm transwell filter for 24 hours, 
followed by TNF-a stimulation for 24 hours. Coculture was established by seeding 
BEC on the opposite side of the filter for 24 hours prior to stimulation with 100U/mL 
of TNF-a for 4 hours. A 4-minute neutrophil (1x106 cells/mL) bolus was perfused at 
0.1Pa, and adhesion assessed at 2 minutes’ post-perfusion. ANOVA showed a 
significant effect of culture conditions on neutrophil adhesion; p<0.01. Data are mean 
± SEM from n=3 independent experiments using three different donors for each cell 
type. * = p<0.05 compared to BEC monoculture by Dunnett post-test.  
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Figure 4-2 Effect of acute priming of MSC with TNF-a on their cross-talk 
with endothelium and modulation of neutrophil behaviour. 
BMMSC were seeded onto the basal surface of a 0.4μm transwell filter for 24 hours, 
followed by TNF-a stimulation for 24 hours. Coculture was established by seeding 
BEC on the opposite side of the filter for 24 hours prior to stimulation with 100U/mL 
of TNF-a for 4 hours. A 4-minute neutrophil (1x106 cells/mL) bolus was perfused at 
0.1Pa, and neutrophil (A) rolling and (B) transmigration assessed at 2 and 9 minutes’ 
post-perfusion. In B, ANOVA showed a significant effect of culture conditions, but not 
time, on transmigration; p<0.01. Data are mean ± SEM from n=3 independent 
experiments using three different donors for each cell type. * = p<0.05, ** = p<0.01 by 
Bonferroni post-test.   
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Similar effects were observed for neutrophil recruitment when BMMSC were treated 
with TNF-a for prolonged periods (72 hours) prior to coculture (Figure 4-3 and Figure 
4-4). TNF-a treatment increased IL-6 secretion in BMMSC monocultures when 
compared to the untreated BMMSC monoculture controls (Figure 4-5). However, this 
increase was lost upon coculture with BEC, with similar levels of IL-6 detected in 
cocultures incorporating primed or resting BMMSC (Figure 4-5). Furthermore, resting 
BMMSC coculture had no effect on the level of IL-6 compared to resting BMMSC 
monoculture controls (Figure 4-5). 
 
TNF-a treatment has been shown to skew the phenotype of fibroblasts in culture 
from resolving to inflammation based on the differential expression of PDPN and 
CD248 (Croft et al. 2016). Indeed, inflamed stroma have been shown to express the 
cell adhesion molecules ICAM1 and VCAM1 in association with PDPN [reviewed by 
(Buckley et al. 2015)]. Whilst, IDO1 is involved in MSC immunomodulation (Ling et al. 
2014), and fibroblast activation protein (FAP) is a protease expressed at sites of 
inflammation, and has also been shown to regulate BMMSC migration (Brokopp et al. 
2011; Chung et al. 2014). We subsequently examined the effects of TNF-a priming 
on gene expression of the above molecules in BMMSC to determine whether these 
were modified. Comparisons were made to rheumatoid synovial fibroblasts (RASF) 
as a model for pro-inflammatory stromal cells in culture. Neither acute nor prolonged 
TNF-a treatment had any effect on BMMSC gene expression of PDPN, CD248, FAP, 
or VCAM1; or RASF gene expression of PDPN, CD248, FAP, IDO1, or VCAM1 
(Figure 4-6 and Figure 4-7). However, IDO1 was significantly increased in response 
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to TNF-a treatment in BMMSC, and ICAM1 was increased for both BMMSC and 
RASF in response to TNF-a at both 24 and 72 hours (Figure 4-6E and Figure 4-7E). 
 
Next, we examined whether taking a pathogenically transformed cell from a 
chronically inflamed tissue might influence MSC functions (and vice-versa). We 
therefore cocultured BMMSC with RASF for 24 hours and analysed the expression of 
inflammation-associated genes compared to their respective monoculture controls. 
No significant changes were observed in PDPN, FAP, CD248, IDO1, or VCAM1 gene 
expression (Figure 4-8 and Figure 4-9). The exception was decreased ICAM1 gene 
expression for both BMMSC coculture with RASF (Figure 4-8E) and RASF coculture 
with BMMSC when compared to their respective monoculture controls (Figure 4-9E). 
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Figure 4-3 Effect of prolonged priming of MSC with TNF-a on their cross-
talk with endothelium and recruitment of neutrophils from flow. 
BMMSC were seeded onto the basal surface of a 0.4μm transwell filter for 24 hours, 
followed by TNF-a stimulation for 72 hours. Coculture was established by seeding 
BEC on the opposite side of the filter for 24 hours prior to stimulation with 100U/mL 
of TNF-a for 4 hours. A 4-minute neutrophil (1x106 cells/mL) bolus was perfused at 
0.1Pa, and adhesion assessed at 2 minutes’ post-perfusion. ANOVA showed no 
effect of culture conditions on neutrophil adhesion; p=0.12. Data are mean ± SEM 
from n=3 independent experiments using three different donors for each cell type.   
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Figure 4-4 Effect of prolonged priming of MSC with TNF-a on their cross-
talk with endothelium and modulation of neutrophil behaviour. 
BMMSC were seeded onto the basal surface of a 0.4μm transwell filter for 24 hours, 
followed by TNF-a stimulation for 72 hours. Coculture was established by seeding 
BEC on the opposite side of the filter for 24 hours prior to stimulation with 100U/mL 
of TNF-a for 4 hours. A 4-minute neutrophil (1x106 cells/mL) bolus was perfused at 
0.1Pa, and neutrophil (A) rolling and (B) transmigration assessed at 2 and 9 minutes’ 
post-perfusion. In B, ANOVA showed a significant effect of time, but not culture 
conditions, on neutrophil transmigration; p<0.01. Data are mean ± SEM from n=3 
independent experiments using three different donors for each cell type. * = p<0.05 
by Bonferroni post-test.  
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Figure 4-5 Effect of acute priming of MSC with TNF-a on their production 
of IL-6. 
IL-6 concentration was measured by ELISA from BMMSC monocultures or cocultures 
with BEC. pMSC denotes 24-hour TNF-a stimulation of BMMSC monoculture. ANOVA 
showed a significant effect of culture conditions; p<0.01. Data are mean ± SEM from 
n=4-13 experiments using three different donors for each cell type. * = p<0.05, ** = 
p<0.01 by Bonferroni post-test.  
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Figure 4-6 Effect of TNF-a priming on MSC gene expression. 
BMMSC were stimulated with 0U/mL or 100U/mL TNF-a stimulation for 24 or 72 hours. 
Gene expression for (A) PDPN, (B) FAP, (C) CD248, (D) IDO1, (E) ICAM1, and (F) 
VCAM1 were examined by qPCR. ANOVA showed a significant effect of treatment, 
but not time, on (D) IDO1 and (E) ICAM1 gene expression; p<0.05. In (F), ANOVA 
showed a borderline significant effect of treatment, but not time on VCAM-1 
expression, p=0.06. * = p<0.05 by Bonferroni post-test. Data are mean ± SEM from 
n=3 independent experiments using three different donors.  
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Figure 4-7 Effect of TNF-a priming on RASF gene expression. 
RASF were stimulated with 0U/mL or 100U/mL TNF-a stimulation for 24 or 72 hours. 
Gene expression for (A) PDPN, (B) FAP, (C) CD248, (D) IDO1, (E) ICAM1, and (F) 
VCAM1 were examined by qPCR. ANOVA showed a significant effect of treatment, 
but not time, on (E) ICAM1 gene expression; p<0.05. * = p<0.05 by Bonferroni post-
test. Data are mean ± SEM from n=3 independent experiments using three different 
donors.  
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Figure 4-8 Effect of RASF coculture on MSC gene expression. 
Stromal coculture was established by seeding BMMSC on the opposite side of a 
0.4μm transwell filter to RASF for 24 hours. MSC monocultures were established as a 
control. MSC gene expression for (A) PDPN, (B) FAP, (C) CD248, (D) IDO1, (E) 
ICAM1, and (F) VCAM1 were examined by qPCR. Data are mean ± SEM from n=3 
independent experiments using three different donors for each cell type. ** = p<0.01 
by paired t-test compared to MSC monoculture.  
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Figure 4-9 Effect of MSC coculture on RASF gene expression. 
Stromal coculture was established by seeding BMMSC on the opposite side of a 
0.4μm transwell filter to RASF for 24 hours. RASF monocultures were established as 
a control. MSC RASF gene expression for (A) PDPN, (B) FAP, (C) CD248, (D) IDO1, 
(E) ICAM1, and (F) VCAM1 were examined by qPCR. Data are mean ± SEM from 
n=3 independent experiments using three different donors for each cell type. * = 
p<0.05 by paired t-test compared to RASF monoculture control.  
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4.3. DISCUSSION 
Here we aimed to understand the effect of the inflammatory microenvironment on 
MSC phenotype and immunomodulation of endothelium. We observed that neither 
acute nor prolonged TNF-a priming affected the ability of BMMSC to suppress 
neutrophil recruitment to endothelium. BMMSC coculture increased neutrophil 
transmigration, whilst primed BMMSC coculture saw no difference in transmigration 
compared to endothelial monoculture. BMMSC secretion of IL-6 was increased by 
acute TNF-a priming. Coculture produced less IL-6 compared to BMMSC 
monoculture, independent of BMMSC priming. Acute and prolonged TNF-a priming 
upregulated ICAM-1 gene expression in both BMMSC and RASF, as well as IDO1 
gene expression in BMMSC. BMMSC coculture with RASF, reduced ICAM-1 gene 
expression in RASF. We propose that the immunomodulatory capacity of BMMSC is 
unaltered by exposure to exogenous TNF-a stimulation, instead it would appear that 
BMMSC are still able to suppress neutrophil recruitment to microvascular 
endothelium. This has implications both in MSC cell-based therapy, and in 
understanding the pathogenesis of inflammatory disorders. 
 
MSC are endogenous multipotent cells, enriched within the perivascular niche 
(Crisan et al. 2008). As such, they contribute to the maintenance, repair, and 
immunomodulation of the vascular compartment [reviewed by (Pankajakshan & 
Agrawal 2014)]. Indeed, adipose-derived MSC have been shown to support the 
formation of stable vessels in cardiac tissue through the upregulation of pro-
angiogenic factors, such as VEGF and HGF (Rubina et al. 2009). MSC are also a 
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migratory population of cells, enabling them to respond and move toward 
inflammatory stimuli where they can exert their immunosuppressive and reparative 
functions (see Chapter 5). This supportive phenotype is of importance for MSC-
based therapeutics. By understanding the ways in which MSC respond to 
inflammatory stimuli we can effectively ‘prime’ these cells to amplify certain functions 
during treatment. Furthermore, investigations into the impact of the chronic 
inflammatory microenvironment on MSC function will benefit our understanding of 
progression of chronicity and failure to resolve. 
 
The inflammatory microenvironment is composed of a large variety of different 
context specific stimuli, e.g. cytokines, chemokines, or pathogen- or damage-
associated molecular patterns. The overall outcome of such signalling is an 
orchestrated response between different cell types that defines the switch between 
acute resolving and chronic persistent inflammation. Attempts to model these 
scenarios by stimulating MSC with pro-inflammatory cytokines are well documented, 
with some studies demonstrating that priming enhances MSC function (Table 1-2). 
However, other groups have reported conflicting data, where priming has no effect on 
MSC function. For example, treatment of murine BMMSC with TNF-a was shown to 
increase PGE2 secretion and HGF expression whilst reducing TGF-b secretion 
(English et al. 2007), however, contradictory results saw decreased PGE2 secretion 
and HGF expression but increased TGF-b1 expression (Wu et al. 2015; Prasanna et 
al. 2010). Likewise, the ability to polarise BMMSC to an anti- or pro-inflammatory 
phenotype was deemed possible through TLR3 or TLR4 priming with poly(I:C) or 
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LPS respectively (Waterman et al. 2010). TLR stimulation of BMMSC has also been 
shown to upregulate the expression of ICAM1 and VCAM1, promoting their adhesion 
to lymphocytes (Kota et al. 2014). Indeed, we found that TNF-a stimulation 
upregulated gene expression of ICAM1 on both BMMSC and RASF. Interestingly, 
increased expression of ICAM1 is suggested to be the mechanism by which MSC 
bind infiltrating leukocytes during the inflammatory response and exert their contact-
dependent or local immunosuppressive factors (Kota et al. 2014; Ren et al. 2010; 
Schena et al. 2010). However, subsequent studies reported conflicting findings to 
those made by Waterman. Raicevic et al., (2011) showed no effect of TLR3 or TLR4 
priming on TGF-b expression, suppression of T-cell proliferation, or PGE2 secretion 
compared to unstimulated controls (Raicevic et al. 2011). Whilst, Liotta et al., (2008) 
demonstrated no effect of TLR3 or TLR4 priming on IDO activity, but equally impaired 
suppression of T-cell proliferation and increased IL-6, IL-8, and CXCL10 secretion 
regardless of which TLR was primed (Liotta et al. 2008). These studies would 
suggest that MSC describe a heterogeneous population of cells and that their 
responses to inflammatory stimuli differ greatly depending on environmental 
conditions. 
 
Flow-based adhesion assays have previously demonstrated that MSC differ in their 
ability to modulate endothelial recruitment of neutrophils based on their tissue source 
(Munir et al. 2016). Indeed, in vitro adipogenic differentiation of these MSC, through 
prior exposure to a number of chemicals and growth factors, has caused them to lose 
their immunosuppressive capacity (Munir et al. 2017). This is of consequence in the 
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physiological formation of ectopic fat at inflammatory sites (Goodpaster & D. Wolf 
2004; Arend et al. 2013), and how this contributes to the failure to resolve the 
inflammatory response. However, we observed no effect of TNF-a priming on the 
ability of BMMSC to suppress neutrophil recruitment to endothelium. In fact, BMMSC 
coculture increased neutrophil transmigration as described in Chapter 3, whereas 24-
hour priming inhibits this increase. This may be an attempt by MSC to limit the 
neutrophil infiltrate in response to an additional inflammatory stimulus. Indeed, RASF 
have been shown to prolong NF-kB pathway activation in response to re-stimulation 
with TNF-a, whilst the response from dermal fibroblasts remained unaltered (Crowley 
et al. 2017). However, the response of BMMSC to repeated inflammatory stimuli 
remains unknown within the literature, though our primed BMSMC undergo a 24-hour 
rest period during BEC coculture, prior to a secondary 4-hour stimulus of TNF-a and 
subsequent incorporation into the parallel-plate flow-based adhesion assay. Overall, 
these data indicate that stromal cells issue site-specific responses that are modified 
according to prior exposure. 
 
MSC suppression of leukocyte recruitment to HUVEC is IL-6 dependent, with 
MSC:HUVEC coculture increasing the level of MSC IL-6 secretion (Luu et al. 2013; 
Munir et al. 2016). To determine the ability of BMMSC to secrete IL-6 in response to 
TNF-a priming, we measured its concentration in 24 hour conditioned medium by 
ELISA. Acute priming with TNF-a significantly increased the secretion of soluble IL-6 
by BMMSC monoculture compared to untreated BMMSC. Comparisons with other 
studies showed that primed BMMSC monoculture secreted similar soluble IL-6 
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concentrations to those released by late-passage BMMSC (Munir et al. 2016). 
Contrary to previous reports, we also found that endothelial coculture reduced the 
concentration of soluble IL-6 compared to MSC monoculture, independent of prior 
priming (Munir et al. 2016; Luu et al. 2013). Indeed, the similarities in soluble IL-6 
concentration between primed and unprimed coculture could account for the parallel 
observation in neutrophil adhesion. We also used microvascular BEC in place of 
macrovascular HUVEC, suggesting that different signalling factors may be involved 
in BMMSC-endothelial crosstalk. Furthermore, when scaffolds of BMMSC cocultured 
with HUVEC were subcutaneously implanted into non-obese diabetic/severe 
combined immunodeficient mice, reduced IL-6 gene and protein expression, as well 
as reduced CD11b-positive infiltrates were observed compared to BMMSC alone 
scaffolds (Bartaula-Brevik et al. 2014). Overall, these data suggest that endothelium 
can both upregulate or downregulate BMMSC secretion of soluble IL-6, though it 
doesn’t appear to be dependent on the source of endothelium. The impact of 
different concentrations of soluble IL-6 on leukocyte recruitment is unknown. Indeed, 
passage seven BMMSC and UCMSC secrete more soluble IL-6 than at passage 
three, yet BMMSC lose their suppressive function at passage seven (Munir et al. 
2016). Furthermore, RASF from resolving arthritis patients secrete equivalent soluble 
IL-6 to those from joint replacement patients, however only resolving arthritis RASF 
were capable of upregulating SOCS3 and suppressing lymphocyte adhesion to 
cocultured endothelium (Filer et al. 2017). Indeed, differential secretion of soluble IL-
6 may be important in determining the outcome of MSC immunomodulation of 
endothelium, as demonstrated by antibody blocking of soluble IL-6 or its receptor on 
BMMSC-HUVEC coculture no longer suppressing neutrophil recruitment (Munir et al. 
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2016; Luu et al. 2013). This leads us to speculate that stromal suppression of 
endothelium is dependent upon other factors, though further work is required to 
conclude what these may be. 
 
The development of chronic inflammation requires that the immunosuppressive 
properties of endogenous stroma are overridden or transformed by their 
microenvironment, resulting in a failure to resolve the inflammatory response 
[reviewed by (McGettrick et al. 2012)]. However, the effect of prolonged exposure to 
the inflammatory microenvironment on stromal cell function is poorly defined, with 
very few studies approaching this longstanding question. Croft et al., (2016) showed 
that treating RASF with TNF-a or TGF-b1 for 72 hours was required for predominant 
expression of PDPN or CD248 respectively, with little change following 24 hours of 
exposure (Croft et al. 2016). These PDPN-positive RASF were also positive for FAP 
and VCAM1, and were associated with a pro-inflammatory phenotype as shown by 
cartilage destruction and transmigration from their site of origin to alternative sites of 
cartilage where they supported further damage (Croft et al. 2016). However, our data 
showed that TNF-a stimulation had no effect on PDPN, CD248, or FAP gene 
expression in either BMMSC or RASF. Ex vivo studies of BMMSC isolated from 
chronic inflammatory environments (RA, SLE, ITP), revealed a common theme of 
reduced proliferation and shortened telomeres, indicative of cellular senescence 
when compared to healthy controls (Nie et al. 2010; L. Sun et al. 2010; Kastrinaki et 
al. 2008; Pérez-Simón et al. 2009). However, with respect to cell function, only 
BMMSC from RA or ITP patients showed impaired ability to support of 
haematopoiesis or suppress T-cell proliferation respectively (Kastrinaki et al. 2008; 
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Papadaki et al. 2002; Pérez-Simón et al. 2009), whereas BMMSC from SLE patients 
showed normal function in terms of haematopoietic support and suppression of T-cell 
proliferation compared to healthy controls (Nie et al. 2010; L. Sun et al. 2007). In our 
functional assays, we found that prolonged TNF-a priming had no effect on the ability 
of BMMSC to suppress endothelial recruitment of neutrophils compared to acute 
priming. Interestingly, culture of healthy BMMSC in the presence of 20% 
osteoarthritis synovial fluid was capable of upregulating gene expression of the 
immunomodulatory components, IL-6 and IDO1 (van Osch 2012). We also observed 
upregulation of IDO1 gene expression by BMMSC but not transformed RASF, but in 
response to TNF-a stimulation. MSC secrete IDO as a potent suppressor of 
inflammation through induction of T-cell arrest and apoptosis in response to 
tryptophan depletion (François et al. 2012; Meisel et al. 2004; Ling et al. 2014). 
Endothelium has also been shown to upregulate IDO production in response to 
stimulation with IFN-g (Mouratidis & George 2015), with its deletion resulting in 
pulmonary hypertension in mouse models (Xiao et al. 2013). Regardless of its 
immunosuppressive function, overexpression of endothelial IDO was shown to have 
no effect on T-cell transmigration in a static adhesion assay (Mouratidis & George 
2015). Interestingly, upregulation of SOCS3 via IL-6 induces the degradation of IDO 
in dendritic cells (Orabona et al. 2008), however the connotations of a similar result in 
SOCS3-mediated MSC-endothelial crosstalk are unclear. Rather we speculate that 
MSC upregulation of ICAM1 and IDO1 by TNF-a stimulation have a similar role to the 
release of nitric oxide in their murine MSC counterparts, in binding tissue-infiltrating 
leukocytes and suppressing them through the local release of IDO (Ren et al. 2008; 
Ren et al. 2010). IL-6 is a pleiotropic cytokine, in that it has both anti- and pro-
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inflammatory functions [reviewed by (Scheller et al. 2011)]. With regard to the effects 
of IL-6 on endothelium, it is both able to induce SOCS3 resulting in suppressed 
leukocyte adhesion (Luu et al. 2013), whilst conversely promoting recruitment 
through upregulation of ICAM1, VCAM1, and CD62E in HUVEC (Watson et al. 1996). 
Overall, this evidence suggests that stromal cells are modified by chronic 
inflammation, however the mechanism by which these cells are permanently 
polarised toward an inflammatory phenotype or are transiently primed to promote 
resolution is still unclear. Whilst MSC appear resistant to taking on a pro-
inflammatory phenotype, with upregulation of immunomodulatory factors such as IDO 
instead. 
 
Finally, we tested a novel stromal coculture model of the inflammatory 
microenvironment, whereby RASF were cultured with BMMSC for an acute time-
frame of 24 hours and their gene expression profile subsequently analysed. 
Interestingly, we found that BMMSC coculture with RASF reduces ICAM1 gene 
expression, suggesting an anti-inflammatory action of BMMSC based on the intrinsic 
link between ICAM1 and inflammation. Also of interest was that the same reduction 
was observed with BMMSC ICAM1 gene expression in the presence of RASF 
coculture. We suggest further enquiries into this system by prolonging the duration of 
culture and characterising the inflammatory profile and function of these cells 
compared to monocultures. Whilst BMMSC may suppress the inflammatory 
properties of RASF, adipose-derived MSC were found to promote pathogenesis by 
dramatically enhancing the viability, proliferation, and metastatic potential of a breast 
cancer cell line both in in vitro cocultures and in vivo mouse experiments (Kamat et 
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al. 2015). Indeed, MSC are capable of homing to tumourigenic sites and where they 
can promote tumour angiogenesis, establish an anti-inflammatory microenvironment, 
and assist in tumour metastasis [reviewed by (Chang et al. 2015)]. Overall, these 
data suggest that the anti-inflammatory properties of healthy MSC may initially 
overpower that of inflamed tissue, with the result of slowing, halting, or even 
resolving inflammation. However, this phenotype is likely to the detriment of other 
conditions such as cancer and bacterial infections. 
 
The literature on MSC priming varies greatly in the methodology used, making the 
data shown here one of few studies that have made direct comparisons on the 
effects of acute versus prolonged cytokine priming on MSC immunomodulatory 
function. The literature described within this chapter support the notion that tissue-
resident stromal cells may be modified or transformed by their microenvironment, 
perhaps resulting in a change in function of these once regulatory cells and 
perpetuating either the drive of pathogenesis or the failure to resolve the 
inflammatory response. However, we have shown that BMMSC are resilient to these 
changes, at least when considering short exposures (72h or less), by retaining their 
suppressive function over endothelium. Whether this resistance is transient or 
permanent has yet to be determined, but deciphering the mechanisms by which 
these transformations occur in other stromal populations may prove useful in the 
development of new therapeutic targets. This is of importance in MSC-based 
therapies in determining how healthy cells might be influenced by the inflammatory 
environments they are being introduced to and what implications any changes have 
on disease pathogenesis. 
  
 
 
 
Chapter 5. ROLE OF PERIVASCULAR PODOPLANIN IN THE 
INFLAMMATORY MICROENVIRONMENT 
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5.1. INTRODUCTION 
PDPN is a mucin-type transmembrane glycoprotein, whose expression is normally 
restricted to a small number of stromal cells (Breiteneder-Geleff et al. 1997; Farr et 
al. 1992; Schacht et al. 2003), and it is typically associated with a migratory and 
invasive phenotype (Wicki et al. 2006; Tejchman et al. 2017; Suchanski et al. 2017; 
Martín-Villar et al. 2006). In a pathological setting PDPN is upregulated at 
inflammatory sites (Inoue et al. 2015; Croft et al. 2016; Cimini et al. 2017), particularly 
in the perivascular space (Payne et al. 2017; Hitchcock et al. 2015). MSC are also 
enriched within the perivascular niche (Crisan et al. 2008; Feng et al. 2011), and we 
have recently shown that UCMSC differentially express PDPN and interact with 
platelets when administered systemically, raising concerns over their use in therapy 
(Dr L Sheriff, University of Birmingham, 2017, personal communication). It remains 
unclear whether circulating platelet CLEC-2 can interact with PDPN expressed by 
stromal cells in the perivascular niche. This leads us to hypothesise that PDPN 
regulates UCMSC migration and has a role in the perivascular niche that may involve 
interactions with its receptor CLEC-2 on platelets. 
 
5.2. RESULTS 
5.2.1. PDPN REGULATES MSC MIGRATION 
We have recently reported that cultured BMMSC lack PDPN expression, whilst 
UCMSC differentially express PDPN between donors (Figure 5-1) (Dr L Sheriff, 
University of Birmingham, 2017, personal communication). To determine the role of 
PDPN on MSC migration, we screened UCMSC donors for PDPN expression and   
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Figure 5-1 Characterisation of PDPN expression on MSC. 
BMMSC and UCMSC donors were analysed for PDPN surface expression UCMSC 
were split based on PDPN expression into PDPN-negative (PDPN-) or -positive 
(PDPN+) isolates. Data are expressed as the MFI of PDPN staining subtracted from 
the isotype control. Data are mean ± SEM from n=4-9 independent experiments 
using four BMMSC, five PDPN-negative UCMSC and nine PDPN-positive UCMSC 
donors.  
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then analysed their migratory potential using two different in vitro models (transwell 
filter and spheroid collagen gel assay). Using a transwell migration model, 
significantly more PDPN-positive UCMSC migrated through the filter than PDPN-
negative UCMSC or BMMSC (Figure 5-2A). In the collagen matrix invasion model, 
the percentage of PDPN-negative UCMSC migration did not change over time 
(Figure 5-2B). In contrast, significantly more PDPN-positive UCMSC had migrated 
into the collagen matrix compared to PDPN-negative UCMSC by 48 hours post-
seeding (Figure 5-2B). Indeed, PDPN-positive UCMSC migration increased in a time-
dependent manner between 24 and 48 hours (Figure 5-2B). These data suggest that 
expression of PDPN is associated with a pro-migratory phenotype in UCMSC. 
 
To determine whether increased UCMSC migration was directly mediated by PDPN, 
we transfected MSC with siRNA against PDPN and observed a 41% and 29% 
reduction in PDPN gene and surface expression respectively at 24 hours compared 
to cells treated with scrambled siRNA (Figure 5-3). This reduction remained stable up 
to 72 hours, and at this time point resulted in a 55% reduction in gene expression 
(Figure 5-3A) and 34% reduction in surface protein expression (Figure 5-3B) when 
compared to scrambled controls. This partial knockdown of PDPN had no effect on 
UCMSC proliferation (Figure 5-4A), but was sufficient to cause a significant reduction 
in the migratory capacity of UCMSC within the siRNA-treated group (Figure 5-4B). 
This implies that PDPN directly regulates the migratory, but not the proliferative 
capacity, of MSC.  
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Figure 5-3 Effect of siRNA knockdown on PDPN expression over time. 
PDPN-positive UCMSC were transfected with siRNA against PDPN. (A) Gene 
expression assessed by qPCR and relative expression units normalised as a 
percentage of the scrambled control. (B) Surface protein expression assessed by flow 
cytometry and MFI expression normalised as a percentage of the scrambled MFI 
expression. ANOVA showed a significant effect of treatment, but not time, on PDPN 
mRNA and surface expression; p<0.01. Data are mean ± SEM from (A) n=3, (B) 
n=4-5 independent experiments using at least three different donors. * = p<0.05, ** = 
p<0.01 by Dunnett post-test compared to scrambled controls.  
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Figure 5-4 Effect of PDPN siRNA knockdown on UCMSC proliferation and 
migration. 
PDPN-positive UCMSC were transfected with 50nM of two siRNA PDPN duplexes, a 
non-specific siRNA duplex control (Scr), lipofectamine alone (Lipo), or left untreated 
(Sham) for 24 hours. (A) Effect of PDPN expression on UCMSC proliferation was 
automatically recorded using the Cell-IQ Imagen system for six 12 hour intervals post-
transfection. Data are expressed as the percentage of the number of cells at 0 hours 
(B) UCMSC were seeded in an 8μm pore transwell filter for 48 hours, then detached 
from the upper and lower chambers and counted. Data are expressed as the 
percentage migrated in the lower chamber compared to the total cell count for both 
chambers. ANOVA showed a significant effect of treatment on migration; p<0.05. 
Data are mean ± SEM from (A) n=2-3, (B) n=4 independent experiments using (A) at 
least two, (B) four different donors. * = p<0.05 by Dunnett post-test compared to 
sham.  
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We next wished to see whether absence of PDPN had a more pronounced effect on 
MSC migration. Initially we designed our own CRISPR/Cas9 construct and validated 
the procedure using a PDPN-positive cell line. Firstly, we generated three guide 
RNAs (gRNA) to different regions of the PDPN gene, with the intention of inducing a 
frameshift mutation and subsequent premature stop codon in the open reading frame 
for PDPN (Table 2-4). This occurs through non-homologous end joining when the 
Cas9 endonuclease is guided to the complimentary site and cleaves a double strand 
break in the target DNA. The custom CRISPR/Cas9 plasmid contained a puromycin 
resistance cassette enabling us to select cells that had been successfully transfected 
(Ran et al. 2013). The HEK293T cell line was chosen for validation as it is positive for 
PDPN expression (Figure 5-5A and Figure 5-6B). The minimum concentration of 
puromycin required to kill 100% of HEK293T cells was 2.5µg/mL (Dr P Noy, 
University of Birmingham, 2016, personal communication). For UCMSC, the 
minimum concentration of puromycin required to kill 100% of cells was found to be 
1.0µg/mL, this was the concentration used after UCMSC transfection (Figure 5-7). 
 
HEK293T cells and PDPN-positive UCMSC were transfected with the custom 
CRISR/Cas9 plasmid for each gRNA generated using Lipofectamine. Puromycin 
selection resulted in complete cell death of transfected UCMSC, suggesting an 
inability to transfect these cells using Lipofectamine. Puromycin-resistant HEK293T 
cells were analysed by flow cytometry for PDPN expression (Figure 5-5A), however 
no difference in surface expression was observed between each CRISPR/Cas9 
construct used compared to the untreated control (Figure 5-5A). This suggests that   
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Figure 5-7 Effect of puromycin on UCMSC survival. 
A kill curve depicting the minimum concentration of puromycin required to kill 100% 
of UCMSC. Friedman test showed a significant effect of treatment on percentage 
survival; p<0.01. Data are mean ± SEM from n=5 independent experiments using five 
different donors.  
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either all gRNAs generated were unsuccessful in inducing the deletion of PDPN or 
that the gRNAs did not sufficiently alter the binding epitope for our PDPN antibody 
(NZ-1.3). 
 
We have previously shown that PDPN binds to CLEC-2 expressed on platelets 
inducing platelet aggregation (Dr L Sheriff, University of Birmingham, 2017, personal 
communication). Using this assay, we assessed whether PDPN CRISPR transfected 
cells could induce platelet aggregation when compared to the positive control, 
collagen. Puromycin-resistant HEK293T cells for each custom CRISPR/Cas9 
construct reduced the platelet count to the same extent as untreated HEK293T cells 
(Figure 5-5B). This indicated that PDPN was still functional on these cells and that all 
gRNAs generated were unsuccessful in inducing a functional deletion of PDPN. 
 
A recent publication had shown a commercial CRISPR/Cas9 plasmid targeting PDPN 
[with a green fluorescent protein (GFP) tag] to be successful in knocking out PDPN 
expression in HEK293T cells (Kaneko et al. 2017). We purchased this commercial 
construct and again validated its efficacy in HEK293T cells. The transfected cells 
were positive for GFP (Figure 5-6A) and expressed a bimodal PDPN distribution 
(Figure 5-6B), suggesting a successful deletion of PDPN within this population. The 
PDPN-negative population was isolated by fluorescence-activated cell sorting and 
assessed for their ability to induce platelet aggregation. The transfected and sorted 
PDPN-negative HEK293T cells were unable to aggregate platelets compared to the 
untreated control, indicating that PDPN function was also successfully deleted 
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(Figure 5-6C). Based on the success with the HEK293T cell validation, we 
transfected PDPN-positive UCMSC with the commercial CRISPR/Cas9 plasmid. Due 
to the problems we had previously experienced using Lipofectamine to transfect 
UCMSC, we decided to use an MSC-specific Nucleofector kit to electroporate the 
cells with the plasmid. Nucleofection of the commercial CRISPR/Cas9 plasmid into 
UCMSC resulted in very low transfection efficiencies (Figure 5-8), making them 
unsuitable to expand sufficiently to use experimentally without inducing senescence. 
Thus, we were unable to successfully delete PDPN in UCMSC. 
 
To further validate the role of PDPN in UCMSC migration, we used an antibody 
crosslinking strategy to determine whether stimulation of PDPN resulted in increased 
migratory function. To achieve this, PDPN-positive UCMSC were incubated with rat 
anti-human PDPN (NZ-1.3) and in the presence or absence of goat anti-rat IgG to 
induce crosslinking of the PDPN receptor and their migration assessed using the 
Transwell model. We observed no effect of PDPN crosslinking on UCMSC migration 
(Figure 5-9), indicating that clustering of the PDPN receptor does not induce 
migration-related downstream signalling in UCMSC. In future experiments, we 
directly compared PDPN-positive and -negative UCMSC donors. 
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Figure 5-9 Effect of PDPN crosslinking on UCMSC transwell migration. 
PDPN-positive UCMSC were seeded in an 8μm pore transwell filter for 1 hour before 
the addition of anti-human PDPN for 30 minutes. Goat anti-rat IgG2a was 
subsequently added to induce crosslinking for 47 hours. The cells were detached and 
counted from the upper and lower chambers. Data are expressed as the percentage 
migrated in the lower chamber compared to the total cell count for both chambers. 
Untreated negative control (sham); treated with anti-human PDPN only (primary); 
treated with anti-human PDPN and goat anti-rat IgG2a (X-L). Data are mean ± SEM 
from n=4 independent experiments using four different donors.  
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5.2.2. PDPN-DEPENDENT MIGRATION IS MEDIATED THROUGH RAC1 SIGNALLING 
The Rho GTPase family regulates cell migration through reorganisation of the actin 
cytoskeleton [reviewed by (Sahai & Marshall 2002)]. To determine which pathway 
was involved in PDPN-mediated MSC migration, we used inhibitors to block the 
activities of RhoA, RhoB, and RhoC (CT04), ROCK (Y27632), and Rac1 
(NSC23766). Inhibition of Rho activation with CT04 significantly impaired UCMSC 
migration and cell number in a dose-dependent manner for both PDPN-positive and 
negative UCMSC (Figure 5-10). This suggests that Rho is a global positive regulator 
of UCMSC migration, and not specifically linked to PDPN signalling. In contrast, 
inhibition of ROCK significantly increased migration for both PDPN-positive and 
negative UCMSC, with the largest increase in the presence of 10µM of Y27632 
(Figure 5-11A). Unexpectedly, an increase in cell number for PDPN-negative 
UCMSC was also observed in the presence of 10µM of Y27632 (Figure 5-11B). This 
implies that ROCK acts as a negative regulator of cell migration, and may have roles 
in regulating cell proliferation. Collectively these data suggest that signalling through 
Rho and ROCK both influence UCMSC migration, but are independent of PDPN 
expression. 
 
Inhibition of Rac1 activity with NSC23766 caused a significant and dose-dependent 
decrease in the migration of PDPN-positive UCMSC, but not of PDPN-negative 
UCMSC (Figure 5-12A). Yet, high doses of NSC23766 were toxic with cell numbers 
drastically reduced (Figure 5-12B). Confocal imaging of UCMSC revealed that 
PDPN-positive UCMSC were significantly larger than their negative counterparts   
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Figure 5-10 Effect of the Rho inhibitor CT04 on MSC transwell migration. 
PDPN-negative or -positive UCMSC were seeded in an 8μm pore transwell filter and 
treated with CT04 (0-4μg/mL) for 48 hours. The cells were detached and counted from 
the upper and lower chambers. Data are expressed as migration as a (A) percentage of 
total cells counted from both chambers, and (B) the total cell count of the upper and 
lower chambers. ANOVA showed a significant effect of treatment on migration and 
cell number; p<0.01. Data are mean ± SEM from n=4 independent experiments using 
four different UCMSC donors for each PDPN phenotype. * = p<0.05, ** = p<0.01 by 
Dunnett post-test compared to untreated control (0μg/mL).  
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Figure 5-11 Effect of the ROCK inhibitor Y27632 on MSC transwell 
migration. 
PDPN-negative or -positive UCMSC were seeded in an 8μm pore transwell filter and 
stimulated with Y27632 (0-100μM) for 48 hours. The cells were detached and counted 
from the upper and lower chambers. Data are expressed as the (A) percentage 
migrated in the lower chamber compared to the total cell count for both chambers, and 
(B) the total cell count of the upper and lower chambers. ANOVA showed a significant 
effect of treatment on migration and cell number; p<0.01. Data are mean ± SEM from 
n=4 independent experiments using four different UCMSC donors for each PDPN 
phenotype. * = p<0.05, ** = p<0.01 by Dunnett post-test compared to untreated 
control (0μg/mL).  
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Figure 5-12 Effect of the Rac1 inhibitor NSC23766 on MSC transwell 
migration. 
PDPN-negative or -positive UCMSC were seeded in an 8μm pore transwell filter and 
stimulated with NSC23766 (0-100μM) for 48 hours. The cells were detached and 
counted from the upper and lower chambers. Data are expressed as the (A) 
percentage migrated in the lower chamber compared to the total cell count for both 
chambers, and (B) the total cell count of the upper and lower chambers. ANOVA 
showed a significant effect of treatment on migration and cell number; p<0.01. Data 
are mean ± SEM from n=4 independent experiments using four different UCMSC 
donors for each PDPN phenotype. * = p<0.05, ** = p<0.01 by Dunnett post-test 
compared to untreated control (0μg/mL).  
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(Figure 5-13 and Figure 5-14A). However, Rac1 inhibition had no effect on either cell 
size (Figure 5-14A) or the intensity of PDPN expression (Figure 5-14B). Furthermore, 
analysis of PDPN location in positive UCMSC showed that in the presence of 
NSC23766, the number of cells expressing PDPN at the peripheral edges of the cell 
was significantly reduced (Figure 5-14C, D). These data suggest that PDPN-
mediated migration of UCMSC is dependent on Rac1, and that Rac1 might be 
responsible for the peripheral localisation of PDPN, thus enabling PDPN to exert its 
pro-migratory function. 
 
5.2.3. PDPN EXPRESSING MSC CAN PROTRUDE THROUGH ENDOTHELIAL BARRIERS AND 
CAPTURE PLATELETS 
Given the perivascular localisation of PDPN during inflammation (Payne et al. 2017; 
Hitchcock et al. 2015; Inoue et al. 2015), and that MSC are enriched within the 
perivascular niche (Feng et al. 2011; Crisan et al. 2008). We wondered what the 
localisation of PDPN-positive UCMSC was in situ. Immunohistochemistry staining for 
PDPN in umbilical cord cross-sections, showed PDPN to be localised to the 
perivascular space and fibrous areas of the amnion (Figure 5-15). This data implies 
that PDPN is positioned for involvement in the regulation of the vascular 
compartment rather than the underlying stroma. 
 
We next considered whether PDPN-expressing MSC might activate platelets through 
the PDPN-CLEC-2 interactions. This would be possible if MSC could protrude from 
the perivascular space, presenting PDPN to the blood vessel lumen. To assess this   
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Figure 5-14 Effect of the Rac1 inhibitor NSC23766 on MSC morphology and 
PDPN localisation. 
PDPN-negative or -positive UCMSC were seeded for 24 hours with or without the 
Rac-1 inhibitor, NSC23766. The cells were stained for f-actin (green), PDPN (red), 
and the nucleus (blue), then imaged by confocal microscopy. Data were expressed 
as (A) average cell area in μm2, (B) PDPN fluorescence intensity as measured by the 
average integrated density for PDPN per cell, and (C) PDPN localisation as a 
percentage of cells expressing PDPN at the cell edge alone. (D) Representative 
images of single UCMSC expressing PDPN at (i) the cell edge alone in the absence 
of treatment or (ii) the centre of the cell in the presence of treatment. ANOVA 
showed a significant effect of treatment on cell area and PDPN fluorescence 
intensity; p<0.01. Data are mean ± SEM from n=4 independent experiments using 
four different UCMSC donors for each PDPN phenotype. (A, B) ** = p<0.01 by 
Bonferroni post-test, (C) * = p<0.05 by paired t-test.  
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Figure 5-15 Micrograph analysis of PDPN expression in umbilical cords. 
Umbilical cord cross-sections were stained for PDPN by immunohistochemistry using 
rat IgG2a control or anti-human podoplanin (NZ-1.3) and nuclei stained with 
haematoxylin. (A) Representative images were taken of the; (i), whole umbilical cord 
cross-section or regions of interest (black box) stained with (ii), perivascular IgG 
control or (iii), perivascular PDPN stain. Scale bar represents 500µm. (B) Images 
were quantified for the percentage area of DAB staining in the whole umbilical cord 
cross-section. Data are mean ± SEM from n=6 independent experiments using six 
different UCMSC donors. ** = p<0.01 by paired t-test.  
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possibility, UCMSC were cultured on the basal surface of transwell filters with 
different pore sizes to determine the smallest gap that MSC could extend protrusions 
through. Whole blood was labelled with PE-conjugated anti-CD41 (specifically 
labelling platelets) and added to the apical surface of the filter, and interactions with 
MSC protrusions were assessed by fluorescence microscopy. Platelet adhesion to 
UCMSC protrusions could be detected on 3 and 8µm pore filters, but not 0.4µm 
(Figure 5-16), suggesting basally seeded MSC could extend cellular protrusions 
through gaps larger than 0.4µm. Moreover, platelet aggregates were significantly 
larger on the apical surface of filters with PDPN-positive UCMSC underneath 
compared to PDPN-negative UCMSC on 3µm pores (Figure 5-16B). Platelet 
aggregates for 8µm pores were of a similar size, but showed no difference between 
PDPN-positive and -negative UCMSC (Figure 5-16B). This is possibly explained by 
the ability of UCMSC to migrate from the basal surface to the apical surface on the 
8µm filters over 24 hours, allowing whole cells to interact with the platelets. In 
contrast, UCMSC were unable to traverse across the 3µm pores (as assessed by cell 
counts from the upper chamber being below the limit of detection of the Coulter 
Counter), indicating that platelets were only able to interact with UCMSC that had 
formed protrusions through the 3µm pores. Of note, interaction with PDPN or a 
stimulating factor is required for platelet aggregation. 
 
Subsequently we analysed the ability of PDPN-positive UCMSC protrusions to 
capture platelets from flowing blood using a flow-based adhesion assay. Recruitment 
of platelets was significantly more pronounced after 10 minutes of whole blood   
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Figure 5-16 Effect of filter pore size on UCMSC protrusions. 
PDPN-negative or -positive UCMSC were seeded on inverted 0.4µm, 3µm, 8µm pore 
culture inserts for 24 hours. CD41-labelled whole blood was incubated in the upper 
chamber of the insert for 1 hour. (A) Representative images were taken of 
fluorescent platelet aggregates; (i), 0.4µm PDPN-; (ii), 3µm PDPN-; (iii), 8µm PDPN-; 
(iv), 0.4µm PDPN-positive; (v), 3µm PDPN-positive; (vi), 8µm PDPN-positive. Scale 
bar represents 200µm. (B) Data are expressed as aggregate size in μm2 as 
measured by the average size of fluorescent particles. ANOVA showed a significant 
effect of PDPN status, but not pore size, on aggregate size; p<0.05. Data are mean ± 
SEM from n=4 independent experiments using four different UCMSC donors for each 
PDPN phenotype. * = p<0.05 by Bonferroni post-test.   
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perfusion for the PDPN-positive than negative UCMSC, with lesser difference seen at 
the earlier 5-minute time point (Figure 5-17B). To establish whether platelet 
aggregates were a result of PDPN binding, we used human recombinant CLEC-2 
(rCLEC-2) to competitively interfere with CLEC-2-PDPN interactions as previously 
described (Suzuki-Inoue et al. 2007). Pre-treatment of PDPN-positive UCMSC 
protrusions with rCLEC-2 prior to whole blood perfusion, resulted in a significant 
reduction in the average size of platelet aggregates compared to the untreated 
control (Figure 5-18). Platelet aggregation through platelet-platelet binding is 
mediated through αIIbβ3-integrin (Fullard 2004). We also utilised the αIIbβ3-integrin 
inhibitor integrilin (Thomas et al. 2011) to determine whether PDPN induces platelet 
activation and allows aggregates to form through platelet-platelet binding. Integrilin 
enables platelet adhesion to PDPN on MSC protrusions, but not platelet-platelet 
interactions. The presence of integrilin in the perfused whole blood significantly 
reduced the size of platelet aggregates compared to the untreated control (Figure 5-
18). These data suggest that PDPN-positive UCMSC protrusions are capable of both 
capturing platelets from flow and of activating adherent platelets to aggregate in a 
PDPN-dependent manner. 
 
Given that MSC are able to extend protrusions through pores in a filter, we next 
wanted to determine whether MSC were capable of protruding from the perivascular 
space into the vessel lumen. To do this we seeded a monolayer of BEC on the apical 
surface of the filter. In this model, MSC would need to extend through the BEC in 
order to come into contact with the flowing platelets. PDPN-positive UCMSC 
protrusions induced larger platelet aggregates than their negative counterparts   
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Figure 5-17 Effect of UCMSC protrusions on platelet aggregation in flow. 
PDPN-negative or -positive UCMSC were seeded on inverted 3µm pore culture 
inserts for 24 hours. CD41-labelled whole blood was perfused over the apical surface 
of the filter in a parallel plate chamber for 5 or 10 minutes. (A) Representative images 
were taken of fluorescent platelet aggregates; (i), 5-minute perfusion PDPN-negative; 
(ii), 10-minute perfusion PDPN-negative; (iii), 5-minute perfusion PDPN-positive; (iv), 
10-minute perfusion PDPN-positive. Scale bar represents 200µm. (B) Data are 
expressed as aggregate size in μm2 as measured by the average size of fluorescent 
particles. ANOVA showed a significant effect of PDPN status, but not time, on 
aggregate size; p<0.05. Data are mean ± SEM from n=3-4 independent experiments 
using four different UCMSC donors for each PDPN phenotype. * = p<0.05, ** = 
p<0.01 by Bonferroni post-test.  
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Figure 5-18 Effect of rCLEC-2 or integrilin on platelet aggregation on 
UCMSC protrusions. 
PDPN-positive UCMSC were seeded on 3µm pore culture inserts for 24 hours. 
CD41-labelled whole blood was perfused over the apical surface of the filter in a 
parallel plate chamber for 5 minutes, with or without rCLEC-2 pre-treatment, or in the 
presence or absence of integrilin. (A) Representative images were taken of 
fluorescent platelet aggregates; (i), untreated; (ii), rCLEC-2 pre-treatment; (iii), 
integrilin treatment. Scale bar represents 200µm. (B) Data are expressed as 
aggregate size in μm2 as measured by the average size of fluorescent particles. 
ANOVA showed a significant effect of treatment on aggregate size; p<0.05. Data are 
mean ± SEM from n=4 independent experiments using four different PDPN-positive 
UCMSC donors. ** = p<0.01 by Dunnett post-test compared to untreated.  
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(Figure 5-19). Furthermore, the presence of an endothelial monolayer had no effect 
on aggregate size (Figure 5-19). Endothelial monoculture (EC) adhered few very 
platelets (Figure 5-20). Again, we confirmed that the platelet aggregation was 
dependent on PDPN by using rCLEC-2 to block platelet-PDPN interactions. Pre-
treatment of cocultures with rCLEC-2 significantly reduced platelet aggregate size to 
the same level as seen on endothelial monocultures (Figure 5-20). These data 
suggest that invasive perivascular MSC are capable of protruding through the 
endothelial vessel lining and activating platelets through PDPN and thus contributing 
to thrombosis. 
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Figure 5-19 Effect of endothelial coculture on the ability of UCMSC 
protrusions to induce platelet aggregation. 
PDPN-negative or -positive UCMSC were seeded on inverted 3µm pore culture 
inserts for 1 hour. The inserts were reinverted and the apical surface seeded with 
BEC to form coculture (EC:MSC). MSC monocultures were used as comparison. 
CD41-labelled whole blood was perfused over the apical surface of the filter in a 
parallel plate chamber for 10 minutes. (A) Representative images were taken of 
fluorescent platelet aggregates; (i), PDPN-negative MSC; (ii), PDPN-negative 
MSC:EC; (iii), PDPN-positive MSC; (iv), PDPN-positive MSC:EC. Scale bar 
represents 200µm. (B) Data are expressed as aggregate size in μm2 as measured by 
the average size of fluorescent particles. ANOVA showed a significant effect of 
PDPN status, but not culture conditions, on aggregate size; p<0.05. Data are mean ± 
SEM from n=3 independent experiments using three different donors for each PDPN 
phenotype and cell type. ** = p<0.01 by Bonferroni post-test.  
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Figure 5-20 Effect of endothelial coculture on the ability of PDPN-positive 
UCMSC protrusions to induce platelet aggregation. 
PDPN-positive UCMSC were seeded on inverted 3µm pore culture inserts for 1 hour. 
The inserts were reinverted and the apical surface seeded with BEC to form 
coculture (EC:MSC). BEC mono-cultures were used as a control (EC). CD41-labelled 
whole blood was perfused over the apical surface of the filter in a parallel plate 
chamber for 10 minutes, with or without rCLEC-2 pre-treatment. (A) Representative 
images were taken of fluorescent platelet aggregates; (i), EC; (ii), PDPN-positive 
MSC:EC; (iii), PDPN-positive MSC:EC with rCLEC-2 pre-treatment. Scale bar 
represents 200µm (B) Data are expressed as aggregate size in μm2 as measured by 
the average size of fluorescent particles. ANOVA showed a significant effect of 
treatment on aggregate size; p<0.05. Data are mean ± SEM from n=4 independent 
experiments using four different donors for each cell type. * = p<0.05 by Bonferroni 
post-test.  
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5.3. DISCUSSION 
Here we aimed to understand the role of PDPN in MSC function, specifically looking 
at their migratory capacity and their ability to interact with circulating platelets given 
their perivascular location. Expression of PDPN by UCMSC promoted their ability to 
completely traverse a transwell filter and to migrate out of a spheroid and into a 
collagen gel when compared to UCMSC negative for PDPN. Knockdown of PDPN or 
inhibition of Rac1 significantly retarded UCMSC migration. We determined that both 
Rho and ROCK also played a role in UCMSC migration, but that this occurred 
independently of PDPN expression. From their perivascular location, PDPN-positive 
UCMSC were able to protrude through endothelial cells to interact with platelets, 
inducing platelet activation and aggregation. These processes could be reversed 
when we blocked either platelet-PDPN interactions, or platelet-platelet interactions 
with rCLEC-2 or integrilin respectively. We propose that this invasive phenotype 
facilitates the intravasation of stromal cells expressing PDPN, enabling interactions 
with circulating platelet CLEC-2 and presenting implications for the maintenance of 
vascular integrity, thromboembolism in inflammatory disorders, and cancer 
metastasis. 
 
5.3.1. PDPN AND CELLULAR MIGRATION 
Previous studies have also shown that PDPN is associated with a pro-migratory and 
invasive phenotype (Wicki et al. 2006; Martín-Villar et al. 2006; Takeuchi et al. 2017). 
Indeed, the ability to mediate cell contraction is integral for migration. Astarita et al., 
(2015) demonstrated that PDPN regulates both cell size (by confocal microscopy) 
and contraction of fibroblastic reticular cells (by their ability to retract collagen 
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matrices when suspended within) when compared to PDPN-negative counterparts, 
additionally, treatment with rCLEC-2 was shown to relax the contracted state of these 
cells (Astarita et al. 2015). We also observed an increase in cell size for the PDPN-
positive compared to PDPN-negative UCMSC. Furthermore, transfection of a PDPN 
construct into an MCF7 breast cancer line conferred increased migratory and 
invasive potential compared to untransfected controls both in vitro and in vivo, with 
localisation of PDPN at cellular protrusions (Wicki et al. 2006; Petrie et al. 2012). This 
agrees with our data whereby we also observed PDPN localisation at peripheral 
protrusions of UCMSC. Indeed, cell migration studies in lymphatic endothelium and 
cancer cell lines have shown varied downstream signalling components for PDPN 
from ERM proteins to regulators of the actin cytoskeleton; Rho, ROCK, Cdc42, and 
Rac1 (Martín-Villar et al. 2006; Wicki et al. 2006; Navarro et al. 2011; Sahai & 
Marshall 2002). However, there are many discrepancies associated with the 
mechanism of action for PDPN in migration as discussed below. 
 
Regarding signalling components involved in cell migration, Rho/ROCK signalling is 
used in amoeboid-like migration of tumour cells and leukocytes (Lämmermann & Sixt 
2009; Sahai & Marshall 2003). Indeed, Martín-Villar et al., (2006) observed an 
increase in RhoA in MDCK tumour cells but no change for Cdc42 or Rac1 (Martín-
Villar et al. 2006), suggesting that PDPN-mediated migration is promoted through 
RhoA signalling in MDCK cells. Interestingly, siRNA knockdown of PDPN in 
lymphatic endothelium reduced GTP-bound RhoA and migratory capacity (Navarro et 
al. 2011). Hence, also implying that RhoA is required for PDPN-mediated migration 
of lymphatic endothelium, but employed in amoeboid-like migration. In BMMSC, 
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inhibition of Rho (C2I-C3) or ROCK (Y27632) both promoted their migratory capacity, 
suggesting Rho/ROCK signalling acts as a negative regulator of BMMSC migration 
(Jaganathan et al. 2007). This agrees with MSC migrating using mesenchymal-like 
processes. Conversely, we observed that inhibition of Rho resulted in a reduction of 
UCMSC migration, regardless of PDPN status, suggesting Rho may act as a global 
positive regulator of UCMSC migration.  
 
Expression of PDPN by fibroblastic cell lines has been shown to increase their 
migratory properties in a ROCK-dependent manner when compared to PDPN-
negative counterparts or in the presence of the ROCK inhibitor (Y27632) using a 
transwell assay (Suchanski et al. 2017). Conversely, in primary fibroblasts ROCK 
inhibition saw increased migration (Piltti et al. 2015), but again impaired migration in 
carcinoma cell lines (Z.-M. Wang et al. 2016). ROCK signalling has also been shown 
to promote BMMSC migration in response to CXCL12, but impair BMMSC 
transmigration through endothelium (Park et al. 2017; Lin et al. 2013). However, HIF-
1a was also shown to promote BMMSC migration through both ROCK and Rac 
signalling (Choi et al. 2016). Again, we observed conflicting results with ROCK 
inhibition resulting in enhanced UCMSC migration, regardless of PDPN status, 
suggesting ROCK may act as a global negative regulator of UCMSC migration.  
 
Interestingly, CLEC-2 activation via PDPN also promoted the migration of dendritic 
cells from the periphery to the lymph nodes through actin polymerisation and 
induction of membrane protrusions by Rac1 (Acton et al. 2012). Indeed, Rac1 has 
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been shown to drive mesenchymal-like migration by stabilising lamellipodia formation 
at the leading edge (Ridley et al. 1992; Sanz-Moreno et al. 2008), with PDPN closely 
associated with these protrusions (Wicki et al. 2006; Petrie et al. 2012; Martin-Villar 
et al. 2015). Indeed, IL-17A stimulation induces migration of RASF in a Rac1-
dependent manner (Moran et al. 2011). PI3K has been shown to signal through Rac1 
(Henderson et al. 2015), with BMMSC transmigration through endothelium promoted 
in a PI3K-dependent manner. This disagrees with our data showing PDPN signals 
through Rac1, as we found BMMSC to be negative for PDPN expression. Indeed, 
Rac1 promoted CXCL12-induced UCMSC migration (Park et al. 2017), which agrees 
with our data showing that Rac1 inhibition selectively impairs PDPN-positive but not 
PDPN-negative UCMSC migration. This suggests that PDPN-mediated migration is 
Rac1 dependent and that Rac1 acts as a positive regulator of PDPN-mediated 
migration in UCMSC. These studies demonstrate that PDPN is strongly associated 
with a pro-migratory phenotype in stromal cells, but that the downstream signalling 
varies between cell types. Indeed, the differences observed in the signalling for MSC 
migration might be attributed to the tissue-specific sources of MSC, implying that 
differential migration-related signalling occurs as a result of their previous 
microenvironment. 
 
Therapeutic administration of PDPN-positive MSC by intravenous injection has 
serious implications in their thrombotic potential (see below). However, the pro-
migratory phenotype associated with PDPN expression is desirable for improving the 
efficiency of MSC homing to sites of tissue damage or inflammation. The data here 
highlights targeting ROCK inhibition in PDPN-negative MSC as a plausible method of 
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increasing the migratory capacity of these cells. Indeed, inhibition of Rac1 is also a 
potential therapeutic target in preventing PDPN-positive tumour cell invasion and 
metastasis. The therapeutic potential of several Rac1 inhibitors is a topic of current 
scientific interest in the treatment of cancer, cardiovascular, and neurodegenerative 
diseases [reviewed by (Marei & Malliri 2017)]. 
 
5.3.2. PDPN AND THROMBOINFLAMMATION 
Here we aimed to understand the mechanisms by which perivascular stromal cells 
present PDPN to circulating platelets and the effect of this interaction on platelet 
activation. Indeed, umbilical cord cross-sections revealed PDPN expression to be 
localised to the perivascular region, thus we hypothesised that these PDPN-positive 
pro-migratory MSC were capable of engaging platelet CLEC-2 by invading into the 
blood vessel lumen. 
 
In normal human tissue, PDPN was expressed in discrete layers at the interface 
between dense regular and dense irregular connective tissue within the skin, cervix, 
esophagus, prostate, breast glands, salivary glands, and thymus (Schacht et al. 
2005). Lymphoid tissue showed dispersed staining of PDPN by fibroblastic reticular 
cells, whilst PDPN was restricted to alveolar type I cells within the lung (Schacht et al. 
2005). The physiological role of PDPN is still largely unknown. However, a common 
theme of PDPN deletion in mice was the leakage of blood into the lymphatics 
(Schacht et al. 2003; Bianchi et al. 2017; Fu et al. 2008). This might suggest an issue 
in the maintenance of vascular integrity. Indeed, Herzog et al., (2013) suggested that 
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under basal conditions vascular integrity is continuously disrupted at high endothelial 
venules by circulating lymphocytes (Herzog et al. 2013). It was only through 
perivascular PDPN-mediated activation of platelets and their release of S1P that 
barrier function was restored through upregulation of VE-cadherin by endothelium 
(Herzog et al. 2013). However, it is unknown how platelets support vascular integrity 
during inflammation (Goerge et al. 2008). Platelet release of S1P has also been 
shown to promote the proliferation and survival of liver sinusoidal endothelium, as 
well as induce the secretion of VEGF and IL-6 (Nowatari et al. 2015). Such 
responses could enhance angiogenesis (Leung et al. 1989), but also have the 
potential to impede leukocyte recruitment through IL-6 induced expression of SOCS3 
(Luu et al. 2013). Indeed, the release of S1P by endothelium has also been shown to 
impair memory T-cell transmigration through the inactivation of b2-integrin via S1P 
receptors 1/4 (Chimen et al. 2015). These studies would suggest a protective role for 
PDPN interactions with platelet CLEC-2 on vascular integrity. However, other 
protective functions may also be in place, as was the case in a mouse model of 
inflammatory arthritis whereby deletion of CLEC-2 resulted in increased inflammation 
and tissue damage through an undefined mechanism (Desanti et al. 2017).  
 
With regard to pathology, expression of PDPN was strongly associated with 
metastasis in bladder tumours and oral ‘squamous cell carcinoma’ (SCC) (Yuan et al. 
2006; Takagi et al. 2014). PDPN also correlates with a poor prognosis and 
aggressive tumours in liver, breast, lung and pancreatic cancers (Kawase et al. 2008; 
Hoshino et al. 2011; Pula et al. 2011; Yurugi et al. 2017). PDPN was also 
upregulated in skin and ovarian cancer, with staining limited to the dense regular but 
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not dense irregular connective tissue (Schacht et al. 2005). This may explain the 
laminar appearance of PDPN in the inflamed perivascular space (Payne et al. 2017; 
Hitchcock et al. 2015; Inoue et al. 2015), with expression on stromal cells forming 
dense regular connective tissue. We also found expression of PDPN to be restricted 
to the dense regular areas of the umbilical cord surrounding the vasculature and 
along the amnion. However, its function in these areas is unclear. As discussed 
earlier, Astarita et al., (2015) showed PDPN to be an important contractile element of 
fibroblastic reticular cells, contact with its receptor CLEC-2 on dendritic cells inhibited 
this contraction and resulted in the overall expansion of the lymph node during an 
inflammatory response (Astarita et al. 2015). Another study also demonstrated PDPN 
to be expressed on different populations within the chronically infarcted myocardium, 
with their function divided into lymphangiogenesis or fibrosis and scar formation 
(Cimini et al. 2017). Expression of PDPN may correlate with a pro-fibrotic phenotype 
of stromal cells in certain contexts, this may have implications in vascular fibrosis 
during inflammation, given its perivascular expression profile. 
 
A review by Wicki and Christofori has shown PDPN expression to be upregulated in 
the tumour mass periphery, where they indicated it was important for the collective 
invading edge of the tumour (Wicki & Christofori 2007). Indeed, intravasation of cells 
from the tissue stroma and into blood vessels is well described within the cancer field 
[reviewed by (Chiang et al. 2016)]. However, it remains unclear as to the mechanism 
by which circulating platelet CLEC-2 comes into contact with PDPN, due to the 
endothelial lining separating these two compartments (Suzuki-Inoue 2017). Here we 
have shown that perivascular UCMSC protrusions are able to partially intravasate 
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through the endothelial lining and both recruit and activate platelets in a PDPN-
dependent manner. The ability for PDPN to capture platelets has been previously 
described, with recombinant PDPN or PDPN-expressing lymphatic endothelium able 
to readily capture platelets from flow; Src/Syk platelet signalling was required for 
stable binding of CLEC-2 (Navarro-Nunez et al. 2015). These data suggest that in 
pathology, cells are capable of penetrating the endothelial lining and interacting with 
platelet CLEC-2 through PDPN. 
 
In addition to the role of PDPN-CLEC-2 interactions in maintaining vascular integrity, 
a recent study has also demonstrated that PDPN activation of platelets by tumour 
cells induces the release of platelet TGF-b, which subsequently enhanced epithelial-
mesenchymal transition (EMT) of tumour cells promoting metastasis (Takemoto et al. 
2017). Martín-Villar et al., (2006) also reported that EMT was induced by PDPN, but 
through direct interactions with ERM proteins and activation of RhoA (Martín-Villar et 
al. 2006). Indeed, treatment of a PDPN expressing bladder SCC cell line with 
supernatants from PDPN-activated platelets significantly enhanced their 
invasiveness through a matrigel-overlaid transwell model (Takemoto et al. 2017). 
Suggesting that PDPN-CLEC-2 interactions may assist in driving stromal 
intravasation in a positive-feedback loop. Furthermore, metastasis could be blocked 
in mouse tumour models by therapeutic administration of a TGF-b neutralising 
antibody, implicating PDPN as a critical mediator of this process (Takemoto et al. 
2017). However, the mechanism by which these PDPN-expressing cells breach the 
endothelial lining has not shown until this study. We have demonstrated for the first 
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time that PDPN-positive UCMSC can breach the endothelial lining and activate 
platelet CLEC-2. However, the role of TGF-b in promoting the intravasation of non-
tumourigenic cells, such as UCMSC, requires further investigation.  
 
Excessive PDPN-mediated platelet activation may also lead to the pro-thrombotic 
phenotype seen in a number of inflammatory disorders [reviewed by (Aksu et al. 
2012)]. Gestational vascular diseases, such as pre-eclampsia, are also closely 
associated with inflammation and thrombosis, posing a major cause of morbidity and 
mortality to the pregnancy (Kohli & Isermann 2017). Thromboembolism describes the 
process by which a thrombus breaks off and obstructs another vessel, resulting in 
local ischemia and potential fatalities. Indeed, patients with PDPN-positive brain 
tumours were shown to have significantly reduced platelet counts and increased risk 
of thromboembolism (Riedl et al. 2017). Indicating a role for PDPN-CLEC-2 
interactions in thromboinflammation. Furthermore, scanning electron micrographs of 
the inferior vena cava in TNF-a-stimulated mice saw the formation of microthrombi at 
sites of increased leukocyte transmigration (Eriksson et al. 2005). Indeed, real-time 
observations in mouse models of deep vein thrombosis (DVT) link inflammation and 
leukocyte recruitment as an initiator of thrombosis (Brühl et al. 2012). This would 
agree with similar data whereby neutrophil transmigration over stiff substrates was 
shown to induce mechanical damage to the endothelial monolayer (Stroka & Aranda-
Espinoza 2011). Indeed, perivascular PDPN-mediated contraction and fibrosis could 
promote vessel stiffness (Astarita et al. 2015; Cimini et al. 2017), thereby resulting in 
damage to endothelium during neutrophil recruitment. Indeed, vascular integrity was 
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shown to be disrupted in a mouse model of systemic Salmonella Typhimurium 
infection, resulting in thrombosis at these sites through PDPN interactions (Hitchcock 
et al. 2015). Furthermore, it is unknown how vascular integrity is maintained during 
inflammation (Goerge et al. 2008), but it may the case that PDPN activation of CLEC-
2 restores integrity through release of S1P as reported by Herzog et al., (2013) 
(Herzog et al. 2013). Indeed, the release of other pro-migratory stimuli by PDPN-
activated platelets, namely FGF and TGF-b may assist stromal intravasation in a 
positive-feedback loop (Langer et al. 2009; Takemoto et al. 2017). 
 
Overall, we propose that the following could occur during an inflammatory response: 
PDPN is upregulated on the underlying stroma, increasing vessel stiffness and 
impairing endothelial maintenance of integrity in response to neutrophil 
transmigration. This may or may not assist perivascular stroma protrusion into the 
vessel lumen. However, the presence of luminal PDPN could further enhance 
stromal intravasation through the release of FGF and TGF-b by PDPN-activated 
platelets in a positive-feedback loop. Ultimately, PDPN-activated platelet release of 
S1P could protect vascular integrity, as well as moderate the levels of leukocyte 
recruitment and migration as part of an endogenous stromal-platelet mediated 
regulatory pathway. However, further work is required to validate this concept and 
evaluate the role of this proposed pathway in chronic inflammatory diseases or 
cancer. 
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In conclusion, we have shown that expression of PDPN contributes a pro-migratory 
phenotype to MSC through Rac1 signalling, and that this function enables the 
presentation of PDPN through the endothelial lining to circulating platelets, inducing 
their activation via CLEC-2. We suggest that these invasive PDPN-expressing 
perivascular stromal cells are upregulated in pathology and may contribute to 
vascular integrity, immunosuppressive, metastatic, or thromboinflammatory 
processes. 
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6.1. SUMMARY OF THE MAIN FINDINGS 
BMMSC responses to prolonged TNF-a priming were evaluated using an in vitro 
model of neutrophil recruitment and their transcriptional profile recorded for several 
inflammation-associated genes. Of which, the expression and function of PDPN was 
characterised using several models of cell migration. The downstream signalling 
pathways for PDPN-mediated migration were assessed with inhibitors against 
several members of the Rho GTPase family. Finally, the mechanism by which 
perivascular PDPN interacts with circulating platelet CLEC-2 was elucidated. The 
main findings of this thesis are: 
• Prolonged priming of BMMSC with TNF-a had no effect on their ability to 
communicate with endothelium to suppress neutrophil adhesion. 
• TNF-a priming also increased ICAM-1 gene expression and impaired the 
increased neutrophil transmigration observed by BMMSC coculture. 
• PDPN expression increases UCMSC migration in a Rac1 dependent manner. 
• PDPN-expressing cells are localised to the perivascular niche of the umbilical 
cord, and UCMSC protrusions are capable of platelet capture and activation 
through endothelium via PDPN.  
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6.2. CONTEXT OF FINDINGS WITHIN THE LITERATURE 
6.2.1. EFFECT OF THE INFLAMMATORY MICROENVIRONMENT ON MSC 
We have previously shown that coculture of BMMSC with HUVEC suppresses 
neutrophil recruitment, but that this effect is varied with coculture contact, passage, 
and adipogenic differentiation according to the tissue microenvironment from which 
the MSC were isolated (Munir et al. 2016; Munir et al. 2017). Here, we found that 
using TNF-a priming as a model for the inflammatory microenvironment had no 
impact on the capacity of BMMSC to suppress neutrophil adhesion to BEC. Instead, 
BMMSC coculture increased neutrophil transmigration, with TNF-a priming reverting 
this response to levels seen in endothelial monocultures. This disagrees with 
previous reports showing that BMMSC-HUVEC coculture either suppresses (Luu et 
al. 2013), or has no effect on neutrophil transmigration (Munir et al. 2016). We 
speculate that the differences in neutrophil transmigration observed in the presence 
of BMMSC coculture are because of the different endothelial cell sources used. 
Indeed, MSC are capable of secreting neutrophil chemoattractants such as IL-8, 
CXCL1, and CXCL2 (Luu et al. 2013; Ren et al. 2008; Guijarro-Muñoz et al. 2014). 
However, the impact of endothelial coculture on these secretions are unknown. 
Perhaps these differences are to ensure preferential neutrophil transmigration across 
post-capillary venules over macrovascular veins. Interestingly, prior TNF exposure 
abolished the increase in neutrophil transmigration observed with BMMSC coculture. 
We suggest that this is a protective response to reduce neutrophil penetration into 
tissues already exposed to inflammation, though this warrants further functional 
comparisons with pro-inflammatory stromal cells such as RASF. 
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Overall, BMMSC do not appear to undergo a functional transformation with regard to 
their immunomodulatory capacity when exposed to exogenous TNF-a stimulation. 
Indeed, it would appear that BMMSC are initially able to dampen the pro-
inflammatory microenvironment. As shown by BMMSC suppressing neutrophil 
recruitment in BEC coculture post-priming, and reducing inflammation-associated 
ICAM-1 gene expression in RASF coculture. Luu et al., demonstrated that BMMSC 
suppression of neutrophil transmigration through HUVEC was dependent on TGF-b 
(Luu et al. 2013). Future experiments should investigate whether TGF-b is increased 
in TNF-a primed compared to untreated BMMSC-BEC coculture, and hence 
explaining why we see a reduction in neutrophil transmigration in the primed 
coculture. Indeed, TGF-b appears to be differentially regulated in response to priming 
with TNF-a with one study seeing reduced secretion (English et al. 2007), and the 
other seeing increased gene expression compared to untreated MSC (Wu et al. 
2015). However, the long-term repercussions of inflammation on MSC function 
cannot be modelled in vitro, with future work instead focussing on ex vivo functional 
comparisons between MSC isolated from a variety of chronic inflammatory conditions 
and healthy controls. Indeed, short-term exposure of MSC to inflammatory cytokines 
in vitro has been shown to have differential effects on MSC secretion of 
immunomodulatory factors and in their ability to suppress leukocyte proliferation and 
function (Prasanna et al. 2010; English et al. 2007; Waterman et al. 2010; Liotta et al. 
2008; Raicevic et al. 2011). However, a greater proportion of studies overall report 
that MSC function is enhanced through cytokine priming. Few groups have 
investigated the effect of prolonged cytokine priming, and only a small number have 
characterised MSC from chronically inflamed sites, systemically they appear altered 
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and there are conflicting reports on how this impacts their function (Table 1-3). More 
work is required in general, but in our assays with a relatively short priming we see 
little difference. Ideally, MSC should be isolated from chronic tissues to determine 
whether they exhibit the same epigenetic imprinting as their progeny and 
incorporated into these adhesion assays to investigate how the inflammatory 
microenvironment impacts MSC crosstalk with endothelium. 
 
6.2.2. ROLE OF PDPN EXPRESSION IN MSC 
Here we have shown that UCMSC differentially express PDPN. PDPN is typically 
associated with sites of inflammation and cancer-supporting stroma, whereby it 
increases the metastatic capacity of these cells. In agreement with this, we show for 
the first time that PDPN signalling through Rac1 is responsible for MSC migration 
using several in vitro models. This is also of importance for the regenerative medicine 
field and understanding the relocalisation of MSC to sites of tissue damage where 
they exert their reparative function. PDPN also mediates the invasiveness of oral 
SCC cells through RhoA and Cdc42 activity, however, neither PDPN overexpression 
or knockdown had any impact on Rac1 activity (Y.-Y. Li et al. 2015). Yet, 
overexpression of PDPN in MCF7 cells resulted in reduced Rac1, RhoA, and Cdc42 
(Wicki et al. 2006), but no change in Rac1 nor Cdc42 activity in MDCK cells (Martín-
Villar et al. 2006). Even though ERM proteins (upstream of Rho GTPases) colocalise 
with PDPN at cell-surface protrusions (Martín-Villar et al. 2006). However, another 
study attributed activated Rac1 expression with increased metastatic potential in 
colorectal carcinoma (Zhong et al. 2009). The literature regarding PDPN downstream 
signalling is lacking, but overall these data suggest that the mechanism of PDPN-
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mediated migration and invasion greatly differ depending on the cell type. Further 
investigation is required in this area to better understand how PDPN regulates the 
migration of stromal cells both in health and disease. 
 
Payne et al., (2017) recently identified that PDPN regulates the size but not the 
prevalence of thrombi in a sterile-inflammation deep vein thrombosis mouse model 
through interactions with platelet CLEC-2 (Payne et al. 2017). Indeed, confocal 
microscopy of thrombi in the inferior vena cava, showed extensive perivascular 
PDPN staining but the cells expressing it and the mechanism of contact were 
unknown (Payne et al. 2017). In a non-sterile mouse model of inflammation, 
Hitchcock et al., (2015) also saw perivascular PDPN expression driving thrombosis at 
sites of endothelial disruption, but this was attributed to inflammatory macrophages 
(Hitchcock et al. 2015). Here we investigated the upstream signalling of MSC PDPN 
and the mechanism by which it comes into contact with its receptor, CLEC-2 on 
circulating platelets. PDPN-expressing MSC were capable of capturing and activating 
platelets through 3µm pores, but not migrating through them. Since expression of 
PDPN is concentrated at cellular protrusions (Martin-Villar et al. 2010; Wicki et al. 
2006), we speculated that these were infiltrating the pores and presenting PDPN to 
platelets. Indeed, immunohistochemistry staining of umbilical cord sections revealed 
PDPN to be localised to the perivascular niche and the fibrous areas of the amnion. 
With this in mind, we setup UCMSC cocultures with microvascular endothelium, and 
demonstrated that the size of platelet aggregates was determined by MSC 
expression of PDPN through the endothelial lining, albeit with reduced prevalence 
compared to UCMSC monocultures. These data pose particular importance to the 
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field of thromboinflammation. Indeed, PDPN is found to be upregulated in a number 
of inflammatory disorders, including; RA, DVT, atherosclerosis, systemic infection, 
and cancer (Kawase et al. 2008; Shields et al. 2010; Inoue et al. 2015; Payne et al. 
2017; Hitchcock et al. 2015; Del Rey et al. 2014; Croft et al. 2016; Ekwall et al. 2011; 
Hatakeyama et al. 2012). Whilst in brain cancer patients, platelet counts are reduced 
in associated with tumour expression of PDPN, these patients are also predisposed 
to thromboembolism (Riedl et al. 2017). The interaction between perivascular PDPN 
and CLEC-2 on circulating platelets has far reaching roles in understanding the 
mechanisms by which thrombosis, pulmonary embolism, and stroke occurs in 
inflammatory disorders [reviewed by (Aksu et al. 2012)]. Conversely, upregulation of 
PDPN in the perivascular space, and activation of platelets may also serve to protect 
vascular integrity during inflammation (Herzog et al. 2013). 
 
Furthermore, this line of enquiry would also benefit from experiments addressing the 
role of Rac1 in PDPN-mediated MSC migration. Indeed, in the presence of the Rac1 
inhibitor we observed a reduction in the number of UCMSC expressing PDPN at the 
cell periphery, suggesting that Rac1 may be involved in localising PDPN to the cell 
edge whereby it can exert its migratory function. It would also be prudent to acquire 
samples from mouse models of inflammation or patients with chronic inflammatory 
disorders to determine whether PDPN has a perivascular expression profile in these 
samples also and if this is associated with vessel fibrosis and or the presence of 
thrombi (Astarita et al. 2015; Cimini et al. 2017; Hitchcock et al. 2015; Payne et al. 
2017). The work undertaken by Takemoto et al., (2017) should be verified here to 
determine whether PDPN-activation of platelet CLEC-2 induces the release of MSC 
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invasion factors such as TGF-b and FGF and further enhances the intravasation of 
MSC into the vessel lumen (Langer et al. 2009; Takemoto et al. 2017). Lastly, the 
effect of S1P derived from PDPN-activated platelets should be investigated in its 
ability to enhance the integrity of inflamed endothelium and potentially suppress the 
transmigration of memory T-cell subsets (Herzog et al. 2013; Chimen et al. 2015).  
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6.3. CONCLUSION 
In conclusion, we have shown that priming with TNF-a had no effect on the ability of 
BMMSC to communicate with microvascular endothelium and suppress neutrophil 
adhesion. BMMSC resisted functional transformation during TNF-a exposure, 
maintaining their immunomodulatory capacity and profile. Therefore, we support their 
use in MSC-based therapy in that they can retain their suppressive function over 
endothelium in the context of the inflammatory microenvironment and not further 
contribute toward disease pathogenesis through transformation as seen in 
endogenous stroma. 
 
PDPN expression is known to be upregulated by the inflammatory microenvironment 
and was found to be differentially expressed by UCMSC. Expression of PDPN 
promoted MSC migration through Rac1-dependent signalling, enabling these 
perivascular MSC to potentially interact with CLEC-2-positive myeloid and dendritic 
cells (Lowe et al. 2015). Here we demonstrated that PDPN induced the activation of 
platelets from flow through UCMSC protrusions in the microvascular endothelial 
lining. These results implicate both detrimental roles for PDPN-CLEC-2 interactions 
in thromboinflammation or beneficial outcomes in the maintenance of vascular 
integrity and potential suppression of T-cell transmigration at inflammatory sites. 
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6.4. FUTURE STUDIES 
The data presented within this thesis give rise to new questions and further studies to 
be performed. Possible suggestions of these experiments are listed below:  
1. Investigate the mechanism by which TNF-a primed BMMSC-BEC coculture 
inhibits neutrophil transmigration compared to untreated. Attention should be 
drawn to the concentration of TGF-b in conditioned medium. 
2. Identify differences in leukocyte recruitment to endothelium when cocultured 
with MSC isolated from patients with systemic chronic inflammation or those 
isolated from the site of inflamed tissue itself. 
3. Characterise the effect of prolonged BMMSC coculture with RASF, and the 
impact on their ability to modulate leukocyte recruitment to endothelium. 
4. Investigate the role of Rac1 in PDPN-mediated migration of MSC. Attention 
should be drawn to whether Rac1 localises PDPN to cellular protrusions. 
5. Stain samples of inflamed vessels from mouse models or patient samples for 
perivascular PDPN, fibrosis, and thrombi, to determine the conditions under 
which PDPN is expressed and the effect on vessel stiffness. Attention should 
be drawn to samples from inflammatory disorders predisposed to thrombosis. 
6. Determine whether platelet lysates enhance PDPN-positive UCMSC 
protrusion through the endothelial lining, and the subsequent impact on 
platelet recruitment and activation. 
7. Investigate whether supernatant from PDPN-activated platelets contains S1P 
and if it enhances the integrity of inflamed endothelium or impairs T-cell 
transmigration. 
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